Warner Chilcott 10-Q 8 Aug 19 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Aug. 06, 2019
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Trading Symbol	AGN
Entity Registrant Name	Allergan plc
Entity Central Index Key	0001578845
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		328,032,715
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Interactive Data Current	Yes
Entity File Number	001-36867
Entity Tax Identification Number	98-1114402
Title of 12(b) Security	Allergan plc Ordinary Shares, $0.0001 par value
Security Exchange Name	NYSE
Document Quarterly Report	true
Document Transition Report	false
Entity Address, Address Line One	Clonshaugh Business and Technology Park
Entity Address, Address Line Two	Coolock
Entity Address, City or Town	Dublin
Entity Address, Country	IE
Entity Address, Postal Zip Code	E400
City Area Code	862
Local Phone Number	261-7000
Entity Incorporation, State or Country Code	L2
Warner Chilcott Limited [Member]
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Entity Registrant Name	Warner Chilcott Limited
Entity Central Index Key	0001620602
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		0
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Interactive Data Current	Yes
Entity File Number	001-36887
Entity Tax Identification Number	98-0496358
Document Quarterly Report	true
Document Transition Report	false
Entity Address, Address Line One	Canon’s Court
Entity Address, Address Line Two	22 Victoria Street
Entity Address, City or Town	Hamilton
Entity Address, Country	BM
Entity Address, Postal Zip Code	HM 12
City Area Code	441
Local Phone Number	295-2244
Entity Incorporation, State or Country Code	D0

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 1,651.4	$ 880.4
Marketable securities	322.3	1,026.9
Accounts receivable, net	3,086.3	2,868.1
Inventories	1,004.5	846.9
Current assets held for sale		34
Prepaid expenses and other current assets	2,508.3	819.1
Total current assets	8,572.8	6,475.4
Property, plant and equipment, net	1,821	1,787
Right of use asset - operating leases	457.9
Investments and other assets	335.2	1,970.6
Non current assets held for sale	32.5	882.2
Deferred tax assets	689.1	1,063.7
Product rights and other intangibles	41,231.5	43,695.4
Goodwill	42,340.7	45,913.3
Total assets	95,480.7	101,787.6
Current liabilities:
Accounts payable and accrued expenses	4,995.3	4,787.2
Income taxes payable	91	72.4
Current portion of long-term debt	3,094.2	868.3
Current portion of lease liability - operating	123.2
Total current liabilities	8,303.7	5,727.9
Long-term debt	19,609.3	22,929.4
Lease liability - operating	414.8
Other long-term liabilities	821.4	882
Other taxes payable	1,667	1,615.5
Deferred tax liabilities	4,968.4	5,501.8
Total liabilities	35,784.6	36,656.6
Commitments and contingencies (Refer to Note 20)
Equity:
Ordinary shares; $0.0001 par value per share; 1,000.0 million shares authorized, 327.9 million and 332.6 million shares issued and outstanding, respectively	0	0
Additional paid-in capital	55,811.9	56,510
Retained earnings	2,581.1	7,258.9
Accumulated other comprehensive income	1,281.7	1,345.2
Total shareholders’ equity	59,674.7	65,114.1
Noncontrolling interest	21.4	16.9
Total equity	59,696.1	65,131
Noncontrolling interest	21.4	16.9
Total equity	59,696.1	65,131
Total liabilities and equity	95,480.7	101,787.6
Warner Chilcott Limited [Member]
Current assets:
Cash and cash equivalents	1,650	878.6
Marketable securities	322.3	1,026.9
Accounts receivable, net	3,086.3	2,868.1
Receivables from Parents	210.6	640.9
Inventories	1,004.5	846.9
Current assets held for sale		34
Prepaid expenses and other current assets	2,505	818.7
Total current assets	8,778.7	7,114.1
Property, plant and equipment, net	1,821	1,787
Right of use asset - operating leases	457.9
Investments and other assets	335.2	1,970.6
Non current assets held for sale	32.5	882.2
Deferred tax assets	689.1	1,063.7
Product rights and other intangibles	41,231.5	43,695.4
Goodwill	42,340.7	45,913.3
Total assets	95,686.6	102,426.3
Current liabilities:
Accounts payable and accrued expenses	4,995.2	4,787.4
Payables to Parents	2,491.7	2,829.2
Income taxes payable	93.6	72.4
Current portion of long-term debt	3,094.2	868.3
Current portion of lease liability - operating	123.2
Total current liabilities	10,797.9	8,557.3
Long-term debt	19,609.3	22,929.4
Lease liability - operating	414.8
Other long-term liabilities	821.4	882
Other taxes payable	1,660.8	1,615.5
Deferred tax liabilities	4,968.5	5,501.8
Total liabilities	38,272.7	39,486
Commitments and contingencies (Refer to Note 20)
Equity:
Member's capital	64,509.4	65,797.9
Retained earnings	(8,398.6)	(4,219.7)
Accumulated other comprehensive income	1,281.7	1,345.2
Total members’ equity	57,392.5	62,923.4
Noncontrolling interest	21.4	16.9
Total equity	57,413.9	62,940.3
Noncontrolling interest	21.4	16.9
Total equity	57,413.9	62,940.3
Total liabilities and equity	$ 95,686.6	$ 102,426.3

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Ordinary shares, par value	$ 0.0001	$ 0.0001
Ordinary shares, shares authorized	1,000,000,000	1,000,000,000
Ordinary shares, shares issued	327,900,000	332,600,000
Ordinary shares, shares outstanding	327,900,000	332,600,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Net revenues	$ 4,090.1	$ 4,124.2	$ 7,687.2	$ 7,796.3
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)	652.3	481.8	1,150.1	1,004.6
Research and development	450	689.2	885	1,163.9
Selling and marketing	873.3	853.4	1,677.3	1,653.4
General and administrative	324.2	334.1	632.5	630
Amortization	1,402	1,697.1	2,801.4	3,394.7
Goodwill impairments	1,085.8		3,552.8
In-process research and development impairments	436	276	436	798
Asset sales and impairments, net	129.4	259.6	124.2	272.7
Total operating expenses	5,353	4,591.2	11,259.3	8,917.3
Operating (loss)	(1,262.9)	(467)	(3,572.1)	(1,121)
Interest income	9.7	6.3	31	23.6
Interest (expense)	(195.4)	(230)	(397.2)	(480.6)
Other (expense) / income, net	(4.7)	215.4	9.1	136.6
Total other income (expense), net	(190.4)	(8.3)	(357.1)	(320.4)
Income / (loss) before income taxes and noncontrolling interest	(1,453.3)	(475.3)	(3,929.2)	(1,441.4)
Provision (benefit) for income taxes	301.6	(5.2)	233	(687.4)
Net (loss) / income	(1,754.9)	(470.1)	(4,162.2)	(754)
(Income) attributable to noncontrolling interest	(4.1)	(2.4)	(4.8)	(4.6)
Net (loss) attributable to shareholders	(1,759)	(472.5)	(4,167)	(758.6)
Dividends on preferred shares				46.4
Net (loss) attributable to ordinary shareholders	$ (1,759)	$ (472.5)	$ (4,167)	$ (805)
(Loss) per share attributable to ordinary shareholders
(Loss) per share attributable to ordinary shareholders - basic	$ (5.37)	$ (1.39)	$ (12.63)	$ (2.39)
(Loss) per share attributable to ordinary shareholders - diluted	$ (5.37)	$ (1.39)	$ (12.63)	$ (2.39)
Weighted average shares outstanding:
Basic	327.8	339.1	329.9	336.9
Diluted	327.8	339.1	329.9	336.9
Warner Chilcott Limited [Member]
Net revenues	$ 4,090.1	$ 4,124.2	$ 7,687.2	$ 7,796.3
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)	652.3	481.8	1,150.1	1,004.6
Research and development	450	689.2	885	1,163.9
Selling and marketing	873.3	853.4	1,677.3	1,653.4
General and administrative	316.4	299.5	622.5	593.6
Amortization	1,402	1,697.1	2,801.4	3,394.7
Goodwill impairments	1,085.8		3,552.8
In-process research and development impairments	436	276	436	798
Asset sales and impairments, net	129.4	259.6	124.2	272.7
Total operating expenses	5,345.2	4,556.6	11,249.3	8,880.9
Operating (loss)	(1,255.1)	(432.4)	(3,562.1)	(1,084.6)
Interest income	9.7	71.8	31	142.1
Interest (expense)	(195.4)	(230)	(397.2)	(480.6)
Other (expense) / income, net	(4.7)	215.4	9.1	136.6
Total other income (expense), net	(190.4)	57.2	(357.1)	(201.9)
Income / (loss) before income taxes and noncontrolling interest	(1,445.5)	(375.2)	(3,919.2)	(1,286.5)
Provision (benefit) for income taxes	301.6	(5.2)	232.9	(687.4)
Net (loss) / income	(1,747.1)	(370)	(4,152.1)	(599.1)
(Income) attributable to noncontrolling interest	(4.1)	(2.4)	(4.8)	(4.6)
Net (loss) / income attributable to members	$ (1,751.2)	$ (372.4)	$ (4,156.9)	$ (603.7)

Consolidated Statements of Comp

Consolidated Statements of Comprehensive (Loss) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Net (loss)	$ (1,754.9)	$ (470.1)	$ (4,162.2)	$ (754)
Other comprehensive income / (loss)
Foreign currency translation gains / (losses)	66.5	(448.6)	(61.3)	(264.8)
Unrealized (losses), net of tax	(1.2)		(2.2)
Total other comprehensive income / (loss), net of tax	65.3	(448.6)	(63.5)	(264.8)
Comprehensive (loss)	(1,689.6)	(918.7)	(4,225.7)	(1,018.8)
Comprehensive (income) attributable to noncontrolling interest	(4.1)	(2.4)	(4.8)	(4.6)
Comprehensive (loss) attributable to ordinary shareholders	(1,693.7)	(921.1)	(4,230.5)	(1,023.4)
Warner Chilcott Limited [Member]
Net (loss)	(1,747.1)	(370)	(4,152.1)	(599.1)
Other comprehensive income / (loss)
Foreign currency translation gains / (losses)	66.5	(448.6)	(61.3)	(264.8)
Unrealized (losses), net of tax	(1.2)		(2.2)
Total other comprehensive income / (loss), net of tax	65.3	(448.6)	(63.5)	(264.8)
Comprehensive (loss)	(1,681.8)	(818.6)	(4,215.6)	(863.9)
Comprehensive (income) attributable to noncontrolling interest	(4.1)	(2.4)	(4.8)	(4.6)
Comprehensive (loss) attributable to members	$ (1,685.9)	$ (821)	$ (4,220.4)	$ (868.5)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash Flows From Operating Activities:
Net (loss)	$ (4,162.2)	$ (754)
Reconciliation to net cash provided by operating activities:
Depreciation	96.2	105.2
Amortization	2,801.4	3,394.7
Provision for inventory reserve	83.4	45.4
Share-based compensation	111.8	127.4
Deferred income tax benefit	(166.4)	(1,359.6)
Goodwill impairments	3,552.8
In-process research and development impairments	436	798
Loss on asset sales and impairments, net	124.2	272.7
Gain on sale of business		(53)
Non-cash extinguishment of debt	0.2	4
Cash charge related to extinguishment of debt		(13.1)
Amortization of deferred financing costs	9.1	11.9
Non-cash lease expense	68
Contingent consideration adjustments, including accretion	46.8	(101.8)
Other, net	(19.3)	(0.3)
Changes in assets and liabilities (net of effects of acquisitions):
Decrease / (increase) in accounts receivable, net	(220.6)	90.3
Decrease / (increase) in inventories	(179.3)	(113.3)
Decrease / (increase) in prepaid expenses and other current assets	23.9	39.3
Increase / (decrease) in accounts payable and accrued expenses	161.6	(40.4)
Increase / (decrease) in income and other taxes payable	(44.2)	365.4
Increase / (decrease) in other assets and liabilities	(79.1)	(59.4)
Net cash provided by operating activities	2,644.3	2,698.5
Cash Flows From Investing Activities:
Additions to property, plant and equipment	(152.3)	(106.5)
Additions to product rights and other intangibles	(46)
Additions to investments	(738.2)	(1,455.9)
Proceeds from sale of investments and other assets	1,462	5,651.3
Proceeds from sales of property, plant and equipment	17.7	11.5
Acquisitions of businesses, net of cash acquired	(80.6)
Net cash provided by investing activities	462.6	3,634.4
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness, including credit facility	3.3	709
Payments on debt, including finance lease obligations and credit facility	(1,039.1)	(5,366.8)
Cash charge related to extinguishment of debt		13.1
Payments of contingent consideration and other financing	(4.1)	(10.6)
Proceeds from stock plans	23.6	69.2
Repurchase of ordinary shares	(833.5)	(1,572.1)
Dividends paid	(488.8)	(563.7)
Net cash (used in) financing activities	(2,338.6)	(6,490.4)
Effect of currency exchange rate changes on cash and cash equivalents	2.7	15
Net increase / (decrease) in cash and cash equivalents	771	(142.5)
Cash and cash equivalents at beginning of period	880.4	1,817.2
Cash and cash equivalents at end of period	1,651.4	1,674.7
Cash paid during the year for:
Income taxes other, net of refunds	450.9	336.1
Interest	401.1	520.9
Schedule of Non-Cash Investing and Financing Activities:
Conversion of mandatory convertible preferred shares		4,929.7
Settlement of secured financing		(465.5)
Dividends accrued	1.1	1.4
Warner Chilcott Limited [Member]
Cash Flows From Operating Activities:
Net (loss)	(4,152.1)	(599.1)
Reconciliation to net cash provided by operating activities:
Depreciation	96.2	105.2
Amortization	2,801.4	3,394.7
Provision for inventory reserve	83.4	45.4
Share-based compensation	111.8	127.4
Deferred income tax benefit	(166.4)	(1,359.6)
Goodwill impairments	3,552.8
In-process research and development impairments	436	798
Loss on asset sales and impairments, net	124.2	272.7
Gain on sale of Teva securities, net		(60.9)
Gain on sale of business		(53)
Non-cash extinguishment of debt	0.2	4
Cash charge related to extinguishment of debt		(13.1)
Amortization of deferred financing costs	9.1	11.9
Non-cash lease expense	68
Contingent consideration adjustments, including accretion	46.8	(101.8)
Other, net	(19.3)	(0.3)
Changes in assets and liabilities (net of effects of acquisitions):
Decrease / (increase) in accounts receivable, net	(220.6)	90.3
Decrease / (increase) in inventories	(179.3)	(113.3)
Decrease / (increase) in prepaid expenses and other current assets	26.8	40.6
Increase / (decrease) in accounts payable and accrued expenses	161.9	(38.2)
Increase / (decrease) in income and other taxes payable	(44.2)	365.4
Increase / (decrease) in other assets and liabilities, including receivable / payable with Parents	(102.2)	(181)
Net cash provided by operating activities	2,634.5	2,735.3
Cash Flows From Investing Activities:
Additions to property, plant and equipment	(152.3)	(106.5)
Additions to product rights and other intangibles	(46)
Additions to investments	(738.2)	(1,455.9)
Proceeds from sale of investments and other assets	1,462	5,651.3
Payments to settle Teva related matters		(466)
Proceeds from sales of property, plant and equipment	17.7	11.5
Acquisitions of businesses, net of cash acquired	(80.6)
Net cash provided by investing activities	462.6	3,634.4
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness, including credit facility	3.3	709
Payments on debt, including finance lease obligations and credit facility	(1,039.1)	(5,366.8)
Cash charge related to extinguishment of debt		13.1
Payments of contingent consideration and other financing	(4.1)	(10.6)
Proceeds from forward sale of Teva securities		465.5
Payments to settle Teva related matters		(234)
Dividend to Parent	1,288.5	2,103.7
Net cash (used in) financing activities	(2,328.4)	(6,527.5)
Dividends to Parents	(1,288.5)	(2,103.7)
Effect of currency exchange rate changes on cash and cash equivalents	2.7	15
Net increase / (decrease) in cash and cash equivalents	771.4	(142.8)
Cash and cash equivalents at beginning of period	878.6	1,816.3
Cash and cash equivalents at end of period	$ 1,650	1,673.5
Schedule of Non-Cash Investing and Financing Activities:
Settlement of secured financing		(465.5)
Teva [Member]
Reconciliation to net cash provided by operating activities:
Gain on sale of Teva securities, net		(60.9)
Cash Flows From Investing Activities:
Payments to settle Teva related matters		(466)
Cash Flows From Financing Activities:
Proceeds from forward sale of Teva securities		465.5
Payments to settle Teva related matters		(234)
Schedule of Non-Cash Investing and Financing Activities:
Settlement of Teva Shares		465.5
Teva [Member] | Warner Chilcott Limited [Member]
Cash Flows From Investing Activities:
Payments to settle Teva related matters		(466)
Cash Flows From Financing Activities:
Proceeds from forward sale of Teva securities		465.5
Payments to settle Teva related matters		(234)
Schedule of Non-Cash Investing and Financing Activities:
Settlement of Teva Shares		$ 465.5

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) $ in Millions	Total	Ordinary Shares [Member]	Preferred Shares [Member]	Additional Paid-in Capital [Member]	Retained Earnings/(Accumulated Deficit) [Member]	Accumulated Other Comprehensive Income / (Loss) [Member]	Noncontrolling Interest [Member]
Balance at Dec. 31, 2017	$ 73,837.1		$ 4,929.7	$ 54,013.5	$ 12,957.2	$ 1,920.7	$ 16
Balance, shares at Dec. 31, 2017		330,200,000	5,100,000
Implementation of new accounting pronouncements at Dec. 31, 2017	361.7				424.7	(63)
Adjusted Balance at Dec. 31, 2017	74,198.8		$ 4,929.7	54,013.5	13,381.9	1,857.7	16
Comprehensive (loss):
Net (loss) attributable to shareholders	(286.1)				(286.1)
Other comprehensive income, net of tax	183.8					183.8
Share-based compensation	72.5			72.5
Ordinary shares issued under employee stock plans	35.5			35.5
Ordinary shares issued under employee stock plans, shares		700,000
Dividends declared	(296.3)				(296.3)
Conversion of Mandatory Preferred Shares			$ (4,929.7)	4,929.7
Issuance of Mandatory Convertible Preferred Shares, shares		17,800,000	(5,100,000)
Repurchase of ordinary shares under the share repurchase programs	(1,540)			(1,540)
Repurchase of ordinary shares under the share repurchase programs, shares		(9,600,000)
Repurchase of ordinary shares	(24.3)			(24.3)
Repurchase of ordinary shares, shares		(100,000)
Movement in noncontrolling interest	2.1						2.1
Balance at Mar. 31, 2018	72,346			57,486.9	12,799.5	2,041.5	18.1
Balance, shares at Mar. 31, 2018		339,000,000
Balance at Dec. 31, 2017	73,837.1		$ 4,929.7	54,013.5	12,957.2	1,920.7	16
Balance, shares at Dec. 31, 2017		330,200,000	5,100,000
Implementation of new accounting pronouncements at Dec. 31, 2017	361.7				424.7	(63)
Adjusted Balance at Dec. 31, 2017	74,198.8		$ 4,929.7	54,013.5	13,381.9	1,857.7	16
Comprehensive (loss):
Net (loss) attributable to shareholders	(758.6)
Balance at Jun. 30, 2018	71,264			57,567.7	12,082.9	1,592.9	20.5
Balance, shares at Jun. 30, 2018		339,300,000
Balance at Mar. 31, 2018	72,346			57,486.9	12,799.5	2,041.5	18.1
Balance, shares at Mar. 31, 2018		339,000,000
Comprehensive (loss):
Net (loss) attributable to shareholders	(472.5)				(472.5)
Other comprehensive income, net of tax	(448.6)					(448.6)
Share-based compensation	54.9			54.9
Ordinary shares issued under employee stock plans	33.7			33.7
Ordinary shares issued under employee stock plans, shares		300,000
Dividends declared	(244.1)				(244.1)
Repurchase of ordinary shares	(7.8)			(7.8)
Movement in noncontrolling interest	2.4						2.4
Balance at Jun. 30, 2018	71,264			57,567.7	12,082.9	1,592.9	20.5
Balance, shares at Jun. 30, 2018		339,300,000
Balance at Dec. 31, 2018	65,131			56,510	7,258.9	1,345.2	16.9
Balance, shares at Dec. 31, 2018		332,600,000
Implementation of new accounting pronouncements at Dec. 31, 2018	(22)				(22)
Adjusted Balance at Dec. 31, 2018	65,109			56,510	7,236.9	1,345.2	16.9
Comprehensive (loss):
Net (loss) attributable to shareholders	(2,408)				(2,408)
Other comprehensive income, net of tax	(128.8)					(128.8)
Share-based compensation	52.3			52.3
Ordinary shares issued under employee stock plans	9.7			9.7
Ordinary shares issued under employee stock plans, shares		700,000
Dividends declared	(246.1)				(246.1)
Repurchase of ordinary shares under the share repurchase programs	(799.7)			(799.7)
Repurchase of ordinary shares under the share repurchase programs, shares		(5,300,000)
Repurchase of ordinary shares	(29.5)			(29.5)
Repurchase of ordinary shares, shares		(200,000)
Movement in noncontrolling interest	0.7						0.7
Balance at Mar. 31, 2019	61,559.6			55,742.8	4,582.8	1,216.4	17.6
Balance, shares at Mar. 31, 2019		327,800,000
Balance at Dec. 31, 2018	65,131			56,510	7,258.9	1,345.2	16.9
Balance, shares at Dec. 31, 2018		332,600,000
Implementation of new accounting pronouncements at Dec. 31, 2018	(22)				(22)
Adjusted Balance at Dec. 31, 2018	65,109			56,510	7,236.9	1,345.2	16.9
Comprehensive (loss):
Net (loss) attributable to shareholders	$ (4,167)
Repurchase of ordinary shares, shares	(5,300,000)
Balance at Jun. 30, 2019	$ 59,696.1			55,811.9	2,581.1	1,281.7	21.4
Balance, shares at Jun. 30, 2019		327,900,000
Balance at Mar. 31, 2019	61,559.6			55,742.8	4,582.8	1,216.4	17.6
Balance, shares at Mar. 31, 2019		327,800,000
Comprehensive (loss):
Net (loss) attributable to shareholders	(1,759)				(1,759)
Other comprehensive income, net of tax	65.3					65.3
Share-based compensation	59.5			59.5
Ordinary shares issued under employee stock plans	13.9			13.9
Ordinary shares issued under employee stock plans, shares		100,000
Dividends declared	(242.7)				(242.7)
Repurchase of ordinary shares	$ (4.3)			(4.3)
Repurchase of ordinary shares, shares	0
Movement in noncontrolling interest	$ 3.8						3.8
Balance at Jun. 30, 2019	$ 59,696.1			$ 55,811.9	$ 2,581.1	$ 1,281.7	$ 21.4
Balance, shares at Jun. 30, 2019		327,900,000

Consolidated Statements of Shar

Consolidated Statements of Shareholders' and Members' Equity - USD ($) $ in Millions	Total	Retained Earnings/(Accumulated Deficit) [Member]	Accumulated Other Comprehensive Income / (Loss) [Member]	Noncontrolling Interest [Member]	Warner Chilcott Limited [Member]	Warner Chilcott Limited [Member]Member's Capital [Member]	Warner Chilcott Limited [Member]Retained Earnings/(Accumulated Deficit) [Member]	Warner Chilcott Limited [Member]Accumulated Other Comprehensive Income / (Loss) [Member]	Warner Chilcott Limited [Member]Noncontrolling Interest [Member]
Balance at Dec. 31, 2017	$ 73,837.1	$ 12,957.2	$ 1,920.7	$ 16	$ 81,282.2	$ 72,935.1	$ 6,410.4	$ 1,920.7	$ 16
Balance, shares at Dec. 31, 2017						100
Implementation of new accounting pronouncements at Dec. 31, 2017	361.7	424.7	(63)		361.7		424.7	(63)
Adjusted Balance at Dec. 31, 2017	74,198.8	13,381.9	1,857.7	16	81,643.9	$ 72,935.1	6,835.1	1,857.7	16
Comprehensive (loss):
Net income (loss)attributable to shareholders					(231.3)		(231.3)
Other comprehensive income, net of tax	183.8		183.8		183.8			183.8
Dividends to Parents					(1,859.5)		(1,859.5)
Movement in noncontrolling interest	2.1			2.1	2.1				2.1
Balance at Mar. 31, 2018	72,346	12,799.5	2,041.5	18.1	79,739	$ 72,935.1	4,744.3	2,041.5	18.1
Balance, shares at Mar. 31, 2018						100
Balance at Dec. 31, 2017	73,837.1	12,957.2	1,920.7	16	81,282.2	$ 72,935.1	6,410.4	1,920.7	16
Balance, shares at Dec. 31, 2017						100
Implementation of new accounting pronouncements at Dec. 31, 2017	361.7	424.7	(63)		361.7		424.7	(63)
Adjusted Balance at Dec. 31, 2017	74,198.8	13,381.9	1,857.7	16	81,643.9	$ 72,935.1	6,835.1	1,857.7	16
Comprehensive (loss):
Net income (loss)attributable to shareholders					(603.7)
Balance at Jun. 30, 2018	71,264	12,082.9	1,592.9	20.5	78,676.2	$ 72,935.1	4,127.7	1,592.9	20.5
Balance, shares at Jun. 30, 2018						100
Balance at Mar. 31, 2018	72,346	12,799.5	2,041.5	18.1	79,739	$ 72,935.1	4,744.3	2,041.5	18.1
Balance, shares at Mar. 31, 2018						100
Comprehensive (loss):
Net income (loss)attributable to shareholders					(372.4)		(372.4)
Other comprehensive income, net of tax	(448.6)		(448.6)		(448.6)			(448.6)
Dividends to Parents					(244.2)		(244.2)
Movement in noncontrolling interest	2.4			2.4	2.4				2.4
Balance at Jun. 30, 2018	71,264	12,082.9	1,592.9	20.5	78,676.2	$ 72,935.1	4,127.7	1,592.9	20.5
Balance, shares at Jun. 30, 2018						100
Balance at Dec. 31, 2018	65,131	7,258.9	1,345.2	16.9	62,940.3	$ 65,797.9	(4,219.7)	1,345.2	16.9
Balance, shares at Dec. 31, 2018						100
Implementation of new accounting pronouncements at Dec. 31, 2018	(22)	(22)			(22)		(22)
Adjusted Balance at Dec. 31, 2018	65,109	7,236.9	1,345.2	16.9	62,918.3	$ 65,797.9	(4,241.7)	1,345.2	16.9
Comprehensive (loss):
Net income (loss)attributable to shareholders					(2,405.7)		(2,405.7)
Other comprehensive income, net of tax	(128.8)		(128.8)		(128.8)			(128.8)
Dividends to Parents					(1,045.8)	(1,045.8)
Movement in noncontrolling interest	0.7			0.7	0.7				0.7
Balance at Mar. 31, 2019	61,559.6	4,582.8	1,216.4	17.6	59,338.7	$ 64,752.1	(6,647.4)	1,216.4	17.6
Balance, shares at Mar. 31, 2019						100
Balance at Dec. 31, 2018	65,131	7,258.9	1,345.2	16.9	62,940.3	$ 65,797.9	(4,219.7)	1,345.2	16.9
Balance, shares at Dec. 31, 2018						100
Implementation of new accounting pronouncements at Dec. 31, 2018	(22)	(22)			(22)		(22)
Adjusted Balance at Dec. 31, 2018	65,109	7,236.9	1,345.2	16.9	62,918.3	$ 65,797.9	(4,241.7)	1,345.2	16.9
Comprehensive (loss):
Net income (loss)attributable to shareholders					(4,156.9)
Balance at Jun. 30, 2019	59,696.1	2,581.1	1,281.7	21.4	57,413.9	$ 64,509.4	(8,398.6)	1,281.7	21.4
Balance, shares at Jun. 30, 2019						100
Balance at Mar. 31, 2019	61,559.6	4,582.8	1,216.4	17.6	59,338.7	$ 64,752.1	(6,647.4)	1,216.4	17.6
Balance, shares at Mar. 31, 2019						100
Comprehensive (loss):
Net income (loss)attributable to shareholders					(1,751.2)		(1,751.2)
Other comprehensive income, net of tax	65.3		65.3		65.3			65.3
Dividends to Parents					(242.7)	$ (242.7)
Movement in noncontrolling interest	3.8			3.8	3.8				3.8
Balance at Jun. 30, 2019	$ 59,696.1	$ 2,581.1	$ 1,281.7	$ 21.4	$ 57,413.9	$ 64,509.4	$ (8,398.6)	$ 1,281.7	$ 21.4
Balance, shares at Jun. 30, 2019						100

General

General	6 Months Ended
	Jun. 30, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
General	NOTE 1 — General Allergan plc is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology. The Company has operations in more than 100 countries. Warner Chilcott Limited is an indirect wholly-owned subsidiary of Allergan plc and has the same principal business activities. The accompanying consolidated financial statements should be read in conjunction with the Company’s annual report on Form 10-K for the year ended December 31, 2018 (“Annual Report”). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with United States generally accepted accounting principles (“GAAP”) have been condensed or omitted from the accompanying consolidated financial statements. The accompanying year end consolidated balance sheet was derived from the audited financial statements included in the Annual Report. The accompanying interim financial statements are unaudited and reflect all adjustments which are in the opinion of management necessary for a fair statement of the Company’s consolidated financial position, results of operations, comprehensive (loss) / income and cash flows for the periods presented. All such adjustments are of a normal, recurring nature. All intercompany transactions and balances have been eliminated in consolidation. The Company’s results of operations, comprehensive (loss) / income and cash flows for the interim periods are not necessarily indicative of the results of operations, comprehensive (loss) / income and cash flows that it may achieve in future periods. References throughout to “we,” “our,” “us,” the “Company” or “Allergan” refer to financial information and transactions of Allergan plc. References to “Warner Chilcott Limited” refer to Warner Chilcott Limited, the Company’s indirect wholly-owned subsidiary, and, unless the context otherwise requires, its subsidiaries.

Reconciliation of Warner Chilco

Reconciliation of Warner Chilcott Limited Results to Allergan plc Results	6 Months Ended
	Jun. 30, 2019
Adjusted Earnings Before Interest Taxes Depreciation And Amortization And Other Non Cash Items [Abstract]
Reconciliation of Warner Chilcott Limited Results to Allergan plc Results	NOTE 2 — Reconciliation of Warner Chilcott Limited results to Allergan plc results Warner Chilcott Limited is an indirect wholly-owned subsidiary of Allergan plc, the ultimate parent of the group (together with other direct or indirect parents of Warner Chilcott Limited, the “Parents”). The results of Warner Chilcott Limited are consolidated into the results of Allergan plc. Due to the deminimis activity between Warner Chilcott Limited and the Parents (including Allergan plc), content throughout this filing relates to both Allergan plc and Warner Chilcott Limited. Warner Chilcott Limited disclosures relate only to itself and not to any other company. Except where otherwise indicated, and excluding certain insignificant cash and non-cash transactions at the Allergan plc level, these notes relate to the consolidated financial statements for both separate registrants, Allergan plc and Warner Chilcott Limited. In addition to certain inter-company payable and receivable amounts between the entities, the following is a reconciliation of the financial position and results of operations of Warner Chilcott Limited to Allergan plc ($ in millions): As of June 30, 2019 As of December 31, 2018 Allergan plc Warner Chilcott Limited Difference Allergan plc Warner Chilcott Limited Difference Cash and cash equivalents $ 1,651.4 $ 1,650.0 $ 1.4 $ 880.4 $ 878.6 $ 1.8 Prepaid expenses and other current assets 2,508.3 2,505.0 3.3 819.1 818.7 0.4 Accounts payable and accrued liabilities 4,995.3 4,995.2 0.1 4,787.2 4,787.4 (0.2 ) Income taxes payable 91.0 93.6 (2.6 ) 72.4 72.4 - Other taxes payable 1,667.0 1,660.8 6.2 1,615.5 1,615.5 - Deferred tax liabilities 4,968.4 4,968.5 (0.1 ) 5,501.8 5,501.8 - Total equity 59,696.1 57,413.9 2,282.2 65,131.0 62,940.3 2,190.7 Three Months Ended June 30, 2019 Six Months Ended June 30, 2019 Allergan plc Warner Chilcott Limited Difference Allergan plc Warner Chilcott Limited Difference General and administrative expenses $ 324.2 $ 316.4 $ 7.8 $ 632.5 $ 622.5 $ 10.0 Operating (loss) (1,262.9 ) (1,255.1 ) (7.8 ) (3,572.1 ) (3,562.1 ) (10.0 ) (Loss) before income taxes and noncontrolling interest (1,453.3 ) (1,445.5 ) (7.8 ) (3,929.2 ) (3,919.2 ) (10.0 ) Provision for income taxes 301.6 301.6 - 233.0 232.9 0.1 Net (loss) (1,754.9 ) (1,747.1 ) (7.8 ) (4,162.2 ) (4,152.1 ) (10.1 ) Net (loss) attributable to ordinary shareholders/members (1,759.0 ) (1,751.2 ) (7.8 ) (4,167.0 ) (4,156.9 ) (10.1 ) Three Months Ended June 30, 2018 Six Months Ended June 30, 2018 Allergan plc Warner Chilcott Limited Difference Allergan plc Warner Chilcott Limited Difference General and administrative expenses $ 334.1 $ 299.5 $ 34.6 $ 630.0 $ 593.6 $ 36.4 Operating (loss) (467.0 ) (432.4 ) (34.6 ) (1,121.0 ) (1,084.6 ) (36.4 ) Interest income 6.3 71.8 (65.5 ) 23.6 142.1 (118.5 ) (Loss) before income taxes and noncontrolling interest (475.3 ) (375.2 ) (100.1 ) (1,441.4 ) (1,286.5 ) (154.9 ) Net (loss) (470.1 ) (370.0 ) (100.1 ) (754.0 ) (599.1 ) (154.9 ) Dividends on preferred shares - - - 46.4 - 46.4 Net (loss) attributable to ordinary shareholders/members (472.5 ) (372.4 ) (100.1 ) (805.0 ) (603.7 ) (201.3 ) The differences between general and administrative expenses in the three and six months ended June 30, 2019 and 2018 were due to corporate related expenses incurred at Allergan plc. The differences in total equity were due to historical differences in the results of operations of the companies and differences in equity awards and dividends. During the three and six months ended June 30, 2018, the difference in interest income between Allergan plc and Warner Chilcott Limited was due to $5.8 billion and $4.0 billion in Receivables from the Parents and Non-current Receivables from the Parents, respectively. These Receivables were related to intercompany loans between Allergan plc and subsidiaries of Warner Chilcott Limited and caused a difference in interest income between the two entities in the prior year. These Receivables were contributed to the Parents during the year ended December 31, 2018 as an equity contribution and were reclassified from receivables to equity.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 3 — Summary of Significant Accounting Policies The following are interim updates to certain of the policies described in “Note 4” of the notes to the Company’s audited consolidated financial statements for the year ended December 31, 2018 included in the Annual Report. Implementation of New Guidance In February 2016, the Financial Accounting Standards Board (“FASB”) established Topic 842, Leases, by issuing Accounting Standards Update (“ASU”) No. 2016-02, which requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842; ASU No. 2018-10, Codification Improvements to Topic 842, Leases; and ASU No. 2018-11, Targeted Improvements. The new standard establishes a right-of-use model (“ROU”) that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. On January 1, 2019, the Company adopted the new standard using the modified retrospective transition approach applied to all leases existing at the effective date of initial application of January 1, 2019. Prior period amounts are not adjusted and continue to be reported in accordance with historical accounting practices and the disclosures under the new standard are not required for dates and periods prior to January 1, 2019. When evaluating whether a contract contains a lease under the new standard, Allergan considers whether (1) the contract explicitly or implicitly identifies assets that are contractually defined and (2) the Company obtains substantially all of the economic benefits from the use of that underlying asset and directs how and for what purpose the asset is used during the term of the contract. The Company does not have the right to use an identified asset if the supplier has the substantive right to substitute the asset throughout the period without the Company’s approval. The new standard provides a number of optional practical expedients in transition. The Company elected the ‘package of practical expedients’ which permits us not to reassess our prior conclusions about lease identification, lease classification and initial direct costs under the new standard. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter was not applicable to the Company. This standard has a significant impact on our consolidated balance sheet but did not have a significant impact on our consolidated statements of operations. The most significant effects relate to the recognition of ROU assets and lease liabilities on our balance sheet for our real estate and fleet operating leases. Upon adoption, the Company recognized lease liabilities and corresponding ROU assets as follows ($ in millions): ROU Asset Lease Liability Real estate $ 304.2 $ 370.6 Fleet 100.4 100.4 Other 57.5 77.6 Total operating leases $ 462.1 $ 548.6 The cumulative effective adjustment as of the effective date of $22.0 million was recorded to opening retained earnings. The Company has an immaterial amount of finance leases. The new standard also provides practical expedients for an entity’s ongoing accounting. The Company elected the lease recognition exemption for all leases with lease terms of 12 months or less. For leases that qualify under this exception, the Company will not recognize ROU assets or lease liabilities and did not recognize ROU assets or lease liabilities for existing short-term leases of those assets in transition. The Company also elected the practical expedient to not separate lease and non-lease components for leases of real estate, fleet, IT and office equipment. Refer to “NOTE 13 – Leases” for further information related to the Company’s leases. In February 2018, the FASB issued ASU No. 2018-02, Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. This update allows for the optional reclassification of stranded tax effects resulting from the Tax Cuts and Jobs Act (“TCJA”) from accumulated other comprehensive income to retained earnings. The amount of the reclassification is calculated as the difference between the historical and newly enacted tax rates on deferred taxes originally recorded through accumulated other comprehensive income. The Company adopted the standard as of January 1, 2019; however, due to the immaterial amount of the stranded tax effects, the Company elected not to reclassify the income tax effects from accumulated other comprehensive income to retained earnings. Tax effects unrelated to the TCJA are released from accumulated other comprehensive income using either the specific identification approach or the portfolio approach based on the nature of the underlying item. The Company adopted ASU 2016-01, Financial Instruments on January 1, 2018. The new standard required modified retrospective adoption through 2018 beginning Retained Earnings and Accumulated Other Comprehensive Income. This was incorrectly recorded as a loss through Other Comprehensive Income of $63.0 million during the quarter ended March 31, 2018. This was corrected during 2018 and therefore, has no impact on the annual consolidated financial statements. The Company has determined that the adjustment was not material to any previously reported interim period. The Consolidated Statement of Comprehensive (Loss) for the six months ended , 2018 has been adjusted to correct for this error. Revenue Recognition General ASU No. 2014-09, “Revenue from Contracts with Customers” (“Topic 606”) provides that revenues are recognized when control of the promised goods under a contract is transferred to a customer, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods as specified in the underlying terms with the customer. The Company warrants products against defects and for specific quality standards, permitting the return of products under certain circumstances. Product sales are recorded net of all sales-related deductions including, but not limited to: chargebacks, trade discounts, commercial and government rebates, customer loyalty programs, fee-for-service arrangements with certain distributors, returns, and other allowances which we refer to in the aggregate as sales returns and allowances (“SRA”). The Company’s performance obligations are primarily achieved when control of the products is transferred to the customer. Transfer of control is based on contractual performance obligations, but typically occurs upon receipt of the goods by the customer as that is when the customer has obtained control of significantly all of the economic benefits . Refer to “NOTE 8 – Reportable Segments” for our revenues disaggregated by product and segment and our revenues disaggregated by geography for our international segment. We believe this level of disaggregation best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. The following table summarizes the activity from operations in the Company’s major categories of SRA ($ in millions): Chargebacks Rebates Returns and Other Allowances Cash Discounts Total Balance at December 31, 2018 $ 61.8 $ 1,908.5 $ 566.6 $ 30.7 $ 2,567.6 Provision related to sales in 2019 553.2 2,876.3 835.8 159.2 4,424.5 Credits and payments (545.1 ) (2,769.3 ) (781.5 ) (156.9 ) (4,252.8 ) Balance at June 30, 2019 $ 69.9 $ 2,015.5 $ 620.9 $ 33.0 $ 2,739.3 Contra accounts receivable at June 30, 2019 $ 69.9 $ 81.1 $ 34.6 $ 33.0 $ 218.6 Accounts payable and accrued expenses at June 30, 2019 $ - $ 1,934.4 $ 586.3 $ - $ 2,520.7 The following table summarizes the balance sheet classification of our SRA reserves ($ in millions): June 30, 2019 December 31, 2018 Contra accounts receivable $ 218.6 $ 207.7 Accounts payable and accrued expenses 2,520.7 2,359.9 Total $ 2,739.3 $ 2,567.6 The SRA provisions recorded to reduce gross product sales to net product sales were as follows ($ in millions): Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Gross product sales $ 6,295.6 $ 6,095.5 $ 11,955.5 $ 11,711.6 Provisions to reduce gross product sales to net product sales (2,284.8 ) (2,087.3 ) (4,424.5 ) (4,122.4 ) Net product sales $ 4,010.8 $ 4,008.2 $ 7,531.0 $ 7,589.2 Percentage of SRA provisions to gross sales 36.3 % 34.2 % 37.0 % 35.2 % Collectability Assessment At the time of contract inception or customer account set-up, the Company performs a collectability assessment on the creditworthiness of such customer. The Company assesses the probability that the Company will collect the consideration to which it will be entitled in exchange for the goods sold. In evaluating collectability, the Company considers the customer’s ability and intention to pay consideration when it is due. On a recurring basis, the Company estimates the amount of receivables considered uncollectible after sale to the customer to reflect allowances for doubtful accounts. Provision for bad debts, included in general and administrative expenses, were $3.9 million and $4.0 million in the three months ended June 30, 2019 and 2018, respectively. Provision for bad debts, included in general and administrative expenses, were $7.3 million and $14.1 million in the six months ended June 30, 2019 and 2018, respectively. Goodwill and Intangible Assets with Indefinite Lives General The Company tests goodwill and intangible assets with indefinite lives for impairment annually in the second quarter. Additionally, the Company may perform interim tests if an event occurs or circumstances change that could potentially reduce the fair value of a reporting unit or an indefinite lived intangible asset below its carrying amount. The carrying value of each reporting unit is determined by assigning the assets and liabilities, including the existing goodwill and intangible assets, to those reporting units. The Company tests goodwill for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation is an assessment of factors, including Reporting Unit specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of a Reporting Unit is less than its carrying amount, including goodwill. The Company may elect to bypass this qualitative assessment for some or all of its Reporting Units and perform a quantitative test as of the measurement date of the test . Goodwill is considered impaired if the carrying amount of the net assets exceeds the fair value of the reporting unit. Impairment, if any, would be recorded in operating income / (loss) and this could result in a material impact to net income / (loss) and income / (loss) per share. Prior to Allergan’s 2018 annual impairment test, the Company adopted the new guidance under Accounting Standard Update No. 2017-04, Intangibles – Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment Acquired in-process research and development (“IPR&D”) intangible assets represent the value assigned to research and development projects acquired in a business combination that, as of the date acquired, represent the right to develop, use, sell and/or offer for sale a product or other intellectual property that has not been completed or approved. The IPR&D intangible assets are subject to impairment testing until completion or abandonment of each project. Upon abandonment, the assets are impaired if there is no future alternative use or ability to sell the asset. Impairment testing requires the development of significant estimates and assumptions involving the determination of estimated net cash flows for each year for each project or product (including net revenues, cost of sales, research and development (“R&D”) costs, probability of success of development projects, selling and marketing costs and other costs which may be allocated), determination of the appropriate discount rate in order to measure the risk inherent in each future cash flow stream, assessment of each asset’s life cycle, potential regulatory and commercial success risks, and competitive trends impacting the asset and each cash flow stream as well as other factors. The major risks and uncertainties associated with the timely and successful completion of IPR&D projects include legal risk, market risk and regulatory risk. Changes in our assumptions could result in future impairment charges. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change or the timely completion of each project and commercial success will occur. For these and other reasons, actual results may vary significantly from estimated results. Upon successful completion of each project and approval of a product, we will make a separate determination of the useful life of the intangible asset, transfer the amount to currently marketed products (“CMP”) and amortization expense will be recorded over the estimated useful life. Refer to “NOTE 11 –Goodwill, Product Rights, and Other Intangible Assets” for further discussion on the Company’s goodwill and intangible assets balances and impairments. Earnings Per Share (“EPS”) The Company computes EPS in accordance with Accounting Standards Codification (“ASC”) Topic 260, “Earnings Per Share” (“ASC 260”) and related guidance, which requires two calculations of EPS to be disclosed: basic and diluted. Basic EPS is computed by dividing net (loss) by the weighted average ordinary shares outstanding during a period. Diluted EPS is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and restricted stock units. Ordinary share equivalents have been excluded where their inclusion would be anti-dilutive. A reconciliation of the numerators and denominators of basic and diluted EPS follows ($ in millions, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Net (loss): Net (loss) attributable to ordinary shareholders $ (1,759.0 ) $ (472.5 ) $ (4,167.0 ) $ (805.0 ) Basic weighted average ordinary shares outstanding 327.8 339.1 329.9 336.9 Basic EPS: Net (loss) per share $ (5.37 ) $ (1.39 ) $ (12.63 ) $ (2.39 ) Dividends per ordinary share $ 0.74 $ 0.72 $ 1.48 $ 1.44 Diluted weighted average ordinary shares outstanding 327.8 339.1 329.9 336.9 Diluted EPS: Net (loss) per share $ (5.37 ) $ (1.39 ) $ (12.63 ) $ (2.39 ) Stock awards to purchase 1.6 million and 1.8 million ordinary shares for the three and six months ended June 30, 2019, respectively, were outstanding, but not included in the computation of diluted EPS, because the awards were anti-dilutive. No shares were repurchased in the three months ended June 30, 2019. The impact of the 5.3 million shares repurchased in the six months ended June 30, 2019 on basic EPS was 3.0 million weighted average shares. Stock awards to purchase 2.2 million ordinary shares for the three and six months ended June 30, 2018 were outstanding, but not included in the computation of diluted EPS, because the awards were anti-dilutive. The Company’s preferred shares were mandatorily converted to ordinary shares on March 1, 2018. The weighted average impact of ordinary share equivalents of 5.8 million for the six months ended June 30, 2018, which would result from the mandatory conversion of the Company’s preferred shares at the beginning of the period, were not included in the calculation of diluted EPS as their impact would be anti-dilutive. Refer to “NOTE 16 –Shareholders’ Equity” for further discussion on the Company’s share repurchase programs. Research and Development Activities Research and development (“R&D”) activities are expensed as incurred and consist of self-funded R&D costs, the costs associated with work performed under collaborative R&D agreements, regulatory fees, and acquisition and license related milestone payments, if any. As of June 30, 2019, we are developing a number of products, some of which utilize novel drug delivery systems, through a combination of internal and collaborative programs, and we additionally have products in development as part of our life-cycle management strategy for our existing product portfolio. These development projects include but are not limited to the following: Product Therapeutic Area Indication Expected Launch Year Phase Cariprazine Central Nervous System Bipolar Depression 2019 Approved Ubrogepant Central Nervous System Acute Migraine 2020 Review Bimatoprost SR Eye Care Glaucoma 2020 Review Abicipar Eye Care Age Related Macular Degeneration 2020 III Atogepant Central Nervous System Prophylaxis Migraine 2021 III Presbysol Eye Care Presbyopia 2021 III Cenicriviroc Gastrointestinal NASH 2022 III Relamorelin Gastrointestinal Gastroparesis 2023 III Brimonidine DDS Eye Care Geographic Atrophy 2023 II Botox Medical Aesthetics Platysma/Masseter 2025/2024 II Abicipar Eye Care Diabetic Macular Edema 2025 II Brazikumab Gastrointestinal Crohn's Disease 2025 II Brazikumab Gastrointestinal Ulcerative Colitis 2026 II Recent Accounting Pronouncements In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606. The ASU provides more comparability in the presentation of revenue for certain transactions between collaborative arrangement participants and only allows a company to present units of account in collaborative arrangements that are within the scope of the revenue recognition standard together with revenue accounted for under the revenue recognition standard. The parts of the collaborative arrangement that are not in the scope of the revenue recognition standard should be presented separately from revenue accounted for under the revenue recognition standard. The amendments in ASU No. 2018-18 are effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company is evaluating the impact, if any, that this pronouncement will have on our financial position and results of operations. In August 2018, the FASB issued ASU No. 2018-15, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40), relating to a customer's accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement that is hosted by a vendor (i.e., a service contract). Under the new guidance, a customer will apply the same criteria for capitalizing implementation costs as it would for an arrangement that has a software license. The new guidance also prescribes the balance sheet, income statement, and cash flow classification of the capitalized implementation costs and related amortization expense, and requires additional quantitative and qualitative disclosures. The ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early application is permitted. The Company can choose to adopt the new guidance (1) prospectively to eligible costs incurred on or after the date this guidance is first applied or (2) retrospectively. The Company is evaluating the impact, if any, that this pronouncement will have on our financial position and results of operations. In August 2018, the FASB issued ASU No. 2018-14, Compensation - Retirement Benefits - Defined Benefit Plans - General (Subtopic 715-20) – Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans, which amends ASC 715 to add, remove, and clarify disclosure requirements related to defined benefit pension and other postretirement plans. The revisions to the disclosure requirements affect only the year-end financial statements of plan sponsors, as there are no changes related to interim financial statements. The ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early application is permitted. The ASU provisions will be applied on a retrospective basis to all periods presented. This pronouncement only has an impact to disclosure requirements and does not have an impact on our financial position or results of operations. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, which removes, adds and modifies certain disclosure requirements for fair value measurements The Company will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, and the valuation processes of Level 3 fair value measurements. However, the Company will be required to additionally disclose the changes in unrealized gains and losses included in other comprehensive income for recurring Level 3 fair value measurements, and the range and weighted average of assumptions used to develop significant unobservable inputs for Level 3 fair value measurements. permitted to early adopt either the entire ASU or only the provisions that eliminate or modify the requirements.

Buisness Transactions

Buisness Transactions	6 Months Ended
	Jun. 30, 2019
Business Combinations [Abstract]
Buisness Transactions	NOTE 4 — Business Transactions 2019 Transactions The following are the significant transactions that were completed or announced in the six months ended June 30, 2019. AbbVie Inc. On June 25, 2019, the Company announced that it entered into a transaction agreement (the “AbbVie Agreement”) under which AbbVie Inc. (“AbbVie”), a global, research-driven biopharmaceutical company, would acquire Allergan plc in a stock and cash transaction (the “AbbVie Transaction”), valued at $188.24 per Allergan share, or approximately $63.0 billion, based on AbbVie’s then-current stock price at the time the AbbVie Transaction was announced. At the closing of the proposed AbbVie Transaction, Company shareholders will receive 0.8660 shares of AbbVie common stock and $120.30 in cash for each of their existing shares. The AbbVie Transaction is subject to customary regulatory and shareholder approvals and other customary closing conditions. The AbbVie Transaction is anticipated to close in early 2020. Envy Medical, Inc. On March 26, 2019, the Company acquired Envy Medical, Inc. (“Envy”), a privately held medical aesthetics company that specializes in non-surgical, non-invasive skin resurfacing systems for an acquisition accounting purchase price of $81.4 million, which includes $67.4 million of product rights and other intangibles, $34.1 million of goodwill and other assets and liabilities. The transaction was treated as a business combination. The acquisition combines Envy’s skin care product portfolio with the Company’s leading medical aesthetics business.

Assets Held for Sale

Assets Held for Sale	6 Months Ended
	Jun. 30, 2019
Assets Held For Sale Not Part Of Disposal Group [Abstract]
Assets Held for Sale	NOTE 5 — Assets Held for Sale The following represents the assets held for sale ($ in millions): June 30, December 31, 2019 2018 Assets held for sale: Inventories $ - $ 34.0 Property, plant and equipment, net 32.5 32.8 Product rights and other intangibles - 849.4 Total assets held for sale $ 32.5 $ 916.2 As of December 31, 2018, the Company had concluded that its Anti-Infectives business met the criteria for held for sale based on management’s intent and ability to divest the business within the next twelve months. Assets held for sale also include miscellaneous properties. As of June 30, 2019, and as a result of the proposed AbbVie Transaction, the Company concluded that the Anti-Infectives business no longer met the criteria for held for sale. The Anti-Infectives intangible assets and inventory were reclassified to held in use at the lower of their carrying amount before the asset was recorded as held for sale less any amortization that would have been recognized had the asset been continuously classified as held and used or their fair value at the date of the subsequent decision not to sell. As a result of the reclassification, the Company recorded a charge of $129.6 million, primarily related to amortization that would have been recorded if the assets were held and used, within Assets, sales and impairments, net for the six month period the assets were held for sale.

Other (Expense) _ Income

Other (Expense) / Income	6 Months Ended
	Jun. 30, 2019
Other Income And Expenses [Abstract]
Other (Expense) / Income	NOTE 6 – Other (Expense) / Income Other (expense) / income, net consisted of the following ($ in millions): Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Teva Share Activity $ - $ 138.6 $ - $ 60.9 Sales of business - 53.0 - 53.0 Debt extinguishment other 0.1 9.1 (0.2 ) 9.1 Other (expense) / income, net (4.8 ) 14.7 9.3 13.6 Other (expense) / income, net $ (4.7 ) $ 215.4 $ 9.1 $ 136.6 Teva Share Activity During the three and six months ended June 30, 2018, the Company recorded the following movements in its investment in Teva securities (“Teva Share Activity”) ($ in millions except per share information): Shares Carrying Value per Share Market Price Proceeds Received Value of Marketable Securities Unrealized Gain / (Loss) as a Component of Other Comprehensive Income Gain / (Loss) Recognized in Other Income/ (Expense), Net Derivative Instrument (Liability)/ Asset Retained Earnings Teva securities as of December 31, 2017 95.9 $ 17.60 $ 18.95 n.a. $ 1,817.7 $ 129.3 $ - $ (62.9 ) $ - Impact of ASU No. 2016-01 - - - - - (129.3 ) - - 129.3 Settlement of initial accelerated share repurchase ("ASR"), net (25.0 ) 18.95 16.53 * 413.3 (473.8 ) - 2.5 62.9 - Forward sale entered into during the three months ended March 31, 2018 ** n.a. n.a. 372.3 n.a. - 19.0 (353.3 ) - Open market sales (11.5 ) n.a. 19.95 229.9 (218.5 ) - 11.5 - - Other fair value movements during the three months ended March 31, 2018 - n.a. n.a. n.a. (110.7 ) - (110.7 ) - - Teva securities as of and for the three months ended March 31, 2018 59.4 $ 17.09 $ 17.09 $ 1,015.5 $ 1,014.7 $ - $ (77.7 ) $ (353.3 ) $ 129.3 Settlement of forward sale entered into during the three months ended March 31, 2018, net (25.0 ) 17.09 18.61 *** 93.2 (427.3 ) - 19.2 353.3 - Open market sales (34.4 ) n.a. 20.55 706.8 (587.4 ) - 119.4 - - Teva securities as of and for the six months ended June 30, 2018 - $ - $ - $ 1,815.5 $ - $ - $ 60.9 $ - $ 129.3 * Market price represented average price over the life of the contract. On the January 17, 2018 settlement date, the closing stock price of Teva securities was $21.48. ** On February 13, 2018, the Company entered into a forward sale transaction under which we delivered 25.0 million Teva shares to the transaction counterparty and received proceeds of $372.3 million in exchange for the shares. The forward sale transaction settled during the second quarter of 2018. As a result of the transaction, and in accordance with ASC Topic 860 - Transfers and Servicing, the marketable securities were reported on the Company's balance sheet until the contract settled on May 7, 2018. ***Market price represented average price over the life of the contract. On the May 7, 2018 settlement date, the closing stock price of Teva securities was $18.62. Sale of Business During the three and six months ended June 30, 2018, the Company completed the sale of a non-strategic asset group held for sale as of December 31, 2017, which was deemed a business based on the applicable guidance at the time, for $55.0 million in cash plus deferred consideration of $20.0 million. As a result of this transaction, the Company recognized a gain of $53.0 million. Debt Extinguishment Other During the three and six months ended June 30, 2019, the Company repurchased $97.8 million and $249.8 million, respectively, of senior notes in the open market. The net gain / (loss) on the debt extinguishments was not material. During the three and six months ended June 30, 2018, the Company repurchased $455.9 million of senior notes in the open market. As a result of the debt extinguishment, the Company recognized a net gain of $9.1 million, within “Other income / (expense)” for the cash discount received of $13.1 million, including the non-cash write-off of premiums and debt fees related to the repaid notes of $4.0 million. During the three and six months ended June 30, 2019 and 2018, the Company redeemed and retired the following senior notes ($ in millions): Three Months Ended June 30, 2019 Six Months Ended June 30, 2019 Tranche Face Value Retired Cash Paid for Retirement Face Value Retired Cash Paid for Retirement Remaining Value at June 30, 2019 3.000% due 2020 $ 97.8 $ 97.8 $ 180.7 $ 180.7 $ 2,526.0 3.450% due 2022 - - 62.3 62.3 2,878.2 3.800% due 2025 - - 6.8 6.8 3,020.7 Total $ 97.8 $ 97.8 $ 249.8 $ 249.8 $ 8,424.9 Three and Six Months Ended June 30, 2018 Tranche Face Value Retired Cash Paid for Retirement Remaining Value at June 30, 2018 2.450% due 2019 $ 8.8 $ 8.8 $ 491.2 3.000% due 2020 40.7 40.6 3,459.3 3.450% due 2022 59.5 58.6 2,940.5 3.850% due 2024 11.2 10.9 1,188.8 3.800% due 2025 85.0 82.6 3,915.0 4.550% due 2035 115.0 110.1 2,385.0 4.850% due 2044 59.0 57.3 1,441.0 4.750% due 2045 76.7 73.9 1,123.3 Total $ 455.9 $ 442.8 $ 16,944.1 Other (Expense) / Income, Net Other (expense) / income, net includes the mark to market losses of $7.2 million and gains of $3.2 million, respectively, on equity securities held by the Company during the three and six months ended June 30, 2019.

Share-Based Compensation

Share-Based Compensation	6 Months Ended
	Jun. 30, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-Based Compensation	NOTE 7 — Share-Based Compensation The Company recognizes compensation expense for all share-based compensation awards made to employees and directors based on the fair value of the awards on the date of grant. The Company grants awards with the following features: • Time-based restricted stock and restricted stock unit awards (including, in certain foreign jurisdictions, cash-settled restricted stock unit awards, which are recorded as a liability); • Performance-based restricted stock unit awards measured against performance-based targets defined by the Company, including, but not limited to, total shareholder return metrics and R&D milestones, as defined by the Company; and • Non-qualified options to purchase outstanding shares. The Company recognizes share-based compensation expense for granted awards over the applicable vesting period. Fair Value Assumptions All restricted stock and restricted stock units (whether time-based or performance-based) are granted and expensed using the fair value per share on the applicable grant date, over the applicable vesting period. Non-qualified options to purchase ordinary shares are granted to employees at exercise prices per share equal to the closing market price per share on the date of grant. The fair value of non-qualified options is determined on the applicable grant dates using the Black-Scholes method of valuation and that amount is recognized as an expense over the vesting period. Using the Black-Scholes valuation model, the fair value of options is based on the following assumptions: 2019 Grants 2018 Grants Dividend yield 1.7 - 1.8% 1.5% Expected volatility 26.4% 27.0% Risk-free interest rate 1.9% 2.2 - 2.9% Expected term (years) 7.0 7.0 Share-Based Compensation Expense Share-based compensation expense recognized in the Company’s results of operations for the three and six months ended June 30, 2019 and 2018 was as follows ($ in millions): Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Equity-based compensation awards $ 59.5 $ 54.9 $ 111.8 $ 127.4 Total share-based compensation expense $ 59.5 $ 54.9 $ 111.8 $ 127.4 Unrecognized future share-based compensation expense was $409.1 million as of June 30, 2019. This amount will be recognized as an expense over a remaining weighted average period of 1.7 years. Share-based compensation is being amortized and charged to operations over the same period as the restrictions are eliminated for the participants, which is generally on a straight-line basis. Share Activity The following is a summary of equity award activity for unvested restricted stock and stock units in the period from December 31, 2018 through June 30, 2019 (in millions, except per share data): Shares Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (Years) Aggregate Grant Date Fair Value Restricted shares / units outstanding at December 31, 2018 2.5 $ 190.27 1.6 $ 472.9 Granted 1.5 139.83 207.8 Vested (0.7 ) 209.91 (138.8 ) Forfeited (0.1 ) 177.79 (19.3 ) Restricted shares / units outstanding at June 30, 2019 3.2 $ 161.46 1.8 $ 522.6 The following is a summary of equity award activity for non-qualified options to purchase ordinary shares in the period from December 31, 2018 through June 30, 2019 (in millions, except per share data): Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding, vested and expected to vest at December 31, 2018 6.3 $ 122.74 4.4 $ 69.0 Granted 0.3 140.29 Exercised (0.3 ) 82.45 Cancelled (0.1 ) 217.07 Outstanding, vested and expected to vest at June 30, 2019 6.2 $ 124.78 4.3 $ 265.2 The increase in the aggregate intrinsic value of the options is primarily related to an increase in the Company’s stock from $133.66 as of December 31, 2018 to $167.43 as of June 30, 2019.

Reportable Segments

Reportable Segments	6 Months Ended
	Jun. 30, 2019
Segment Reporting [Abstract]
Reportable Segments	NOTE 8 — Reportable Segments The Company’s businesses are organized into the following segments: US Specialized Therapeutics, US General Medicine and International. In addition, certain revenues and shared costs, and the results of corporate initiatives, are managed outside of the three segments. During the second quarter of 2019, the Company changed the operational and management structure for its in-development calcitonin gene-related peptide (“CGRP”) receptors, Ubrogepant and Atogepant. These development products were previously reported within the US Specialized Therapeutics segment and have been transferred to the US General Medicine segment to align these development products with the management structure and reporting. The revenues and cost of sales related to these products in the prior periods were zero and any selling and marketing expenses and general and administrative expenses were de minimis and therefore it was not necessary to recast prior periods. The operating segments are organized as follows: • The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the U.S., including Medical Aesthetics, Medical Dermatology through September 20, 2018, Eye Care and Neuroscience and Urology therapeutic products. • The US General Medicine segment includes sales and expenses relating to branded products within the U.S. that do not fall into the US Specialized Therapeutics business units, including Central Nervous System, Gastrointestinal, Women’s Health, Anti-Infectives and Diversified Brands. • The International segment includes sales and expenses relating to products sold outside the U.S. The Company evaluates segment performance based on segment contribution. Segment contribution for our segments represents net revenues less cost of sales (defined below), selling and marketing expenses, and select general and administrative expenses. The Company does not evaluate the following items at the segment level: • Revenues and operating expenses within cost of sales, selling and marketing expenses, and general and administrative expenses that result from the impact of corporate initiatives. Corporate initiatives primarily include integration, restructuring, divestitures, acquisitions, certain milestones and other shared costs. • General and administrative expenses that result from shared infrastructure, including certain expenses located within the United States. • Other select revenues and operating expenses including R&D expenses, amortization, IPR&D impairments, goodwill impairments and asset sales and impairments, net as not all such information has been accounted for at the segment level, or such information has not been used by all segments. • Total assets including capital expenditures. The Company defines segment net revenues as product sales and other revenue derived from our products or licensing agreements. Cost of sales within segment contribution includes standard production and packaging costs for the products we manufacture, third party acquisition costs for products manufactured by others, profit-sharing or royalty payments for products sold pursuant to licensing agreements and finished goods inventory reserve charges. Cost of sales within segment contribution excludes non-standard production costs, such as non-finished goods inventory obsolescence charges, manufacturing variances and excess capacity utilization charges, where applicable. Cost of sales does not include amortization or impairment costs for acquired product rights or other acquired intangibles. Selling and marketing expenses consist mainly of personnel-related costs, product promotion costs, distribution costs, professional service costs, insurance, depreciation and travel costs. General and administrative expenses consist mainly of personnel-related costs, facilities costs, transaction costs, insurance, depreciation, litigation costs and professional services costs which are general in nature and attributable to the segment. Segment net revenues, segment operating expenses and segment contribution information consisted of the following for the three and six months ended June 30, 2019 and 2018 ($ in millions): Three Months Ended June 30, 2019 US Specialized Therapeutics US General Medicine International Total Net revenues $ 1,785.1 $ 1,455.7 $ 847.7 $ 4,088.5 Operating expenses: Cost of sales (1) 151.0 231.3 145.6 527.9 Selling and marketing 368.0 250.1 253.6 871.7 General and administrative 37.6 30.4 28.4 96.4 Segment contribution $ 1,228.5 $ 943.9 $ 420.1 $ 2,592.5 Contribution margin 68.8 % 64.8 % 49.6 % 63.4 % Corporate (2) 352.2 Research and development 450.0 Amortization 1,402.0 Goodwill impairments 1,085.8 In-process research and development impairments 436.0 Asset sales and impairments, net 129.4 Operating (loss) $ (1,262.9 ) Operating margin (30.9 )% (1) (2) Six Months Ended June 30, 2019 US Specialized Therapeutics US General Medicine International Total Net revenues $ 3,328.0 $ 2,705.6 $ 1,649.2 $ 7,682.8 Operating expenses: Cost of sales (1) 271.1 421.8 255.3 948.2 Selling and marketing 724.8 460.6 491.2 1,676.6 General and administrative 92.2 74.2 54.1 220.5 Segment contribution $ 2,239.9 $ 1,749.0 $ 848.6 $ 4,837.5 Contribution margin 67.3 % 64.6 % 51.5 % 63.0 % Corporate (2) 610.2 Research and development 885.0 Amortization 2,801.4 Goodwill impairments 3,552.8 In-process research and development impairments 436.0 Asset sales and impairments, net 124.2 Operating (loss) $ (3,572.1 ) Operating margin (46.5 )% (1) (2) Three Months Ended June 30, 2018 US Specialized Therapeutics US General Medicine International Total Net revenues $ 1,826.7 $ 1,320.0 $ 948.9 $ 4,095.6 Operating expenses: Cost of sales (1) 148.7 201.8 139.4 489.9 Selling and marketing 343.3 254.8 246.2 844.3 General and administrative 48.1 34.7 33.9 116.7 Segment contribution $ 1,286.6 $ 828.7 $ 529.4 $ 2,644.7 Contribution margin 70.4 % 62.8 % 55.8 % 64.6 % Corporate (2) 189.8 Research and development 689.2 Amortization 1,697.1 In-process research and development impairments 276.0 Asset sales and impairments, net 259.6 Operating (loss) $ (467.0 ) Operating margin (11.4 )% (1) (2) Six Months Ended June 30, 2018 US Specialized Therapeutics US General Medicine International Total Net revenues $ 3,405.3 $ 2,543.7 $ 1,812.9 $ 7,761.9 Operating expenses: Cost of sales (1) 282.9 384.4 260.3 927.6 Selling and marketing 656.5 480.3 491.9 1,628.7 General and administrative 98.3 73.6 65.3 237.2 Segment contribution $ 2,367.6 $ 1,605.4 $ 995.4 $ 4,968.4 Contribution margin 69.5 % 63.1 % 54.9 % 64.0 % Corporate (2) 460.1 Research and development 1,163.9 Amortization 3,394.7 In-process research and development impairments 798.0 Asset sales and impairments, net 272.7 Operating (loss) $ (1,121.0 ) Operating margin (14.4 )% (1) (2) The following table presents our net revenue disaggregated by geography for our international segment for the three and six months ended June 30, 2019 and 2018 ($ in millions): Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Europe $ 386.2 $ 413.3 $ 740.6 $ 811.7 Asia Pacific, Middle East and Africa 261.5 283.6 512.2 524.4 Latin America and Canada 182.1 230.8 360.3 442.9 Other* 17.9 21.2 36.1 33.9 Total International $ 847.7 $ 948.9 $ 1,649.2 $ 1,812.9 *Includes royalty and other revenue The following tables present global net revenues for the top products greater than 10% of total revenues of the Company as well as a reconciliation of segment revenues to total net revenues for the three and six months ended June 30, 2019 and 2018 ($ in millions): Three Months Ended June 30, 2019 US Specialized Therapeutics US General Medicine International Total Botox ® $ 699.4 $ - $ 274.6 $ 974.0 Juvederm ® 156.6 - 172.7 329.3 Restasis ® 310.9 - 11.9 322.8 Linzess ® ® - 196.0 4.8 200.8 Vraylar ® - 196.1 - 196.1 Lumigan ® ® 62.1 - 90.4 152.5 Bystolic ® ® - 150.5 0.5 151.0 Lo Loestrin ® - 145.5 - 145.5 Alphagan ® ® 91.6 - 40.9 132.5 Eye Drops 57.8 - 57.3 115.1 Ozurdex ® 29.9 - 81.0 110.9 Viibryd ® ® - 107.8 2.7 110.5 Alloderm ® 101.2 - 2.2 103.4 Coolsculpting ® 60.7 - 20.3 81.0 Zenpep ® - 70.0 - 70.0 Carafate ® ® - 56.2 0.7 56.9 Armour Thyroid - 56.7 - 56.7 Viberzi ® - 50.8 0.3 51.1 Skin Care 42.6 - 3.7 46.3 Asacol ® ® - 31.6 9.7 41.3 Teflaro ® - 37.0 - 37.0 Breast Implants 67.6 - (31.4 ) 36.2 Saphris ® - 32.6 - 32.6 Coolsculpting ® 18.2 - 11.6 29.8 Avycaz ® - 26.7 - 26.7 Namzaric ® - 22.6 - 22.6 Dalvance ® - 20.3 2.2 22.5 Savella ® - 22.3 - 22.3 Liletta ® - 21.9 - 21.9 Canasa ® ® - 8.0 4.1 12.1 Kybella ® ® 8.5 - 0.6 9.1 Namenda ® - 6.1 - 6.1 Rapaflo ® 4.5 - 1.4 5.9 Aczone ® 1.8 - - 1.8 Other 71.7 197.0 85.5 354.2 Total segment revenues $ 1,785.1 $ 1,455.7 $ 847.7 $ 4,088.5 Corporate revenues 1.6 Total net revenues $ 4,090.1 Six Months Ended June 30, 2019 US Specialized Therapeutics US General Medicine International Total Botox ® $ 1,326.5 $ - $ 515.9 $ 1,842.4 Juvederm ® 286.3 - 330.5 616.8 Restasis ® 542.6 - 22.3 564.9 Linzess ® ® - 357.3 10.3 367.6 Vraylar ® - 339.8 - 339.8 Lumigan ® ® 119.8 - 175.5 295.3 Bystolic ® ® - 278.8 0.9 279.7 Lo Loestrin ® - 271.3 - 271.3 Alphagan ® ® 174.6 - 78.5 253.1 Eye Drops 107.2 - 112.7 219.9 Ozurdex ® 60.2 - 144.1 204.3 Alloderm ® 196.2 - 3.8 200.0 Viibryd ® ® - 192.8 4.8 197.6 Coolsculpting ® 108.5 - 38.1 146.6 Zenpep ® - 133.0 - 133.0 Carafate ® ® - 110.5 1.3 111.8 Breast Implants 128.8 - (20.2 ) 108.6 Armour Thyroid - 106.7 - 106.7 Viberzi ® - 88.0 0.6 88.6 Skin Care 77.3 - 6.4 83.7 Asacol ® ® - 56.3 20.0 76.3 Teflaro ® - 70.5 0.2 70.7 Saphris ® - 64.5 - 64.5 Avycaz ® - 56.4 - 56.4 Coolsculpting ® 33.3 - 22.2 55.5 Namzaric ® - 46.0 - 46.0 Savella ® - 43.0 - 43.0 Liletta ® - 36.7 - 36.7 Dalvance ® - 32.3 2.2 34.5 Canasa ® ® - 18.2 7.7 25.9 Rapaflo ® 16.3 - 2.0 18.3 Kybella ® ® 15.8 - 2.2 18.0 Namenda ® - 15.6 - 15.6 Aczone ® 3.4 - - 3.4 Other 131.2 387.9 167.2 686.3 Total segment revenues $ 3,328.0 $ 2,705.6 $ 1,649.2 $ 7,682.8 Corporate revenues 4.4 Total net revenues $ 7,687.2 Three Months Ended June 30, 2018 US Specialized Therapeutics US General Medicine International Total Botox ® $ 658.5 $ - $ 276.0 $ 934.5 Restasis ® 318.2 - 16.0 334.2 Juvederm ® 139.8 - 156.1 295.9 Linzess ® ® - 191.8 6.4 198.2 Lumigan ® ® 73.0 - 100.5 173.5 Bystolic ® ® - 148.1 0.6 148.7 Alphagan ® ® 98.1 - 44.6 142.7 Lo Loestrin ® - 127.8 - 127.8 Eye Drops 53.8 - 72.4 126.2 Breast Implants 75.9 - 39.9 115.8 Vraylar ® - 114.2 - 114.2 Alloderm ® 107.1 - 2.3 109.4 Ozurdex ® 27.6 - 67.9 95.5 Coolsculpting ® 71.9 - 18.5 90.4 Viibryd ® ® - 86.7 1.6 88.3 Zenpep ® - 55.5 - 55.5 Carafate ® ® - 54.3 0.7 55.0 Canasa ® ® - 45.0 4.5 49.5 Armour Thyroid - 49.2 - 49.2 Coolsculpting ® 36.4 - 12.4 48.8 Viberzi ® - 44.9 0.3 45.2 Asacol ® ® - 32.6 12.4 45.0 Skin Care 34.3 - 4.1 38.4 Saphris ® - 33.8 - 33.8 Teflaro ® - 32.4 0.6 33.0 Namzaric ® - 31.8 - 31.8 Avycaz ® - 23.5 - 23.5 Rapaflo ® 19.7 - 1.6 21.3 Aczone ® 21.1 - 0.1 21.2 Savella ® - 19.1 - 19.1 Dalvance ® - 17.7 1.3 19.0 Liletta ® - 15.5 - 15.5 Kybella ® ® 11.2 - 2.3 13.5 Namenda ® - 3.4 - 3.4 Other 80.1 192.7 105.8 378.6 Total segment revenues $ 1,826.7 $ 1,320.0 $ 948.9 $ 4,095.6 Corporate revenues 28.6 Total net revenues $ 4,124.2 Six Months Ended June 30, 2018 US Specialized Therapeutics US General Medicine International Total Botox ® $ 1,231.0 $ - $ 520.8 $ 1,751.8 Restasis ® 574.0 - 34.3 608.3 Juvederm ® 262.6 - 302.2 564.8 Linzess ® ® - 351.1 12.0 363.1 Lumigan ® ® 139.8 - 200.9 340.7 Bystolic ® ® - 280.9 1.1 282.0 Alphagan ® ® 182.3 - 88.8 271.1 Lo Loestrin ® - 242.4 - 242.4 Eye Drops 100.0 - 141.2 241.2 Breast Implants 136.6 - 84.0 220.6 Alloderm ® 206.6 - 4.5 211.1 Vraylar ® - 198.6 - 198.6 Ozurdex ® 53.1 - 132.3 185.4 Viibryd ® ® - 158.4 3.1 161.5 Coolsculpting ® 125.3 - 26.6 151.9 Carafate ® ® - 110.3 1.4 111.7 Zenpep ® - 108.4 - 108.4 Armour Thyroid - 97.4 - 97.4 Asacol ® ® - 70.8 24.1 94.9 Canasa ® ® - 83.6 8.7 92.3 Coolsculpting ® 70.1 - 13.5 83.6 Viberzi ® - 80.8 0.4 81.2 Skin Care 66.2 - 7.9 74.1 Saphris ® - 66.5 - 66.5 Namzaric ® - 65.2 - 65.2 Teflaro ® - 64.6 0.6 65.2 Rapaflo ® 42.5 - 2.8 45.3 Avycaz ® - 45.3 - 45.3 Namenda ® - 44.0 - 44.0 Savella ® - 39.0 - 39.0 Aczone ® 37.1 - 0.2 37.3 Dalvance ® - 29.6 1.3 30.9 Liletta ® - 23.6 - 23.6 Kybella ® ® 19.4 - 3.7 23.1 Other 158.7 383.2 196.5 738.4 Total segment revenues $ 3,405.3 $ 2,543.7 $ 1,812.9 $ 7,761.9 Corporate revenues 34.4 Total net revenues $ 7,796.3 On July 24, 2019, the Company announced a voluntary worldwide recall of BIOCELL® textured breast implants and tissue expanders as a precaution following notification of recently updated global safety information concerning the uncommon incidence of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) provided by the U.S. Food and Drug Administration (“FDA”). In connection with the voluntary recall, the Company recorded an unfavorable adjustment to operating income of $95.9 million. Of this amount, $43.5 million related to estimated customer returns of product previously sold and was recorded as a reduction of net revenues, $44.2 million related to write-offs of inventory and other costs and was recorded in cost of sales, and $8.2 million related to the estimated penalties and costs to undertake the voluntary recall was recorded in selling, general and administrative expense.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2019
Inventory Disclosure [Abstract]
Inventories	NOTE 9 — Inventories Inventories consist of finished goods held for sale and distribution, raw materials and work-in-process. Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value. The Company writes down inventories to net realizable value based on forecasted demand, market conditions or other factors, which may differ from actual results. Inventories consisted of the following ($ in millions): June 30, December 31, 2019 2018 Raw materials $ 335.8 $ 303.2 Work-in-process 145.5 145.7 Finished goods 683.3 520.2 1,164.6 969.1 Less: inventory reserves 160.1 122.2 Total Inventories $ 1,004.5 $ 846.9 In connection with the voluntary recall, the Company recorded a $44.2 million charge in Cost of Sales to write down inventory held by the Company and other costs related to the recall as of June 30, 2019.

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	6 Months Ended
	Jun. 30, 2019
Payables And Accruals [Abstract]
Accounts Payable and Accrued Expenses	NOTE 10 — Accounts Payable and Accrued Expenses Accounts payable and accrued expenses consisted of the following ($ in millions): June 30, December 31, 2019 2018 Accrued expenses: Accrued third-party rebates $ 1,934.4 $ 1,832.1 Accrued returns and other allowances 586.3 527.8 Accrued payroll and related benefits 484.8 694.3 Accrued R&D expenditures 189.8 215.5 Interest payable 187.5 191.4 Accrued pharmaceutical fees 186.1 145.3 Royalties payable 161.8 155.1 Litigation-related reserves and legal fees 158.0 92.0 Accrued non-provision taxes 67.2 68.5 Accrued selling and marketing expenditures 64.4 61.1 Accrued severance, retention and other shutdown costs 24.6 71.6 Current portion of contingent consideration obligations 10.5 8.3 Dividends payable 1.1 1.4 Other accrued expenses 420.3 373.0 Total accrued expenses $ 4,476.8 $ 4,437.4 Accounts payable 518.5 349.8 Total accounts payable and accrued expenses $ 4,995.3 $ 4,787.2

Goodwill, Product Rights and Ot

Goodwill, Product Rights and Other Intangible Assets	6 Months Ended
	Jun. 30, 2019
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill, Product Rights and Other Intangible Assets	NOTE 11 — Goodwill, Product Rights and Other Intangible Assets Goodwill Goodwill for the Company’s reporting segments consisted of the following ($ in millions): US Specialized Therapeutics US General Medicine International Total Balance as of December 31, 2018 $ 20,675.6 $ 17,936.6 $ 7,301.1 $ 45,913.3 Acquisitions 34.1 - - 34.1 Impairments - (3,552.8 ) - (3,552.8 ) Re-allocation to current segments (340.0 ) 340.0 - - Foreign exchange and other adjustments - - (53.9 ) (53.9 ) Balance as of June 30, 2019 $ 20,369.7 $ 14,723.8 $ 7,247.2 $ 42,340.7 During the second quarter of 2019, the Company changed the operational and management structure for its in-development CGRP receptors, Ubrogepant and Atogepant. The development products were previously reported within the US Specialized Therapeutics segment and have been transferred to the US General Medicine segment to align these development products with the management structure and reporting. These development products were acquired as part of an asset acquisition and were therefore expensed in prior years. Goodwill of $340.0 million was re-allocated from the US Specialized Therapeutics segment to the US General Medicine segment based on relative fair value as of June 30, 2019. As a result of the transfer of these development projects, the Company performed its annual goodwill impairment test, both prior to and after, transfer. Annual Testing The Company performed its annual goodwill impairment test during the second quarter of 2019 by quantitatively evaluating its five Reporting Units. As of June 30, 2019, the net asset value of the General Medicine Reporting Unit exceeded its fair value prior to the transfer of the products noted above and the Company recorded a $1,085.8 million goodwill impairment charge to its General Medicine Reporting Unit. The charge is due in part to delays in the clinical studies as well as a reduction in the expected value of certain R&D projects. The fair value of each of the Company’s other four reporting units exceeded its fair value by less than five percent except for the U.S. Botox Therapeutic Reporting Unit. The General Medicine Reporting Unit, International Reporting Unit, US Eye Care Reporting Unit and US Medical Aesthetics Reporting Unit were the most sensitive to change in future valuation assumptions. The Company’s US Eye Care Reporting Unit and US Medical Aesthetics Reporting Unit, which are components of its US Specialized Therapeutics Segment and have an allocated goodwill balance of $9,824.8 million and $7,698.8 million, respectively. While management believes the assumptions used are reasonable and commensurate with the views of a market participant, changes in key assumptions for these Reporting Units, including increasing the discount rate, lowering revenue forecasts, lowering the operating margin, R&D pipeline delays, or lowering the long-term growth rate could result in a future impairment. Other market factors and conditions could also result in downward revisions of the Company’s forecasts on future projected cash flows for these reporting units. Negative events regarding R&D pipeline assets including, but not limited to, Abicipar, Atogepant, Bimatoprost SR, Ceniciviroc, and Ubrogepant, as well as next generation aesthetic products, could lead to further goodwill impairment charges. As a result of the proposed AbbVie Transaction, a component of the Company’s implied enterprise value contemplates the share price of AbbVie as attributed to the Company. If the AbbVie share price were to decline, the overall consideration associated with the AbbVie Transaction could be reduced which could result in a future goodwill impairment triggering event. In performing the annual impairment test, the Company utilized discount rates ranging from 9.5% to 11.0%, which were consistent with the rates utilized in the impairment testing performed in the first quarter of 2019. These rates increased versus the prior year annual testing discount rates of 8.5% to 10.0% to reflect changes in market conditions. The Company also reduced long-term growth rate assumptions consistent with the implied enterprise value. The assumptions used in evaluating goodwill for impairment are significant estimates, are subject to change, are assessed against historical performance by management and could result in additional impairment charges. Non-Annual Testing As of December 31, 2018, the net asset value of the General Medicine Reporting Unit equaled fair value. On March 6, 2019, Allergan announced negative topline results from three pivotal studies of rapastinel as an adjunctive treatment of Major Depressive Disorder (MDD). These results represented a triggering event to perform an impairment test for the Company’s General Medicine Reporting Unit. During the first quarter of 2019, primarily as a result of the impairment test noted above and a delay in clinical studies and anticipated launch of brazikumab, the Company recorded a $2,467.0 million goodwill impairment charge to its General Medicine Reporting Unit. As of June 30, 2019 and December 31, 2018, the gross balance of goodwill, prior to the consideration of impairments, was $48,751.9 million and $48,771.7 million, respectively. Product Rights and Other Intangible Assets Product rights and other intangible assets consisted of the following ($ in millions): Cost Basis Balance as of December 31, 2018 Additions Impairments IPR&D to CMP Transfers Foreign Currency Translation / Other Balance as of June 30, 2019 Intangibles with definite lives: Product rights and other intangibles $ 70,235.1 $ 90.9 $ - $ 75.6 $ 1,809.8 $ 72,211.4 Trade name 690.0 - - - - 690.0 Total definite lived intangible assets $ 70,925.1 $ 90.9 $ - $ 75.6 $ 1,809.8 $ 72,901.4 Intangibles with indefinite lives: IPR&D $ 5,048.1 $ - $ (436.0 ) $ (75.6 ) $ - $ 4,536.5 Total indefinite lived intangible assets $ 5,048.1 $ - $ (436.0 ) $ (75.6 ) $ - $ 4,536.5 Total product rights and other intangibles $ 75,973.2 $ 90.9 $ (436.0 ) $ - $ 1,809.8 $ 77,437.9 Accumulated Amortization Balance as of December 31, 2018 Amortization Impairments IPR&D to CMP Transfers Foreign Currency Translation / Other Balance as of June 30, 2019 Intangibles with definite lives: Product rights and other intangibles $ (31,985.0 ) $ (2,761.4 ) $ (129.6 ) $ - $ (997.6 ) $ (35,873.6 ) Trade name (292.8 ) (40.0 ) - - - (332.8 ) Total definite lived intangible assets $ (32,277.8 ) $ (2,801.4 ) $ (129.6 ) $ - $ (997.6 ) $ (36,206.4 ) Total product rights and other intangibles $ (32,277.8 ) $ (2,801.4 ) $ (129.6 ) $ - $ (997.6 ) $ (36,206.4 ) Net Product Rights and Other Intangibles $ 43,695.4 $ 41,231.5 Six Months Ended June 30, 2019 During the second quarter of 2019, the Company performed its annual IPR&D impairment test and based on events occurring or decisions made within the quarter ended June 30, 2019, the Company recorded the following impairments: • a $133.0 million impairment as a result of competition and a decline in market opportunities of a facial aesthetic product obtained as part of the acquisition of Allergan, Inc. (the “Allergan Acquisition”); • a $176.0 million impairment as a result of reduced cash flow projections including higher than anticipated clinical trial costs for a GI project obtained as part of the acquisition of Tobira Therapeutics, Inc.; and • a $127.0 million impairment for two pipeline programs that had previously been deprioritized and were subsequently deemed to have no alternative use in the period. Six Months Ended June 30 , 2018 During the second quarter of 2018, the Company performed its annual IPR&D impairment test and based on events occurring or decisions made within the quarter ended June 30, 2018, the Company recorded the following impairments: • a $164.0 million impairment as a result of changes in launch plans based on clinical results of an eye care project obtained as part of the Allergan Acquisition; • a $40.0 million impairment due to a delay in clinical studies and anticipated approval date of a project obtained as part of the acquisition of Vitae Pharmaceuticals, Inc. (the “Vitae Acquisition”); • a $27.0 million impairment due to a delay in clinical studies and anticipated approval date of a medical dermatology project obtained as part of the Allergan Acquisition; • a $20.0 million impairment as a result of a strategic decision to no longer pursue approval internationally of an eye care project obtained as part of the Allergan Acquisition; • a $19.0 million impairment due to a delay in clinical studies and anticipated approval date for a CNS project obtained as part of the Allergan Acquisition; and • a $6.0 million impairment due to a delay in clinical studies and anticipated approval date of an eye care project obtained as part of the Allergan Acquisition. In addition to the Company’s annual IPR&D impairment test, the Company impaired its retinoic acid receptor-related orphan receptor gamma (“RORyt”) IPR&D project obtained as part of the Vitae Acquisition by $522.0 million as a result of negative clinical data related to the oral psoriasis indication received in March 2018. Assuming no additions, disposals or adjustments are made to the carrying values and/or useful lives of the intangible assets, annual amortization expense on product rights and other related intangibles as of June 30, 2019 over the remainder of 2019 and each of the next five years is estimated to be as follows ($ in millions): Amortization Expense 2019 remaining $ 2,884.3 2020 $ 5,485.6 2021 $ 4,560.6 2022 $ 4,211.9 2023 $ 3,787.8 2024 $ 2,955.6 The above amortization expense is an estimate. Actual amounts may change from such estimated amounts due to fluctuations in foreign currency exchange rates, additional intangible asset acquisitions, finalization of preliminary fair value estimates, potential impairments, accelerated amortization or other events. Additional amortization may occur as products are approved. In addition, the Company has certain currently marketed products for which operating contribution performance has been below that which was originally assumed in the products’ initial valuations, and certain IPR&D projects which are subject to delays in timing or other events which may negatively impact the asset’s value. The Company, on a quarterly basis, monitors the related intangible assets for these products for potential impairments. It is reasonably possible that impairments may occur in future periods, which may have a material adverse effect on the Company’s results of operations and financial position.

Long-Term Debt

Long-Term Debt	6 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Long Term Debt	NOTE 12 — Long-Term Debt Debt consisted of the following ($ in millions): Balance As of Fair Market Value As of Guarantor Issuance Date / Acquisition Date Interest Payments June 30, 2019 December 31, 2018 June 30, 2019 December 31, 2018 Senior Notes: Floating Rate Notes $500.0 million floating rate notes due March 12, 2020 (1) (4) March 4, 2015 Quarterly 500.0 500.0 503.6 501.9 500.0 500.0 503.6 501.9 Fixed Rate Notes $3,500.0 million 3.000% notes due March 12, 2020 (4) March 4, 2015 Semi-annually 2,526.0 2,706.7 2,533.7 2,694.8 $650.0 million 3.375% notes due September 15, 2020 (5) March 17, 2015 Semi-annually 650.0 650.0 655.6 648.7 $750.0 million 4.875% notes due February 15, 2021 (6) July 1, 2014 Semi-annually 450.0 450.0 463.5 459.4 $1,200.0 million 5.000% notes due December 15, 2021 (6) July 1, 2014 Semi-annually 1,200.0 1,200.0 1,258.5 1,234.8 $3,000.0 million 3.450% notes due March 15, 2022 (4) March 4, 2015 Semi-annually 2,878.2 2,940.5 2,929.9 2,891.0 $1,700.0 million 3.250% notes due October 1, 2022 (5) October 2, 2012 Semi-annually 1,700.0 1,700.0 1,707.6 1,652.2 $350.0 million 2.800% notes due March 15, 2023 (5) March 17, 2015 Semi-annually 350.0 350.0 348.2 332.8 $1,200.0 million 3.850% notes due June 15, 2024 (4) June 10, 2014 Semi-annually 1,036.7 1,036.7 1,073.1 1,021.0 $4,000.0 million 3.800% notes due March 15, 2025 (4) March 4, 2015 Semi-annually 3,020.7 3,027.5 3,119.0 2,956.0 $2,500.0 million 4.550% notes due March 15, 2035 (4) March 4, 2015 Semi-annually 1,789.0 1,789.0 1,818.0 1,690.7 $1,000.0 million 4.625% notes due October 1, 2042 (5) October 2, 2012 Semi-annually 456.7 456.7 447.9 412.4 $1,500.0 million 4.850% notes due June 15, 2044 (4) June 10, 2014 Semi-annually 1,079.4 1,079.4 1,108.8 1,019.1 $2,500.0 million 4.750% notes due March 15, 2045 (4) March 4, 2015 Semi-annually 881.0 881.0 900.2 836.6 18,017.7 18,267.5 18,364.0 17,849.5 Euro Denominated Notes €700.0 million floating rate notes due June 1, 2019 (2) (4) May 26, 2017 Quarterly - 802.7 - 794.9 €700.0 million floating rate notes due November 15, 2020 (3) (4) November 15, 2018 Quarterly 796.1 802.7 795.1 791.3 €750.0 million 0.500% notes due June 1, 2021 (4) May 26, 2017 Annually 853.0 860.0 859.4 849.7 €500.0 million 1.500% notes due November 15, 2023 (4) November 15, 2018 Annually 568.7 573.4 591.7 572.4 €700.0 million 1.250% notes due June 1, 2024 (4) May 26, 2017 Annually 796.1 802.7 815.8 775.5 €500.0 million 2.625% notes due November 15, 2028 (4) November 15, 2018 Annually 568.7 573.4 623.6 573.4 €550.0 million 2.125% notes due June 1, 2029 (4) May 26, 2017 Annually 625.5 630.7 656.3 594.7 4,208.1 5,045.6 4,341.9 4,951.9 Total Senior Notes Gross 22,725.8 23,813.1 23,209.5 23,303.3 Unamortized premium 52.0 64.3 - - Unamortized discount (59.6 ) (64.5 ) - - Total Senior Notes Net $ 22,718.2 $ 23,812.9 $ 23,209.5 $ 23,303.3 Other Indebtedness Debt Issuance Costs (82.4 ) (92.1 ) Other 67.7 69.3 Total Other Borrowings (14.7 ) (22.8 ) Capital Leases (7) n.a. 7.6 Total Indebtedness $ 22,703.5 $ 23,797.7 (1) (2) (3) (4) (5) (6) (7) debt. Fair market value in the table above is determined in accordance with Fair Value Leveling (defined below) under Level 2 based upon quoted prices for similar items in active markets. Companies are required to use a fair value hierarchy as defined in ASC Topic 820 “Fair Value Measurement,” (“ASC 820”) which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value (“Fair Value Leveling”). There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest: Level 1 — Quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 — Unobservable inputs that are supported by little or no market activity. The Level 3 assets are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as instruments for which the determination of fair value requires significant judgment or estimation. Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants. The following represents the significant activity during the six months ended June 30, 2019 to the Company’s total indebtedness: • The Company repurchased and retired $249.8 million of senior notes at face value as a result of open market redemptions; and • The Company repaid the scheduled maturity of the €700.0 million floating rate notes due June 1, 2019. Annual Debt Maturities As of June 30, 2019, annual debt maturities of senior notes gross were as follows ($ in millions): Total Payments 2019 remaining $ - 2020 4,472.1 2021 2,503.0 2022 4,578.2 2023 918.7 2024 1,832.8 2025 and after 8,421.0 Total senior notes gross $ 22,725.8 Amounts represent total anticipated cash payments assuming scheduled repayments.

Leases

Leases	6 Months Ended
	Jun. 30, 2019
Leases [Abstract]
Leases	NOTE 13 — Leases Leases are accounted for under ASC Topic 842. The Company has entered into various lease contracts, mainly operating leases for the use of real estate, fleet, and operating equipment. The Company leases certain assets to limit exposure to the risks of ownership as well as to reduce administrative burdens inherent in the ownership of assets. Term The remaining terms for leases other than real estate leases are between 1 and 9 years as of June 30, 2019. For real estate leases, the remaining lease terms are between 1 and 14 years as of June 30, 2019. The Company has an option for certain lease contracts, mainly for real estate lease contracts, to renew the lease term beyond the noncancelable lease period. The payments associated with the renewal will only be included in the measurement of the lease liability and ROU asset if the exercise of the renewal option is determined to be reasonably certain. The Company considers the timing of the renewal period and other economic factors such as the financial consequences of a decision to extend or not to extend a lease in determining if the renewal option is reasonably certain to be exercised. Discount Rate The Company is primarily a lessee, not a lessor. The Company discounts future lease payments to calculate the present value when determining the lease classification and measuring the lease liability. The rate utilized is either the implicit rate or the incremental borrowing rate. The incremental borrowing rate is not a commonly quoted rate and is derived through a combination of inputs including the Company’s credit rating and the impact of full collateralization. The incremental borrowing rate is based on the Company’s collateralized borrowing capabilities over a similar term of the lease payments. The Company utilizes the consolidated group incremental borrowing rate for all leases as the Company has centralized treasury operations. Other The Company does not have any material residual value guarantee terms in its lease contracts. The Company does not have material variable leases. The Company has chosen to separate lease and non-lease components for its plant operations and research and development equipment. The Company allocates the contract consideration to the lease component using the standalone price from our supplier. As of June 30, 2019, the Company had the following operating ROU assets and lease liabilities ($ in millions): June 30, 2019 ROU Asset Lease Liability Real estate $ 283.9 $ 350.9 Fleet 117.3 117.3 Other 56.7 69.8 Total operating leases $ 457.9 $ 538.0 June 30, 2019 Current lease liability - operating $ 123.2 Long-term lease liability - operating 414.8 Total lease liability - operating $ 538.0 Finance leases are not material as of June 30, 2019. For the three and six months ended June 30, 2019, the Company noted the following lease expense ($ in millions): Three Months Ended June 30, 2019 Six Months Ended June 30, 2019 Operating lease expense* $ 40.1 $ 72.4 Sublease (income) (3.6 ) (7.0 ) Net operating lease expense $ 36.5 $ 65.4 * Includes short-term and variable lease expenses of $0.7 million and $1.6 million, respectively, for the three and six months ended June 30, 2019. As of June 30, 2019, the Company had the following lease commitments ($ in millions): Total Payments 2019 remaining $ 66.8 2020 117.4 2021 103.8 2022 59.6 2023 45.8 2024 39.3 2025 and after 152.3 Total undiscounted cash flows $ 585.0 Future interest (47.0 ) Total lease liability - operating $ 538.0 As of June 30, 2019, the weighted average remaining lease term for operating leases was 7.0 years with a weighted average discount rate of 2.7%. The ROU assets obtained in exchange for operating lease obligations were $40.4 million and $63.8 million, respectively, for the three and six months ended June 30, 2019. The cash paid for amounts included in the measurement of operating lease liabilities were $33.6 million and $74.4 million, respectively, for the three and six months ended June 30, 2019. As of December 31, 2018, the Company had operating leases for certain facilities, vehicles and equipment. Total property rental expense for operating leases for the year ended December 31, 2018 was $63.2 million. Total fleet rental expense for operating leases for the year ended December 31, 2018 was $41.1 million. The Company also had de minimis capital leases for certain facilities and equipment. As of December 31, 2018, the future anticipated property lease rental payments under both capital and operating leases that had remaining terms in excess of one year were ($ in millions): Total Payments 2019 $ 62.5 2020 52.5 2021 47.9 2022 43.3 2023 39.0 Thereafter 173.8 Total minimum lease payments $ 419.0

Other Long-Term Liabilities

Other Long-Term Liabilities	6 Months Ended
	Jun. 30, 2019
Other Liabilities Disclosure [Abstract]
Other Long-Term Liabilities	NOTE 14 — Other Long-Term Liabilities Other long-term liabilities consisted of the following ($ in millions): June 30, December 31, 2019 2018 Acquisition related contingent consideration liabilities $ 376.9 $ 336.3 Long-term pension and post retirement liability 167.8 166.5 Legacy Allergan deferred executive compensation 92.9 90.8 Accrued R&D milestone 75.0 75.0 Deferred revenue 32.8 36.1 Product warranties 28.9 27.9 Long-term severance and restructuring liabilities 11.0 14.2 Long-term contractual obligations - 43.2 Other long-term liabilities 36.1 92.0 Total other long-term liabilities $ 821.4 $ 882.0

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 15 — Income Taxes The Company’s effective tax rate for the six months ended June 30, 2019 was a provision of 5.9%, compared to a benefit of 47.7% for the six months ended June 30, 2018. The effective tax rate for the six months ended June 30, 2019 was favorably impacted by tax benefits of $118.0 million related to excess tax over book basis in a U.S. subsidiary that will reverse in the foreseeable future, $50.8 million for a U.S. capital loss and $107.3 million related to the impairment of certain intangible assets. The effective tax rate was unfavorably impacted by a tax charge of $375.0 million to establish a valuation allowance on certain non-U.S. deferred tax assets, $49.0 million related to an uncertain tax position and the goodwill impairment charge of $3,552.8 million, for which no tax benefit was recorded. The effective tax rate for the six months ended June 30, 2018 was favorably impacted by income earned in jurisdictions with tax rates lower than the Irish statutory rate and U.S. losses tax benefited at rates greater than the Irish statutory rate. This was offset by the additional U.S. tax on the earnings of certain non-U.S. subsidiaries which are considered Global Intangible Low Taxed Income (“GILTI”) and the tax impact of amortization of intangible assets at rates less than the Irish statutory rate. Additionally, the tax benefit for the six months ended June 30, 2018 included tax benefits of $421.9 million related to the restructuring of an acquired business, $231.0 million related to the impairment of certain intangible assets and $79.8 million related to excess tax over book basis in a U.S. subsidiary expected to reverse in the foreseeable future. This was partially offset by tax detriments of $21.2 million for the gain on sale of investments and $25.9 million related to a change in the applicable tax rate on certain temporary differences. Tax Audits The Company conducts business globally and, as a result, files U.S. federal, state and foreign tax returns. The Company strives to resolve open matters with each tax authority at the examination level and could reach agreement with a tax authority at any time. While the Company has accrued for amounts it believes are in accordance with the accounting standard, the final outcome with a tax authority may result in a tax liability that is different than that reflected in the consolidated financial statements. Furthermore, the Company may decide to challenge any assessments, if made, and may exercise its right to appeal. The uncertain tax positions are reviewed quarterly and adjusted as events occur that affect potential liabilities for additional taxes, such as lapsing of applicable statutes of limitations, proposed assessments by tax authorities, negotiations with tax authorities, identification of new issues and issuance of new legislation, regulations or case law. The Company has several concurrent audits open and pending with the IRS as set forth below: IRS Audits Taxable Years Allergan W.C. Holding Inc. f/k/a Actavis W.C. Holding Inc. 2013, 2014, 2015 and 2016 Warner Chilcott Corporation 2010, 2011, 2012 and 2013 Forest Laboratories, Inc. 2010, 2011, 2012, 2013 and 2014 Allergan, Inc. 2009, 2010, 2011, 2012, 2013, 2014 and 3/17/2015

Shareholders' Equity

Shareholders' Equity	6 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Shareholders' Equity	NOTE 16 — Shareholders’ Equity Share Repurchase Programs On January 29, 2019, the Company announced that its Board of Directors approved a $2.0 billion share repurchase program, all of which remained outstanding as of June 30, 2019. The Company’s Board of Directors previously approved a $2.0 billion share repurchase program in July 2018. As of June 30 12.5 June 30 Preferred Shares In the six months ended June 30, 2018, the Company paid $69.6 million of dividends on preferred shares. Each preferred share automatically converted to approximately 3.53 ordinary shares on March 1, 2018, for a total of 17,876,930 ordinary shares.

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	6 Months Ended
	Jun. 30, 2019
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	NOTE 17 — Derivative Instruments and Hedging Activities The Company’s revenue, earnings, cash flows and fair value of its assets and liabilities can be impacted by fluctuations in foreign exchange and interest rates, as applicable. The Company manages the impact of foreign exchange risk and interest rate movements through operational means and through the use of various financial instruments, including derivative instruments such as foreign currency derivatives. Internationally, the Company is a net recipient of currencies other than the U.S. dollar and, as such, benefits from a weaker dollar and is adversely affected by a stronger dollar relative to major currencies worldwide. Accordingly, changes in exchange rates, and in particular a strengthening of the U.S. dollar may negatively affect the Company’s consolidated revenues and favorably impact operating expenses in U.S. dollars. Derivatives Not Designated as Hedging Instruments In November 2018, the Company entered into a 700.0 million Euro forward contract to buy Euros while selling USD. The derivative had a maturity of May 31, 2019. The derivative instrument was marked-to-market to the P&L, offsetting the revaluation (P&L) impact on the Euro 700.0 million variable interest debt which matured on June 1, 2019. As of December 31, 2018, the fair value of the Euro forward contract of $5.9 million was recorded in prepaid expenses and other current assets. For the three and six months ended June 30, 2019, the Company recorded a loss of $7.3 million and $29.8 million, respectively, relating to this instrument in general and administrative expenses. As of June 30, 2019 and December 31, 2018, the Company had additional outstanding third-party foreign currency forward instruments of $21.7 million and $42.1 million, respectively. For the three and six months ended June 30, 2019, these additional outstanding third-party foreign currency forward instruments did not have material mark-to-market adjustments. Derivatives D esignated as H edging I nstruments Cash Flow Hedge In January 2019, Allergan entered into $500.0 million notional floating to fixed interest rate swaps maturing on March 12, 2020 whereby it fixed the interest rates on $500.0 million floating rate notes due March 12, 2020 to an average interest rate of 3.98%. The swaps are being accounted for using hedge accounting treatment. As of June 30, 2019, the fair value of the interest rate swaps of $2.2 million was recorded in accounts payable and accrued expenses. For the three and six months ended June 30, 2019, the corresponding unrealized loss of $1.2 million and $2.2 million, respectively, was recorded in accumulated other comprehensive income / (loss). Net Investment Hedge In the normal course of business, we manage certain foreign exchange risks through a variety of strategies, including hedging. Our hedging strategies include the use of derivatives, as well as net investment hedges. For net investment hedges, the effective portion of the gains and losses on the instruments arising from the effects of foreign exchange are recorded in the currency translation adjustment component of accumulated other comprehensive income / (loss), consistent with the underlying hedged item. Hedging transactions are limited to an underlying exposure. As a result, any change in the value of our hedging instruments would be substantially offset by an opposite change in the value of the underlying hedged items. The Company does not use derivative instruments for trading or speculative purposes. The Company is exposed to foreign exchange risk in its international operations from foreign currency purchases, net investments in foreign subsidiaries, and foreign currency assets and liabilities created in the normal course of business, including its Euro Denominated Notes. In the six months ended June 30, 2019, we used effective net investment hedges to partially offset the effects of foreign currency on our investments in certain of our foreign subsidiaries. The total notional amount of our instruments designated as net investment hedges was $5.1 billion as of , 2019 and December 31, 2018. During the three and six months ended , 2019, the impact of the net investment hedges recorded in other comprehensive loss was a loss of $69.0 million and a gain of $41.8 million, respectively, which offset the currency impact within our net investment in subsidiaries which are impacted by their Euro Denominated Notes. During the three and six months ended , 2018, the impact of the net investment hedges on other comprehensive income was a gain of $197.1 million and $102.0 million, respectively, which offset the currency impact of the Euro Denominated Notes.

Fair Value Measurement

Fair Value Measurement	6 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurement	NOTE 18 — Fair Value Measurement Assets and liabilities that are measured at fair value using Fair Value Leveling or that are disclosed at fair value on a recurring basis as of June 30, 2019 and December 31, 2018 consisted of the following ($ in millions): Fair Value Measurements as of June 30, 2019 Using: Total Level 1 Level 2 Level 3 Assets: Cash equivalents* $ 1,154.1 $ 1,154.1 $ - $ - Short-term investments 322.3 - 322.3 - Deferred executive compensation investments 92.9 78.0 14.9 - Royalty receivable 50.3 - - 50.3 Investments and other 55.1 39.6 15.5 - Total assets $ 1,674.7 $ 1,271.7 $ 352.7 $ 50.3 Liabilities: Deferred executive compensation liabilities $ 92.9 $ 78.0 $ 14.9 $ - Contingent consideration obligations 387.4 - - 387.4 Total liabilities $ 480.3 $ 78.0 $ 14.9 $ 387.4 * Marketable securities with less than 90 days Fair Value Measurements as of December 31, 2018 Using: Total Level 1 Level 2 Level 3 Assets: Cash equivalents* $ 207.1 $ 207.1 $ - $ - Short-term investments 1,026.9 - 1,026.9 - Deferred executive compensation investments 90.8 73.8 17.0 - Royalty receivable 50.3 - - 50.3 Investments and other 46.0 38.5 7.5 - Total assets $ 1,421.1 $ 319.4 $ 1,051.4 $ 50.3 Liabilities: Deferred executive compensation liabilities $ 90.8 $ 73.8 $ 17.0 $ - Contingent consideration obligations 344.6 - - 344.6 Total liabilities $ 435.4 $ 73.8 $ 17.0 $ 344.6 * Marketable securities with less than 90 days remaining until maturity at the time of acquisition are classified as cash equivalents. Marketable securities and investments consist of money market securities, U.S. treasury and agency securities. Unrealized gains or losses on marketable securities are recorded in interest income, while unrealized gains or losses on marketable debt securities are recorded in accumulated other comprehensive income. Investments and other include equity and debt securities of publicly traded companies for which market prices are readily available. Unrealized gains or losses on long-term equity investments are recorded in other income / (expense), net. The Company’s marketable securities and other long-term investments are recorded at fair value based on quoted market prices using the specific identification method. These investments are classified as either current or non-current, as appropriate, in the Company’s consolidated balance sheets. The Company may sell certain of its marketable securities prior to their stated maturities for strategic reasons including, but not limited to, anticipation of credit deterioration and maturity management. Contingent Consideration Obligations The fair value measurement of the contingent consideration obligations is determined using Level 3 inputs and is based on a probability-weighted income approach. The measurement is based upon unobservable inputs supported by little or no market activity, and is based on our own assumptions. Changes in the fair value of the contingent consideration obligations, including accretion, are recorded in our consolidated statements of operations as follows ($ in millions): Three Months Ended June 30, Six Months Ended June 30, Expense / (Income) 2019 2018 2019 2018 Cost of sales $ 25.8 $ (128.8 ) $ 42.0 $ (125.4 ) Research and development 2.3 21.7 4.8 23.6 Total $ 28.1 $ (107.1 ) $ 46.8 $ (101.8 ) The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the six months ended June 30, 2019 and 2018 ($ in millions): Balance as of December 31, 2018 Net transfers in to (out of) Level 3 Purchases, settlements, and other net Net accretion and fair value adjustments Balance as of June 30, 2019 Liabilities: Contingent consideration obligations $ 344.6 $ - $ (4.0 ) $ 46.8 $ 387.4 Balance as of December 31, 2017 Net transfers in to (out of) Level 3 Purchases, settlements, and other net Net accretion and fair value adjustments Balance as of June 30, 2018 Liabilities: Contingent consideration obligations $ 476.9 $ - $ (10.7 ) $ (101.8 ) $ 364.4 During the six months ended June 30, 2019, the activity in contingent consideration obligations by acquisition consisted of the following ($ in millions): Business Acquisition Balance as of December 31, 2018 Fair Value Adjustments and Accretion Payments and Other Balance as of June 30, 2019 Tobira acquisition $ 255.0 $ 4.6 $ - $ 259.6 Medicines 360 acquisition 43.1 42.2 (2.7 ) 82.6 ForSight acquisition 24.1 0.2 0.1 24.4 Forest acquisition 13.6 (0.2 ) (1.2 ) 12.2 AqueSys acquisition 5.4 0.1 - 5.5 Oculeve acquisition 1.7 - - 1.7 Other 1.7 (0.1 ) (0.2 ) 1.4 Total $ 344.6 $ 46.8 $ (4.0 ) $ 387.4 Royalty Receivable The fair value measurement of the royalty receivable is determined using Level 3 inputs and is based on a probability-weighted income approach. The measurement is based upon unobservable inputs supported by little or no market activity, and is based on our own assumptions. There were no material changes noted in the fair value of the royalty receivable for the six months ended June 30, 2019.

Business Restructuring Charges

Business Restructuring Charges	6 Months Ended
	Jun. 30, 2019
Restructuring And Related Activities [Abstract]
Business Restructuring Charges	NOTE 19 — Business Restructuring Charges Restructuring activities for the six months ended June 30, 2019 were as follows ($ in millions): Severance and Retention Other Total Reserve balance at December 31, 2018 $ 71.4 $ 14.4 $ 85.8 Charged to expense Cost of sales 1.2 - 1.2 Selling and marketing 0.3 - 0.3 General and administrative 3.7 2.3 6.0 Total expense 5.2 2.3 7.5 Cash payments (54.8 ) (0.8 ) (55.6 ) Non-cash adjustments (2.1 ) - (2.1 ) Reserve balance at June 30, 2019 $ 19.7 $ 15.9 $ 35.6 During the three and six months ended June 30, 2018, the Company recognized restructuring charges of $6.4 million and $24.3 million, respectively, including severance and other employee related charges of $6.4 million and $21.6 million. The majority of these restructuring severance costs were paid during 2018.

Commitments & Contingencies

Commitments & Contingencies	6 Months Ended
	Jun. 30, 2019
Commitments And Contingencies Disclosure [Abstract]
Commitments & Contingencies	NOTE 20 — The Company and its affiliates are involved in various disputes, governmental and/or regulatory inspections, inquires, investigations and proceedings, and litigation matters that arise from time to time in the ordinary course of business. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters will adversely affect the Company, its results of operations, financial condition and cash flows. The Company’s general practice is to expense legal fees as services are rendered in connection with legal matters, and to accrue for liabilities when losses are probable and reasonably estimable. The Company evaluates, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that is accrued. As of June 30, 2019, the Company’s consolidated balance sheet includes accrued loss contingencies of approximately $ 80.0 The Company’s legal proceedings range from cases brought by a single plaintiff to mass tort actions and class actions with thousands of putative class members. These legal proceedings, as well as other matters, involve various aspects of our business and a variety of claims (including, but not limited to, qui tam actions, antitrust, product liability, breach of contract, securities, patent infringement and trade practices), some of which present novel factual allegations and/or unique legal theories. In addition, a number of the matters pending against us are at very early stages of the legal process (which in complex proceedings of the sort faced by us often extend for several years). As a result, some matters have not yet progressed sufficiently through discovery and/or development of important factual information and legal issues to enable us to estimate a range of possible loss. In those proceedings in which plaintiffs do request publicly quantified amounts of relief, the Company does not believe that the quantified amounts are meaningful because they are merely stated jurisdictional limits, exaggerated and/or unsupported by the evidence or applicable burdens of proof. In matters involving the assertion or defense of the Company’s intellectual property, the Company believes it has meritorious claims and intends to vigorously assert or defend the patents or other intellectual property at issue in such litigation. Similarly, in matters where the Company is a defendant, the Company believes it has meritorious defenses and intends to defend itself vigorously. However, the Company can offer no assurances that it will be successful in a litigation or, in the case of patent enforcement matters, that a generic version of the product at issue will not be launched or enjoined. Failing to prevail in a litigation could adversely affect the Company and could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows. Intellectual Property Litigation Patent Enforcement Matters Bystolic ® . On July 2, 2019, subsidiaries of the Company brought an action for infringement of U.S. Patent No. 6,545,040 in the United States District Court for the District of Delaware against Ajanta Pharma Ltd. and Ajanta Pharma USA Inc. (collectively, “Ajanta”) in connection with an abbreviated new drug application filed with the FDA by Ajanta seeking approval to market a generic version of Bystolic ® and challenging said patent. No trial date or case schedule has been set. Combigan ® ® ® Fetzima ® In April 2019, subsidiaries of the Company and Pierre Fabre Medicament S.A.S. brought an action for infringement of the ‘879, ‘598 and ‘937 Patents against Micro Labs Ltd. and Micro Labs USA, Inc. (“Micro”) in connection with Micro’s abbreviated new drug application seeking approval to market a generic version of Fetzima ® Juvéderm ® Kybella ® . On November 9, 2018, a subsidiary of the Company brought an action for infringement of U.S. Patent Nos. 8,101,593 (the “‘593 Patent”), 8,367,649 (the “‘649 Patent”) and 8,653,058 (the “‘058 Patent”) against Slayback Pharma LLC (“Slayback”) in the U.S. District Court for the District of New Jersey in connection with an abbreviated new drug application filed with the FDA by Slayback seeking approval to market a generic version of Kybella® and challenging said patents. The ‘593, ‘649, and ‘058 Patents expire in March 2030. On April 10, 2019, a subsidiary of the Company, together with Los Angeles Biomedical Research Institute at Harbor UCLA-Medical Center (“LA BioMed”) and The Regents of the University of California (the “Regents”) (all collectively, “Plaintiffs”), filed an amended complaint against Slayback asserting infringement of the ‘593, ‘649 and ‘058 Patents and U.S. Patent Nos. 7,622,130 (the “‘130 Patent”), 7,754,230 (the “‘230 Patent”), 8,298,556 (the “‘556 Patent”) and 8,846,066 (the “‘066 Patent”). The ‘130 and ‘230 Patents expire in December 2027 (not including pending applications for patent term extension (“PTE”)), the ‘556 Patent expires in August 2025, and the ‘066 Patent expires in February 2025. Plaintiffs entered into a settlement agreement with Slayback on June 12, 2019, and the case was dismissed Latisse ® . In December 2016, Sandoz announced the U.S. market launch of its generic copy of Latisse ® ® Latisse ® . On September 25, 2017, subsidiaries of the Company and Duke University brought an action for infringement of U.S. Patent No. 9,579,270 (the “‘270 Patent”) against Alembic Pharmaceuticals, Ltd., Alembic Global Holding SA, and Alembic Pharmaceuticals, Inc. (collectively, “Alembic”) in the U.S. District Court for the District of New Jersey in connection with an abbreviated new drug application filed with FDA by Alembic, seeking approval to market a generic version of Latisse ® Latisse ® . On September 19, 2018, subsidiaries of the Company and Duke University brought an action for infringement of U.S. Patent No. 9,579,270 (the “‘270 Patent”) against Akorn, Inc. and Hi-Tech Pharmacal Co., Inc. (collectively, “Akorn”) in the U.S. District Court for the District of New Jersey in connection with an abbreviated new drug application filed with FDA by Akorn seeking approval to market a generic version of Latisse® and challenging the ‘270 patent. The case is currently in fact discovery and a trial date has not yet been set. Linzess ® . Beginning in November 2016 subsidiaries of the Company and Ironwood Pharmaceuticals, Inc. (collectively, “Plaintiffs”), brought multiple actions for infringement of some or all of U.S. Patent Nos. 7,304,036 (the “‘036 Patent”); 7,371,727 (the “‘727 Patent”); 7,704,947 (the “‘947 Patent”); 7,745,409 (the “‘409 Patent”); 8,080,526 (the “‘526 Patent”); 8,110,553 (the “‘553 Patent”); 8,748,573 (the “‘573 Patent”); 8,802,628 (the “‘628 Patent”); and 8,933,030 (the “‘030 Patent”) against Teva Pharmaceuticals USA, Inc. (“Teva”), Aurobindo Pharma Ltd. (“Aurobindo”), Mylan Pharmaceuticals Inc. (“Mylan”), Sandoz Inc. (“Sandoz”) and Sun Pharma Global FZE (“Sun”) in the U.S. District Court for the District of Delaware in connection with abbreviated new drug applications respectively filed with the FDA by Teva, Aurobindo, Mylan, Sandoz and Sun, each seeking approval to market generic versions of Linzess ® On October 20, 2017, November 30, 2017 and January 20, 2018, Plaintiffs brought actions for infringement of U.S. Patent No. 9,708,371 (the “‘371 Patent”) in the U.S. District Court for the District of Delaware against Teva, Mylan and Sandoz, respectively. The ‘371 Patent expires in 2033. The ‘371 patent actions have been consolidated with the November 2016 Action. On February 2, 2018 and March 29, 2018, Plaintiffs brought actions for infringement of some or all of the ‘036, ‘727, ‘947, ‘409, ‘526, ‘553, ‘030 and ‘371 Patents against Teva and Mylan in the U.S. District Court for the District of Delaware in connection with abbreviated new drug applications respectively filed with the FDA by Teva and Mylan, each seeking approval to market generic versions generic versions of Linzess ® In May and August 2018, the district court granted joint stipulations and orders to dismiss without prejudice all claims, counterclaims, and defenses in the November 2016 Action with respect to the ‘371 Patent and the ‘030 Patent, respectively, as between Plaintiffs, Teva, Mylan and Sandoz. On September 4, 2018, Plaintiffs filed an amended complaint as to Mylan to assert the ‘628 patent against Mylan’s 72 mcg ANDA product. Plaintiffs entered into a settlement agreement with Sun and certain Sun affiliates and the case against Sun was dismissed on January 18, 2018. Plaintiffs entered into a settlement agreement with Aurobindo and the case against Aurobindo was dismissed on May 7, 2018. Plaintiffs entered into a settlement agreement with Mylan and the case against Mylan was dismissed on December 27, 2018. Under the terms of the settlement agreement, Plaintiffs will provide a license to Mylan to market its generic versions of Linzess ® ® Restasis ® . Between August 2015 and July 2016, a subsidiary of the Company brought actions for infringement of U.S. Patent Nos. 8,629,111 (the “‘111 patent”), 8,633,162 (the “‘162 patent”), 8,642,556 (the “‘556 patent”), 8,648,048 (the “‘048 patent”), 8,685,930 (the “‘930 patent”) and 9,248,191 (the “’191 patent”) in the U.S. District Court for the Eastern District of Texas against Akorn, Inc., Apotex, Inc., Mylan Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., InnoPharma, Inc., Famy Care Limited (“Famy Care”), TWi Pharmaceuticals, Inc. (“TWi”) and related subsidiaries and affiliates thereof. The subsidiary entered into settlement agreements with Apotex, TWi, Famy Care and InnoPharma. As a result of certain of these settlements, Allergan will provide a license to certain parties to launch their generic versions of Restasis ® On September 8, 2017, the Company assigned all Orange Book-listed patents for Restasis ® On October 16, 2017, the District Court issued a decision and final judgment finding that the asserted claims of the ‘111 patent, the ‘048 patent, the ‘930 patent and the ‘191 patent were infringed, but invalid on the ground of obviousness. The District Court also held that the asserted claims were not invalid as anticipated, for lack of enablement, or for improper inventorship. On November 13, 2018, the U.S. Court of Appeals for the Federal Circuit issued a decision affirming the district court’s finding of invalidity of the asserted claims of the ‘111, ‘048, ‘930 and ‘191 Patents. On March 6, 2019, the Federal Circuit denied Allergan and the Tribe’s petition for rehearing, and a mandate issued on March 13, 2019. On April 10, 2019, Allergan and the Tribe filed a petition for a writ of certiorari with the United States Supreme Court, which was denied on June 3, 2019. On December 22, 2016, a subsidiary of the Company filed a complaint for infringement of the ’111 patent, ’162 patent, ’556 patent, ’048 patent, ’930 patent, and the ’191 patent in the U.S. District Court for the Eastern District of Texas against Deva Holding A.S. (“Deva”). On March 6, 2018, the district court granted in part and denied in part the parties’ joint motion for entry of a stipulated order, and stayed the case until such time as the Federal Circuit in the lead appeal case with Teva, Mylan and Akron issues a mandate. The parties’ stipulation provides that Deva will be bound by the outcome of that appeal. On April 30, 2019, the district court granted Deva’s motion for entry of final judgment and dismissal with prejudice, and the case was dismissed. On August 10 and September 20, 2018, a subsidiary of the Company and the Tribe filed complaints for infringement of the ’162 patent and the ’556 patent in the U.S. District Court for the District of Delaware against Saptalis and against Amneal Pharmaceuticals, LLC and Amneal Pharmaceuticals Co. India Private Limited (collectively, “Amneal”), respectively. The cases were voluntarily dismissed on January 2, 2019. Restasis ® . On June 6, 2016, a subsidiary of the Company received notification letters that Inter Partes Review of the USPTO (“IPR”) petitions were filed by Mylan Pharmaceuticals Inc. (“Mylan”) regarding U.S. Patent Nos. 8,629,111 (the “‘111 patent”), 8,633,162 (the “‘162 patent”), 8,642,556 (the “‘556 patent”), 8,648,048 (the “‘048 patent”), 8,685,930 (the “‘930 patent”), and 9,248,191 (the “‘191 patent”), which patents expire on August 27, 2024. Mylan filed the IPR petition on June 3, 2016. On June 23, 2016, a subsidiary of the Company received a notification letter that an IPR petition and motion for joinder was filed by Argentum Pharmaceuticals LLC (“Argentum”) regarding the ’111 patent. On December 7, 2016, the Company entered into a settlement agreement with Argentum and Argentum’s petition was withdrawn. On December 8, 2016, the USPTO granted On September 8, 2017, Allergan assigned all Orange Book-listed patents for Restasis ® to the Saint Regis Mohawk Tribe (“the Tribe”), a recognized sovereign tribal government, and concurrently was granted an exclusive field-of-use license to practice the patents in the United States for all FDA-approved uses of the products under the Restasis ® NDAs. That same day, the Tribe filed an updated Mandatory Notice with the USPTO to reflect that the Tribe is the patent owner, and sought permission to file a motion to dismiss based on tribal sovereign immunity. On February 23, 2018, the USPTO issued orders denying the Tribe’s motion to dismiss (or terminate). On July 20, 2018, the Federal Circuit affirmed the USPTO’s denial of the Tribe’s motion to dismiss and Allergan’s motion to withdraw. On August 20, 2018, the Tribe and Allergan filed a petition for rehearing en banc, which the Federal Circuit denied on October 22, 2018. On December 21, 2018, the Company and the Tribe filed a petition for a writ of certiorari with the United States Supreme Court, which was denied on April 15, 2019. Saphris ® . Between September 2014 and May 2015, subsidiaries of the Company brought actions for infringement of some or all of U.S. Patent Nos. 5,763,476 (the “‘476 patent”), 7,741,358 (the “‘358 patent”) and 8,022,228 (the “‘228 patent”) against Sigmapharm Laboratories, LLC (“Sigmapharm”), Hikma Pharmaceuticals, LLC (“Hikma”), Breckenridge Pharmaceutical, Inc. (“Breckenridge”), Alembic Pharmaceuticals, Ltd. (“Alembic”) and Amneal Pharmaceuticals, LLC (“Amneal”), and related subsidiaries and affiliates thereof in the U.S. District Court for the District of Delaware in connection with an abbreviated new drug applications respectively filed with FDA by Sigmapharm, Hikma, Breckenridge, Alembic and Amneal, each seeking approval to market a generic versions of Saphris ® On March 14, 2019, the Federal Circuit vacated the district court’s July 2017 judgment that claims 1 and 4 are not invalid and remanded for the district court to consider a fact question and its impact on the obviousness analysis. On April 15, 2019, Plaintiffs filed a combined petition for panel rehearing and rehearing en banc with respect to this issue, which was denied on May 15, 2019. In its March 14, 2019 order, the Federal Circuit also vacated the judgment of non-infringement of claims 4, 9 and 10 as to Alembic and Breckenridge and remanded for the district court to consider their infringement under a revised claim construction. A separate bench trial concerning Sigmapharm’s infringement of claim 1 of the ‘476 patent began on June 20, 2018, and on November 16, 2018, the court held that Sigmapharms’ proposed ANDA product would infringe claim 1 of the ‘476 patent On November 26, 2018, Sigmapharm sought relief from the November 16, 2018 decision. On November 30, 2018, the Company moved for entry of final judgment. Both motions are currently pending. Trade Secret Matters Botulinum Neurotoxin ITC Investigation . On January 30, 2019, subsidiaries of the Company and Medytox Inc. (collectively, “Complainants”) filed a complaint with the United States International Trade Commission (“ITC”) against Daewoong Pharmaceuticals Co., Ltd., Daewoong Co., Ltd., and Evolus Inc. (collectively, “Respondents”) requesting the ITC commence an investigation with respect to the Respondents’ importation into the United States of Respondents’ botulinum neurotoxin products, including DWP-450 (also known as Jeuveau TM TM TM Trademark Enforcement Matters Juvéderm ® . On April 5, 2017, a subsidiary of the Company brought an action for unfair competition, false advertising, dilution, conspiracy and infringement of Allergan’s Juvéderm ® ® Subsidiaries of the Company requested a preliminary injunction against Dermavita, Dima Corp, Aesthetic Services & Development, Jacqueline Sillam and Dimitri Sillam in the High Court of Paris, France. During June 2017, the Paris Court preliminarily enjoined the defendants, inter alia, to refrain from promoting or selling in France its Juvederm products, to transfer various domain names and to pay provisional damages to Allergan, on the basis that such use would infringe Allergan’s EU and French Juvéderm ® On January 22, 2019, subsidiaries of the Company brought a related action for infringement of the Company’s Juvéderm ® Furthermore, more than 150 trademark opposition and cancellation actions between Allergan and Dermavita have been filed in front of the USPTO, EUIPO and various other national and regional trademark offices around the world. Most of these actions remain pending; however, Allergan has received favorable decisions in more than thirty (30) such actions. Antitrust Litigation Asacol ® . Class action complaints have been filed against certain subsidiaries of the Company on behalf of putative classes of direct and indirect purchasers. The lawsuits have been consolidated in the U.S. District Court for the District of Massachusetts. The complaints allege that plaintiffs paid higher prices for Asacol ® ® ® Loestrin ® . Putative classes of direct and indirect purchasers as well as opt-out direct purchasers have filed complaints that have been consolidated in the U.S. District Court for the District of Rhode Island. The lawsuits allege that subsidiaries of the Company engaged in anticompetitive conduct, including when settling patent lawsuits related to Loestrin ® Namenda ® Litigation . In 2014, the State of New York filed a lawsuit in the U.S. District Court for the Southern District of New York alleging that Forest was acting to prevent or delay generic competition to Namenda® in violation of federal and New York antitrust laws and committed other fraudulent acts in connection with its commercial plans for Namenda ® XR. The district court granted the state’s motion for a preliminary injunction which was later affirmed by the Court of Appeals for the Second Circuit. The parties in that case then reached a settlement to resolve the dispute. Following the conclusion of the New York Attorney General Matter, putative class actions were filed on behalf of direct and indirect purchasers in the same federal court. The class action complaints make claims similar to those asserted by the New York Attorney General and also include claims that Namenda® patent litigation settlements between a Company subsidiary and generic companies also violated the antitrust laws. Plaintiffs seek unspecified injunctive relief, treble damages and attorneys’ fees. The court has denied defendants’ motion for summary judgement in the direct purchaser action, certified the direct purchaser class of plaintiffs and set a trial date for October 2019. The court granted defendants’ motion to bifurcate the trial into separate phases in which the claims relating to the patent litigation settlements will be tried to verdict followed by the claims relating to Forest’s plans for Namenda XR. Restasis ® . Shire, which offers the dry-eye disease drug Xiidra ® ® ® Restasis ® . Several class actions were filed on behalf of putative classes of direct and indirect purchasers of Restasis ® ® Commercial Litigation Celexa ® ® . Certain subsidiaries of the Company were named in federal court actions relating to the promotion of Celexa ® ® Warner Chilcott Marketing Practices . A putative nationwide class of private payer entities, or their assignees, that paid Medicare benefits on behalf of their beneficiaries filed a complaint against certain subsidiaries of the Company in the U.S. District Court for the District of Massachusetts. The complaint asserts claims under the federal RICO statute, state consumer protection statutes, common law fraud, and unjust enrichment with respect to the sale and marketing of certain products. The Court recently granted Defendants’ motion to dismiss the amended complaint. Generic Drug Pricing Securities and ERISA Litigation . Putative classes of shareholders and two individual opt-out plaintiffs filed class action lawsuits against the Company and certain of its current and former officers alleging that defendants made materially false and misleading statements between February 2014 and November 2016 regarding the Company’s internal controls over its financial reporting and that it failed to disclose that its former Actavis generics unit had engaged in illegal, anticompetitive price-fixing with its generic industry peers. These lawsuits have been consolidated in the U.S. District Court for the District of New Jersey. The complaints seek unspecified monetary damages. On April 11, 2019, the court heard oral arguments on the Company’s motion to dismiss the complaint. In addition, class action complaints have been filed premised on the same alleged underlying conduct that is at issue in the securities litigation but that assert claims under the Employee Retirement Income Security Act of 1974 (“ERISA”). These complaints have been consolidated in the district court in New Jersey. The court granted the Company’s motion to dismiss this complaint. The ERISA plaintiffs have appealed this decision to the Third Circuit Court of Appeals. Prescription Opioid Drug Abuse Litigation . The Company has been named as a defendant, along with several other manufacturers and distributors of opioid products, in over 2,000 matters relating to the promotion and sale of prescription opioid pain relievers and additional suits have been filed. The lawsuits allege generally that the manufacturer defendants engaged in a deceptive campaign to promote their products in violation of state laws and seek unspecified monetary damages, penalties and injunctive relief. Plaintiffs in these suits include states, political subdivisions of states (i.e., counties and municipalities), Native American tribes and other private litigants such as insurance plans, hospital systems and consumers who were prescribed opioid products and were subsequently treated for an overdose or addiction. Cases are pending in both federal and state courts. The federal court cases have been consolidated in an MDL in the U.S. District Court for the Northern District of Ohio, with a first set of cases set for trial in October 2019. Testosterone Replacement Therapy Class Action . Subsidiaries of the Company were named in a class action complaint filed on behalf a putative class of third-party payers in the U.S. District Court for the Northern District of Illinois. The suit alleges that the Company’s subsidiaries violated various laws including the federal RICO statute and state consumer protection laws in connection with the sale and marketing of Androderm ® Oculeve Shareholder Dispute . On February 26, 2019, Fortis Advisors LLC, as a representative of the former stockholders of Oculeve, Inc., filed a lawsuit against a subsidiary of the Company in state court in Delaware. The lawsuit centers on a claim that the Company breached the terms of a July 2015 merger agreement. The Company subsidiary has moved to dismiss the complaint. Product Liability Litigation Actonel ® . A subsidiary of the Company is a defendant in over 500 filed cases in federal and various state courts, relating to the bisphosphonate prescription drug Actonel ® ® Breast Implant Litigation . Certain Company subsidiaries are defendants in more than a dozen cases alleging that Allergan’s textured breast implants caused women to develop an uncommon condition known as breast implant associated anaplastic large cell lymphoma (“BIA-ALCL”), and that the defendants failed to properly warn against this risk and failed to promptly and properly report the results of the post-marketing studies relating to these products. These cases have been filed in both federal and state courts in the United States and well as provincial courts in Canada. Five of the Canadian cases have been asserted on behalf putative classes of consumers. On July 24, 2019, Allergan announced a voluntary worldwide recall of unused BIOCELL textured breast implants and tissue expanders. This announcement may impact the number of product liability lawsuits related to BIA-ALCL filed. Benicar ® . A subsidiary of the Company has been named in a number of lawsuits involving allegations that Benicar ® Celexa ® ® . Certain Company subsidiaries are defendants in over 150 actions alleging that Celexa® or Lexapro ® RepliForm ® . A Company subsidiary has been named as a defendant in over 300 cases alleging that its biologic mesh product RepliForm ® Testosterone Litigation . A number of product liability suits were filed against certain Company subsidiaries as well as other manufacturers and distributors of testosterone products, for personal injuries including but not limited to cardiovascular events allegedly arising out of the use of Androderm ® Government Investigations, Government Litigation and Qui Tam Litigation The Company and its subsidiaries are involved in various disputes, governmental and/or regulatory inspections, inquires, investigations and proceedings that could result in litigation, and other litigation matters that arise from time to time. Company subsidiaries have received subpoenas and/or Civil Investigative Demands (“CID”) from the United States Department of Justice, the United States Health and Human Services, Office of Inspector General, United States Congressional Committees as well as various state regulatory and enforcement authorities. Each of the subpoenas and CIDs seek documents and information relating to discrete topics, including but not limited to: the calculation and reporting by certain Company subsidiaries of their Average Manufacturer Prices, Average Wholesale Prices and Best Prices for several of their products; sales and marketing practices of Botox to urology practices; the promotion and sale of two gastroenterology products; the Saint Regis Mohawk Tribe’s acquisition of six Restasis patents and the granting of exclusive licenses to the Restasis product to the Company; and, the promotion and sale of opioid products. In each case, the Company and its subsidiaries are cooperating fully with the governmental authority’s requests. Certain states have initiated lawsuits and qui tam lawsuits have been filed by private parties, also known as relators, on behalf of the federal or state governments. Certain Company subsidiaries have been named as defendants in lawsuits that allege generally that state Medicaid agencies were overcharged for their share of Medicaid drug reimbursement costs due to inflated Average Wholesale Prices (“AWP”) reported by the Company subsidiaries. AWP lawsuits are currently pending in Illinois, Utah and Wisconsin. Namenda XR ® ® . A relator filed a qui tam lawsuit on behalf of the United States government and several individual states against the Company and certain of its subsidiaries along with Adamas Pharma LLC and Adamas Pharmaceuticals, Inc. (collectively, “Adamas”). The lawsuit, filed in the U.S. District Court for the Northern District of California, was unsealed on February 6, 2019. The federal and state governments have declined to intervene in this action. The complaint alleges generally that the Adamas and Allergan defendants each engaged in conduct that delayed generic versions of Namenda XR ® ® Medical Aesthetics Qui Tam . A subsidiary of the Company was recently served with a qui tam lawsuit that was filed in the U.S. District Court for the Central District of California on behalf of the United States and several individual states. The federal and state governments have declined to intervene in this action. The complaint alleges that certain promotional programs and sampling practices of the Company’s Medical Aesthetics business result in price reporting violations and violate anti-kickback statutes. The Company subsidiary has moved to dismiss this complaint. Matters Relating to the Company’s Divested Generics Business The following matters relate to the former generics business of the Company or the transaction pursuant to which that business was sold to Teva, effective August 2, 2016. Teva has agreed to indemnify and defend the Company against all matters asserted in litigation against the Company arising out of the former generics business, including litigations and investigations relating to generic opioid products including, without limitation, the actions described below. Lidoderm ® . The U.S. Federal Trade Commission filed a lawsuit in federal district court in the Eastern District of Pennsylvania against the Company and one of its former global generics business subsidiaries and others alleging that patent litigation settlements relating to Lidoderm were anticompetitive. The FTC voluntarily withdrew its complaint in Pennsylvania and filed a similar complaint in the U.S. District Court for the Northern District California where similar lawsuits filed by private plaintiffs were already pending and where the State of California filed a similar complaint against the same defendants. Defendants in the Pennsylvania action filed a declaratory judgment action against the FTC in the Pennsylvania federal court but the court granted the FTC’s motion to dismiss this lawsuit. The FTC and State of California’s actions were stayed pending the declaratory judgment action in the Eastern District of Pennsylvania. The former global generics entities reached agreements with the government and private plaintiffs to resolve this action in its entirety, including with respect to any claims against the Company. Hydrocortisone Investigation . In 2016, the Company received notice from the UK Competition and Markets Authority (“CMA”) that it would be included within the scope of the CMA’s formal investigation under Section 25 of the Competition Act of 1998 (“CA98”) into suspected abuse of dominance by a former generics business subsidiary of the Company in relation to the supply of 10mg and 20mg hydrocortisone tablets. The CMA is investigating: (i) alleged excessive and unfair prices with respect to hydrocortisone tablets and (ii) whether the former generics business subsidiary entered into anti-competitive agreements with a potential competitor for this product. The CMA has issued statements of objection with respect to both parts of its investigation. The Company intends to cooperate fully with the investigation. Teva Shareholder Derivative Litigation . In 2017, the Company was named as defendant in a proposed Teva shareholder derivative litigation filed in the Economic Division of the Tel Aviv District Court in Israel. The lawsuit contains allegations that the Company aided and abetted Teva’s board of directors violations of Israeli securities laws. To date, the court has not determined whether it will allow plaintiffs to proceed with this action.

Warner Chilcott Limited ("WCL")

Warner Chilcott Limited ("WCL") Guarantor and Non-Guarantor Condensed Consolidating Financial Information	6 Months Ended
	Jun. 30, 2019
Warner Chilcott Acquisition [Member]
Warner Chilcott Limited ("WCL") Guarantor and Non-Guarantor Condensed Consolidating Financial Information	NOTE 21 — Warner Chilcott Limited (“WCL”) Guarantor and Non-Guarantor Condensed Consolidating Financial Information The following financial information is presented to segregate the financial results of WCL, Allergan Funding SCS, and Allergan Finance, LLC (the issuers of the long-term notes), the guarantor subsidiaries for the long-term notes and the non-guarantor subsidiaries. The guarantors jointly and severally, and fully and unconditionally, guarantee the Company’s obligation under the long-term notes. The information includes elimination entries necessary to consolidate the guarantor and the non-guarantor subsidiaries. Investments in subsidiaries are accounted for using the equity method of accounting. The principal elimination entries eliminate investments in subsidiaries, equity and intercompany balances and transactions. WCL, Allergan Capital S.à.r.l. and Allergan Finance, LLC are guarantors of the long-term notes. The Company anticipates future legal entity structure changes which may impact the presentation of this footnote in the future. WCL has revised its consolidating balance sheets as previously presented in Footnote 26 of the December 31, 2018 Annual Report on Form 10-K and its consolidating financial statements as previously presented in Footnote 20 of the June 30 June 30 The following financial information presents the consolidating balance sheets as of June 30 June 30 June 30 Warner Chilcott Limited Consolidating Balance Sheets As of June 30, 2019 (Unaudited; in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited ASSETS Current assets: Cash and cash equivalents $ 0.1 $ 8.1 $ 0.1 $ - $ 1,641.7 $ - $ 1,650.0 Marketable securities - 100.1 - - 222.2 - 322.3 Accounts receivable, net - - - - 3,086.3 - 3,086.3 Receivables from Parents - - - - 210.6 - 210.6 Inventories - - - - 1,004.5 - 1,004.5 Intercompany receivables - 3,298.1 217.2 28.2 27,235.6 (30,779.1 ) - Prepaid expenses and other current assets - - - 33.3 2,471.7 - 2,505.0 Total current assets 0.1 3,406.3 217.3 61.5 35,872.6 (30,779.1 ) 8,778.7 Property, plant and equipment, net - - - - 1,821.0 - 1,821.0 Right of use asset - operating leases - - - - 457.9 - 457.9 Investments and other assets - - - - 335.2 - 335.2 Investment in subsidiaries 57,413.8 65,995.6 25,114.8 95,506.7 - (244,030.9 ) - Non current intercompany receivables - 15,939.7 - - 1,115.4 (17,055.1 ) - Non current assets held for sale - - - - 32.5 - 32.5 Deferred tax assets - 49.6 - - 639.5 - 689.1 Product rights and other intangibles - - - - 41,231.5 - 41,231.5 Goodwill - - - - 42,340.7 - 42,340.7 Total assets $ 57,413.9 $ 85,391.2 $ 25,332.1 $ 95,568.2 $ 123,846.3 $ (291,865.1 ) $ 95,686.6 LIABILITIES AND EQUITY Current liabilities: Accounts payable and accrued expenses - 0.1 154.5 95.6 4,745.0 - 4,995.2 Intercompany payables - 16,431.5 356.5 10,447.6 3,543.5 (30,779.1 ) - Payables to Parents - - - - 2,491.7 - 2,491.7 Income taxes payable - - 2.4 - 91.2 - 93.6 Current portion of long-term debt - - 3,006.4 - 87.8 - 3,094.2 Current portion of lease liability - operating - - - - 123.2 - 123.2 Total current liabilities - 16,431.6 3,519.8 10,543.2 11,082.4 (30,779.1 ) 10,797.9 Long-term debt - - 14,795.2 2,141.0 2,673.1 - 19,609.3 Lease liability - operating - - - - 414.8 - 414.8 Other long-term liabilities - - - - 821.4 - 821.4 Long-term intercompany payables - - - 1,115.4 15,939.7 (17,055.1 ) - Other taxes payable - - - - 1,660.8 - 1,660.8 Deferred tax liabilities - - - - 4,968.5 - 4,968.5 Total liabilities - 16,431.6 18,315.0 13,799.6 37,560.7 (47,834.2 ) 38,272.7 Total equity / (deficit) 57,413.9 68,959.6 7,017.1 81,768.6 86,285.6 (244,030.9 ) 57,413.9 Total liabilities and equity $ 57,413.9 $ 85,391.2 $ 25,332.1 $ 95,568.2 $ 123,846.3 $ (291,865.1 ) $ 95,686.6 Warner Chilcott Limited Consolidating Balance Sheets As of December 31, 2018 (Unaudited; in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited ASSETS Current assets: Cash and cash equivalents $ 0.1 $ 1.8 $ 0.8 $ - $ 875.9 $ - $ 878.6 Marketable securities - 489.9 - - 537.0 - 1,026.9 Accounts receivable, net - - - - 2,868.1 - 2,868.1 Receivables from Parents - - - - 640.9 - 640.9 Inventories - - - - 846.9 - 846.9 Intercompany receivables - 3,534.7 961.0 16.7 24,779.3 (29,291.7 ) - Current assets held for sale - - - - 34.0 - 34.0 Prepaid expenses and other current assets - - - 33.3 785.4 - 818.7 Total current assets 0.1 4,026.4 961.8 50.0 31,367.5 (29,291.7 ) 7,114.1 Property, plant and equipment, net - - - - 1,787.0 - 1,787.0 Investments and other assets - - - - 1,970.6 - 1,970.6 Investment in subsidiaries 62,940.2 73,846.0 26,428.5 99,328.5 - (262,543.2 ) - Non current intercompany receivables - 28,239.4 18,090.2 - 19,674.2 (66,003.8 ) - Non current assets held for sale - - - - 882.2 - 882.2 Deferred tax assets - 43.6 - - 1,020.1 - 1,063.7 Product rights and other intangibles - - - - 43,695.4 - 43,695.4 Goodwill - - - - 45,913.3 - 45,913.3 Total assets $ 62,940.3 $ 106,155.4 $ 45,480.5 $ 99,378.5 $ 146,310.3 $ (357,838.7 ) $ 102,426.3 LIABILITIES AND EQUITY Current liabilities: Accounts payable and accrued expenses - 0.1 156.3 92.9 4,538.1 - 4,787.4 Intercompany payables - 14,315.0 21.7 10,442.6 4,512.4 (29,291.7 ) - Payables to Parents - - - - 2,829.2 - 2,829.2 Income taxes payable - - - - 72.4 - 72.4 Current portion of long-term debt - - 779.6 - 88.7 - 868.3 Total current liabilities - 14,315.1 957.6 10,535.5 12,040.8 (29,291.7 ) 8,557.3 Long-term debt - - 18,090.2 2,135.9 2,703.3 - 22,929.4 Other long-term liabilities - - - - 882.0 - 882.0 Long-term intercompany payables - 18,597.4 - 1,076.8 46,329.6 (66,003.8 ) - Other taxes payable - - - - 1,615.5 - 1,615.5 Deferred tax liabilities - - - - 5,501.8 - 5,501.8 Total liabilities - 32,912.5 19,047.8 13,748.2 69,073.0 (95,295.5 ) 39,486.0 Total equity / (deficit) 62,940.3 73,242.9 26,432.7 85,630.3 77,237.3 (262,543.2 ) 62,940.3 Total liabilities and equity $ 62,940.3 $ 106,155.4 $ 45,480.5 $ 99,378.5 $ 146,310.3 $ (357,838.7 ) $ 102,426.3 Warner Chilcott Limited Consolidating Statements of Operations For the Three Months Ended June 30, 2019 (Unaudited; in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues $ - $ - $ - $ - $ 4,090.1 $ - $ 4,090.1 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 652.3 - 652.3 Research and development - - - - 450.0 - 450.0 Selling and marketing - - - - 873.3 - 873.3 General and administrative - - - - 316.4 - 316.4 Amortization - - - - 1,402.0 - 1,402.0 Goodwill impairments - - - - 1,085.8 - 1,085.8 In-process research and development impairments - - - - 436.0 - 436.0 Asset sales and impairments, net - - - - 129.4 - 129.4 Total operating expenses - - - - 5,345.2 - 5,345.2 Operating (loss) - - - - (1,255.1 ) - (1,255.1 ) Interest (expense) / income, net - (23.5 ) 48.0 (20.0 ) (190.2 ) - (185.7 ) Other (expense), net - - - - (4.7 ) - (4.7 ) Total other (expense) / income, net - (23.5 ) 48.0 (20.0 ) (194.9 ) - (190.4 ) (Loss) / income before income taxes and noncontrolling interest - (23.5 ) 48.0 (20.0 ) (1,450.0 ) - (1,445.5 ) Provision for income taxes - 1.8 - - 299.8 - 301.6 Losses / (earnings) of equity interest subsidiaries 1,751.2 1,715.8 373.9 1,004.6 - (4,845.5 ) - Net (loss) / income $ (1,751.2 ) $ (1,741.1 ) $ (325.9 ) $ (1,024.6 ) $ (1,749.8 ) $ 4,845.5 $ (1,747.1 ) (Income) attributable to noncontrolling interest - - - - (4.1 ) - (4.1 ) Net (loss) / income attributable to members $ (1,751.2 ) $ (1,741.1 ) $ (325.9 ) $ (1,024.6 ) $ (1,753.9 ) $ 4,845.5 $ (1,751.2 ) Other comprehensive income / (loss), net of tax 65.3 (33.0 ) 42.6 145.9 65.3 (220.8 ) 65.3 Comprehensive (loss) / income attributable to members $ (1,685.9 ) $ (1,774.1 ) $ (283.3 ) $ (878.7 ) $ (1,688.6 ) $ 4,624.7 $ (1,685.9 ) Warner Chilcott Limited Consolidating Statements of Operations For the Six Months Ended June 30, 2019 (Unaudited; in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues $ - $ - $ - $ - $ 7,687.2 $ - $ 7,687.2 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 1,150.1 - 1,150.1 Research and development - - - - 885.0 - 885.0 Selling and marketing - - - - 1,677.3 - 1,677.3 General and administrative - - - - 622.5 - 622.5 Amortization - - - - 2,801.4 - 2,801.4 Goodwill impairments - - - - 3,552.8 - 3,552.8 In-process research and development impairments - - - - 436.0 - 436.0 Asset sales and impairments, net - - - - 124.2 - 124.2 Total operating expenses - - - - 11,249.3 - 11,249.3 Operating (loss) - - - - (3,562.1 ) - (3,562.1 ) Interest (expense), net - (46.9 ) (11.6 ) (39.9 ) (267.8 ) - (366.2 ) Other (expense) / income, net - - (0.1 ) - 9.2 - 9.1 Total other (expense), net - (46.9 ) (11.7 ) (39.9 ) (258.6 ) - (357.1 ) (Loss) before income taxes and noncontrolling interest - (46.9 ) (11.7 ) (39.9 ) (3,820.7 ) - (3,919.2 ) Provision for income taxes - 1.8 - - 231.1 - 232.9 Losses / (earnings) of equity interest subsidiaries 4,156.9 4,060.8 1,183.4 3,382.7 - (12,783.8 ) - Net (loss) / income $ (4,156.9 ) $ (4,109.5 ) $ (1,195.1 ) $ (3,422.6 ) $ (4,051.8 ) $ 12,783.8 $ (4,152.1 ) (Income) attributable to noncontrolling interest - - - - (4.8 ) - (4.8 ) Net (loss) / income attributable to members $ (4,156.9 ) $ (4,109.5 ) $ (1,195.1 ) $ (3,422.6 ) $ (4,056.6 ) $ 12,783.8 $ (4,156.9 ) Other comprehensive (loss) / income, net of tax (63.5 ) (173.8 ) (130.3 ) (439.1 ) (63.5 ) 806.7 (63.5 ) Comprehensive (loss) / income attributable to members $ (4,220.4 ) $ (4,283.3 ) $ (1,325.4 ) $ (3,861.7 ) $ (4,120.1 ) $ 13,590.5 $ (4,220.4 ) Warner Chilcott Limited Consolidating Statements of Operations For the Three Months Ended June 30, 2018 (Unaudited; in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues $ - $ - $ - $ - $ 4,124.2 $ - $ 4,124.2 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 481.8 - 481.8 Research and development - - - - 689.2 - 689.2 Selling and marketing - - - - 853.4 - 853.4 General and administrative - - 1.2 - 298.3 - 299.5 Amortization - - - - 1,697.1 - 1,697.1 In-process research and development impairments - - - - 276.0 - 276.0 Asset sales and impairments, net - - - - 259.6 - 259.6 Total operating expenses - - 1.2 - 4,555.4 - 4,556.6 Operating (loss) - - (1.2 ) - (431.2 ) - (432.4 ) Interest income / (expense), net - 267.4 (5.1 ) (20.7 ) (399.8 ) - (158.2 ) Other (expense) / income, net - - 9.2 - 206.2 - 215.4 Total other income / (expense), net - 267.4 4.1 (20.7 ) (193.6 ) - 57.2 Income / (loss) before income taxes and noncontrolling interest - 267.4 2.9 (20.7 ) (624.8 ) - (375.2 ) (Benefit) / provision for income taxes - - - (4.4 ) (0.8 ) - (5.2 ) Losses / (earnings) of equity interest subsidiaries 372.4 512.4 (118.7 ) (550.8 ) - (215.3 ) - Net (loss) / income $ (372.4 ) $ (245.0 ) $ 121.6 $ 534.5 $ (624.0 ) $ 215.3 $ (370.0 ) (Income) attributable to noncontrolling interest - - - - (2.4 ) - (2.4 ) Net (loss) / income attributable to members $ (372.4 ) $ (245.0 ) $ 121.6 $ 534.5 $ (626.4 ) $ 215.3 $ (372.4 ) Other comprehensive (loss) / income, net of tax (448.6 ) (295.6 ) (59.7 ) (195.6 ) (448.6 ) 999.5 (448.6 ) Comprehensive (loss) / income attributable to members $ (821.0 ) $ (540.6 ) $ 61.9 $ 338.9 $ (1,075.0 ) $ 1,214.8 $ (821.0 ) Warner Chilcott Limited Consolidating Statements of Operations For the Six Months Ended June 30, 2018 (Unaudited; in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues $ - $ - $ - $ - $ 7,796.3 $ - $ 7,796.3 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 1,004.6 - 1,004.6 Research and development - - - - 1,163.9 - 1,163.9 Selling and marketing - - - - 1,653.4 - 1,653.4 General and administrative - - 0.5 - 593.1 - 593.6 Amortization - - - - 3,394.7 - 3,394.7 In-process research and development impairments - - - - 798.0 - 798.0 Asset sales and impairments, net - - - - 272.7 - 272.7 Total operating expenses - - 0.5 - 8,880.4 - 8,880.9 Operating (loss) - - (0.5 ) - (1,084.1 ) - (1,084.6 ) Interest income / (expense), net - 526.4 (8.4 ) (41.9 ) (814.6 ) - (338.5 ) Other income, net - - 9.2 - 127.4 - 136.6 Total other income / (expense), net - 526.4 0.8 (41.9 ) (687.2 ) - (201.9 ) Income / (loss) before income taxes and noncontrolling interest - 526.4 0.3 (41.9 ) (1,771.3 ) - (1,286.5 ) Provision / (benefit) for income taxes - - 0.3 (16.6 ) (671.1 ) - (687.4 ) Losses / (earnings) of equity interest subsidiaries 603.7 1,018.4 214.4 99.2 - (1,935.7 ) - Net (loss) / income $ (603.7 ) $ (492.0 ) $ (214.4 ) $ (124.5 ) $ (1,100.2 ) $ 1,935.7 $ (599.1 ) (Income) attributable to noncontrolling interest - - - - (4.6 ) - (4.6 ) Net (loss) / income attributable to members $ (603.7 ) $ (492.0 ) $ (214.4 ) $ (124.5 ) $ (1,104.8 ) $ 1,935.7 $ (603.7 ) Other comprehensive (loss) / income, net of tax (264.8 ) (25.0 ) 59.2 164.4 (264.8 ) 66.2 (264.8 ) Comprehensive (loss) / income attributable to members $ (868.5 ) $ (517.0 ) $ (155.2 ) $ 39.9 $ (1,369.6 ) $ 2,001.9 $ (868.5 ) Warner Chilcott Limited Consolidating Statements of Cash Flows For the Six Months Ended June 30, 2019 (Unaudited; in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash Flows From Operating Activities: Net (loss) / income $ (4,156.9 ) $ (4,109.5 ) $ (1,195.1 ) $ (3,422.6 ) $ (4,051.8 ) $ 12,783.8 $ (4,152.1 ) Reconciliation to net cash provided by / (used in) operating activities: Losses / (earnings) of equity interest subsidiaries 4,156.9 4,060.8 1,183.4 3,382.7 - (12,783.8 ) - Depreciation - - - - 96.2 - 96.2 Amortization - - - - 2,801.4 - 2,801.4 Provision for inventory reserve - - - - 83.4 - 83.4 Share-based compensation - - - - 111.8 - 111.8 Deferred income tax benefit - - - - (166.4 ) - (166.4 ) Goodwill impairments - - - - 3,552.8 - 3,552.8 In-process research and development impairments - - - - 436.0 - 436.0 Loss on asset sales and impairments, net - - - - 124.2 - 124.2 Non-cash extinguishment of debt - - - - 0.2 - 0.2 Amortization of deferred financing costs - - 8.3 0.8 - - 9.1 Non-cash lease expense - - - - 68.0 - 68.0 Contingent consideration adjustments, including accretion - - - - 46.8 - 46.8 Dividends from subsidiaries 1,288.5 - - - - (1,288.5 ) - Other, net - - (2.5 ) (0.9 ) (15.9 ) - (19.3 ) Changes in assets and liabilities (net of effects of acquisitions) - (134.4 ) 1,036.8 40.0 (1,300.0 ) - (357.6 ) Net cash provided by / (used in) operating activities 1,288.5 (183.1 ) 1,030.9 - 1,786.7 (1,288.5 ) 2,634.5 Cash Flows From Investing Activities: Additions to property, plant and equipment - - - - (152.3 ) - (152.3 ) Additions to product rights and other intangibles - - - - (46.0 ) - (46.0 ) Additions to investments - (100.0 ) - - (638.2 ) - (738.2 ) Proceeds from sale of investments and other assets - 289.4 - - 1,172.6 - 1,462.0 Proceeds from sales of property, plant and equipment - - - - 17.7 - 17.7 Acquisitions of businesses, net of cash acquired - - - - (80.6 ) - (80.6 ) Net cash provided by investing activities - 189.4 - - 273.2 - 462.6 Cash Flows From Financing Activities: Proceeds from borrowings of long-term indebtedness, including credit facility - - - - 3.3 - 3.3 Payments on debt, including finance lease obligations and credit facility - - (1,031.6 ) - (7.5 ) - (1,039.1 ) Payments of contingent consideration and other financing - - - - (4.1 ) - (4.1 ) Dividends to Parents (1,288.5 ) - - - (1,288.5 ) 1,288.5 (1,288.5 ) Net cash (used in) / provided by financing activities (1,288.5 ) - (1,031.6 ) - (1,296.8 ) 1,288.5 (2,328.4 ) Effect of currency exchange rate changes on cash and cash equivalents - - - - 2.7 - 2.7 Net increase / (decrease) in cash and cash equivalents - 6.3 (0.7 ) - 765.8 - 771.4 Cash and cash equivalents at beginning of period 0.1 1.8 0.8 - 875.9 - 878.6 Cash and cash equivalents at end of period $ 0.1 $ 8.1 $ 0.1 $ - $ 1,641.7 $ - $ 1,650.0 Warner Chilcott Limited Consolidating Statements of Cash Flows For the Six Months Ended June 30, 2018 (Unaudited; in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash Flows From Operating Activities: Net (loss) / income $ (603.7 ) $ (492.0 ) $ (214.4 ) $ (124.5 ) $ (1,100.2 ) $ 1,935.7 $ (599.1 ) Reconciliation to net cash provided by / (used in) operating activities: Losses / (earnings) of equity interest subsidiaries 603.7 1,018.4 214.4 99.2 - (1,935.7 ) - Depreciation - - - - 105.2 - 105.2 Amortization - - - - 3,394.7 - 3,394.7 Provision for inventory reserve - - - - 45.4 - 45.4 Share-based compensation - - - - 127.4 - 127.4 Deferred income tax benefit - - - - (1,359.6 ) - (1,359.6 ) In-process research and development impairments - - - - 798.0 - 798.0 Loss on asset sales and impairments, net - - - - 272.7 - 272.7 Gain on sale of Teva securities, net - - - - (60.9 ) - (60.9 ) Gain on sale of business - - - - (53.0 ) - (53.0 ) Non-cash extinguishment of debt - - 4.0 - - - 4.0 Cash charge related to extinguishment of debt - - (13.1 ) - - - (13.1 ) Amortization of deferred financing costs - - 11.1 0.8 - - 11.9 Contingent consideration adjustments, including accretion - - - - (101.8 ) - (101.8 ) Dividends from subsidiaries 2,103.7 - - - - (2,103.7 ) - Other, net - - (1.5 ) (0.4 ) 1.6 - (0.3 ) Changes in assets and liabilities (net of effects of acquisitions) - (1,225.0 ) 3,942.3 24.9 (2,578.4 ) - 163.8 Net cash provided by / (used in) operating activities 2,103.7 (698.6 ) 3,942.8 - (508.9 ) (2,103.7 ) 2,735.3 Cash Flows From Investing Activities: Additions to property, plant and equipment - - - - (106.5 ) - (106.5 ) Additions to investments - (400.0 ) - - (1,055.9 ) - (1,455.9 ) Proceeds from sale of investments and other assets - 800.0 - - 4,851.3 - 5,651.3 Payments to settle Teva related matters - - - - (466.0 ) - (466.0 ) Proceeds from sales of property, plant and equipment - - - - 11.5 - 11.5 Net cash provided by investing activities - 400.0 - - 3,234.4 - 3,634.4 Cash Flows From Financing Activities: Proceeds from borrowings of long-term indebtedness, including credit facility - 700.0 - - 9.0 - 709.0 Payments on debt, including finance lease obligations and credit facility - (700.0 ) (3,956.0 ) - (710.8 ) - (5,366.8 ) Cash charge related to extinguishment of debt - - 13.1 - - - 13.1 Payments of contingent consideration and other financing - - - - (10.6 ) - (10.6 ) Proceeds from forward sale of Teva securities - - - - 465.5 - 465.5 Payments to settle Teva related matters - - - - (234.0 ) - (234.0 ) Dividends to Parents (2,103.7 ) - - - (2,103.7 ) 2,103.7 (2,103.7 ) Net cash (used in) / provided by financing activities (2,103.7 ) - (3,942.9 ) - (2,584.6 ) 2,103.7 (6,527.5 ) Effect of currency exchange rate changes on cash and cash equivalents - - - - 15.0 - 15.0 Net (decrease) / increase in cash and cash equivalents - (298.6 ) (0.1 ) - 155.9 - (142.8 ) Cash and cash equivalents at beginning of period 0.1 593.1 0.1 - 1,223.0 - 1,816.3 Cash and cash equivalents at end of period $ 0.1 $ 294.5 $ - $ - $ 1,378.9 $ - $ 1,673.5

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Implementation of New Guidance	Implementation of New Guidance In February 2016, the Financial Accounting Standards Board (“FASB”) established Topic 842, Leases, by issuing Accounting Standards Update (“ASU”) No. 2016-02, which requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842; ASU No. 2018-10, Codification Improvements to Topic 842, Leases; and ASU No. 2018-11, Targeted Improvements. The new standard establishes a right-of-use model (“ROU”) that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. On January 1, 2019, the Company adopted the new standard using the modified retrospective transition approach applied to all leases existing at the effective date of initial application of January 1, 2019. Prior period amounts are not adjusted and continue to be reported in accordance with historical accounting practices and the disclosures under the new standard are not required for dates and periods prior to January 1, 2019. When evaluating whether a contract contains a lease under the new standard, Allergan considers whether (1) the contract explicitly or implicitly identifies assets that are contractually defined and (2) the Company obtains substantially all of the economic benefits from the use of that underlying asset and directs how and for what purpose the asset is used during the term of the contract. The Company does not have the right to use an identified asset if the supplier has the substantive right to substitute the asset throughout the period without the Company’s approval. The new standard provides a number of optional practical expedients in transition. The Company elected the ‘package of practical expedients’ which permits us not to reassess our prior conclusions about lease identification, lease classification and initial direct costs under the new standard. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter was not applicable to the Company. This standard has a significant impact on our consolidated balance sheet but did not have a significant impact on our consolidated statements of operations. The most significant effects relate to the recognition of ROU assets and lease liabilities on our balance sheet for our real estate and fleet operating leases. Upon adoption, the Company recognized lease liabilities and corresponding ROU assets as follows ($ in millions): ROU Asset Lease Liability Real estate $ 304.2 $ 370.6 Fleet 100.4 100.4 Other 57.5 77.6 Total operating leases $ 462.1 $ 548.6 The cumulative effective adjustment as of the effective date of $22.0 million was recorded to opening retained earnings. The Company has an immaterial amount of finance leases. The new standard also provides practical expedients for an entity’s ongoing accounting. The Company elected the lease recognition exemption for all leases with lease terms of 12 months or less. For leases that qualify under this exception, the Company will not recognize ROU assets or lease liabilities and did not recognize ROU assets or lease liabilities for existing short-term leases of those assets in transition. The Company also elected the practical expedient to not separate lease and non-lease components for leases of real estate, fleet, IT and office equipment. Refer to “NOTE 13 – Leases” for further information related to the Company’s leases. In February 2018, the FASB issued ASU No. 2018-02, Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. This update allows for the optional reclassification of stranded tax effects resulting from the Tax Cuts and Jobs Act (“TCJA”) from accumulated other comprehensive income to retained earnings. The amount of the reclassification is calculated as the difference between the historical and newly enacted tax rates on deferred taxes originally recorded through accumulated other comprehensive income. The Company adopted the standard as of January 1, 2019; however, due to the immaterial amount of the stranded tax effects, the Company elected not to reclassify the income tax effects from accumulated other comprehensive income to retained earnings. Tax effects unrelated to the TCJA are released from accumulated other comprehensive income using either the specific identification approach or the portfolio approach based on the nature of the underlying item. retrospective adoption through 2018 beginning Retained Earnings and Accumulated Other Comprehensive Income. This was incorrectly recorded as a loss through Other Comprehensive Income of $63.0 million during the quarter ended March 31, 2018. This was corrected during 2018 and therefore, has no impact on the annual consolidated financial statements. The Company has determined that the adjustment was not material to any previously reported interim period. The Consolidated Statement of Comprehensive (Loss) for the six months ended , 2018 has been adjusted to correct for this error.
Revenue Recognition	Revenue Recognition General ASU No. 2014-09, “Revenue from Contracts with Customers” (“Topic 606”) provides that revenues are recognized when control of the promised goods under a contract is transferred to a customer, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods as specified in the underlying terms with the customer. The Company warrants products against defects and for specific quality standards, permitting the return of products under certain circumstances. Product sales are recorded net of all sales-related deductions including, but not limited to: chargebacks, trade discounts, commercial and government rebates, customer loyalty programs, fee-for-service arrangements with certain distributors, returns, and other allowances which we refer to in the aggregate as sales returns and allowances (“SRA”). The Company’s performance obligations are primarily achieved when control of the products is transferred to the customer. Transfer of control is based on contractual performance obligations, but typically occurs upon receipt of the goods by the customer as that is when the customer has obtained control of significantly all of the economic benefits . Refer to “NOTE 8 – Reportable Segments” for our revenues disaggregated by product and segment and our revenues disaggregated by geography for our international segment. We believe this level of disaggregation best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. The following table summarizes the activity from operations in the Company’s major categories of SRA ($ in millions): Chargebacks Rebates Returns and Other Allowances Cash Discounts Total Balance at December 31, 2018 $ 61.8 $ 1,908.5 $ 566.6 $ 30.7 $ 2,567.6 Provision related to sales in 2019 553.2 2,876.3 835.8 159.2 4,424.5 Credits and payments (545.1 ) (2,769.3 ) (781.5 ) (156.9 ) (4,252.8 ) Balance at June 30, 2019 $ 69.9 $ 2,015.5 $ 620.9 $ 33.0 $ 2,739.3 Contra accounts receivable at June 30, 2019 $ 69.9 $ 81.1 $ 34.6 $ 33.0 $ 218.6 Accounts payable and accrued expenses at June 30, 2019 $ - $ 1,934.4 $ 586.3 $ - $ 2,520.7 The following table summarizes the balance sheet classification of our SRA reserves ($ in millions): June 30, 2019 December 31, 2018 Contra accounts receivable $ 218.6 $ 207.7 Accounts payable and accrued expenses 2,520.7 2,359.9 Total $ 2,739.3 $ 2,567.6 The SRA provisions recorded to reduce gross product sales to net product sales were as follows ($ in millions): Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Gross product sales $ 6,295.6 $ 6,095.5 $ 11,955.5 $ 11,711.6 Provisions to reduce gross product sales to net product sales (2,284.8 ) (2,087.3 ) (4,424.5 ) (4,122.4 ) Net product sales $ 4,010.8 $ 4,008.2 $ 7,531.0 $ 7,589.2 Percentage of SRA provisions to gross sales 36.3 % 34.2 % 37.0 % 35.2 % Collectability Assessment
Goodwill and Intangible Assets with Indefinite Lives	Goodwill and Intangible Assets with Indefinite Lives General The Company tests goodwill and intangible assets with indefinite lives for impairment annually in the second quarter. Additionally, the Company may perform interim tests if an event occurs or circumstances change that could potentially reduce the fair value of a reporting unit or an indefinite lived intangible asset below its carrying amount. The carrying value of each reporting unit is determined by assigning the assets and liabilities, including the existing goodwill and intangible assets, to those reporting units. The Company tests goodwill for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation is an assessment of factors, including Reporting Unit specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of a Reporting Unit is less than its carrying amount, including goodwill. The Company may elect to bypass this qualitative assessment for some or all of its Reporting Units and perform a quantitative test as of the measurement date of the test . Goodwill is considered impaired if the carrying amount of the net assets exceeds the fair value of the reporting unit. Impairment, if any, would be recorded in operating income / (loss) and this could result in a material impact to net income / (loss) and income / (loss) per share. Prior to Allergan’s 2018 annual impairment test, the Company adopted the new guidance under Accounting Standard Update No. 2017-04, Intangibles – Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment Acquired in-process research and development (“IPR&D”) intangible assets represent the value assigned to research and development projects acquired in a business combination that, as of the date acquired, represent the right to develop, use, sell and/or offer for sale a product or other intellectual property that has not been completed or approved. The IPR&D intangible assets are subject to impairment testing until completion or abandonment of each project. Upon abandonment, the assets are impaired if there is no future alternative use or ability to sell the asset. Impairment testing requires the development of significant estimates and assumptions involving the determination of estimated net cash flows for each year for each project or product (including net revenues, cost of sales, research and development (“R&D”) costs, probability of success of development projects, selling and marketing costs and other costs which may be allocated), determination of the appropriate discount rate in order to measure the risk inherent in each future cash flow stream, assessment of each asset’s life cycle, potential regulatory and commercial success risks, and competitive trends impacting the asset and each cash flow stream as well as other factors. The major risks and uncertainties associated with the timely and successful completion of IPR&D projects include legal risk, market risk and regulatory risk. Changes in our assumptions could result in future impairment charges. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change or the timely completion of each project and commercial success will occur. For these and other reasons, actual results may vary significantly from estimated results. Upon successful completion of each project and approval of a product, we will make a separate determination of the useful life of the intangible asset, transfer the amount to currently marketed products (“CMP”) and amortization expense will be recorded over the estimated useful life. Refer to “NOTE 11 –Goodwill, Product Rights, and Other Intangible Assets” for further discussion on the Company’s goodwill and intangible assets balances and impairments.
Earnings Per Share ("EPS")	Earnings Per Share (“EPS”) The Company computes EPS in accordance with Accounting Standards Codification (“ASC”) Topic 260, “Earnings Per Share” (“ASC 260”) and related guidance, which requires two calculations of EPS to be disclosed: basic and diluted. Basic EPS is computed by dividing net (loss) by the weighted average ordinary shares outstanding during a period. Diluted EPS is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and restricted stock units. Ordinary share equivalents have been excluded where their inclusion would be anti-dilutive. A reconciliation of the numerators and denominators of basic and diluted EPS follows ($ in millions, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Net (loss): Net (loss) attributable to ordinary shareholders $ (1,759.0 ) $ (472.5 ) $ (4,167.0 ) $ (805.0 ) Basic weighted average ordinary shares outstanding 327.8 339.1 329.9 336.9 Basic EPS: Net (loss) per share $ (5.37 ) $ (1.39 ) $ (12.63 ) $ (2.39 ) Dividends per ordinary share $ 0.74 $ 0.72 $ 1.48 $ 1.44 Diluted weighted average ordinary shares outstanding 327.8 339.1 329.9 336.9 Diluted EPS: Net (loss) per share $ (5.37 ) $ (1.39 ) $ (12.63 ) $ (2.39 ) Stock awards to purchase 1.6 million and 1.8 million ordinary shares for the three and six months ended June 30, 2019, respectively, were outstanding, but not included in the computation of diluted EPS, because the awards were anti-dilutive. No shares were repurchased in the three months ended June 30, 2019. The impact of the 5.3 million shares repurchased in the six months ended June 30, 2019 on basic EPS was 3.0 million weighted average shares. Stock awards to purchase 2.2 million ordinary shares for the three and six months ended June 30, 2018 were outstanding, but not included in the computation of diluted EPS, because the awards were anti-dilutive. The Company’s preferred shares were mandatorily converted to ordinary shares on March 1, 2018. The weighted average impact of ordinary share equivalents of 5.8 million for the six months ended June 30, 2018, which would result from the mandatory conversion of the Company’s preferred shares at the beginning of the period, were not included in the calculation of diluted EPS as their impact would be anti-dilutive.
Research and Development Activities	Research and Development Activities Research and development (“R&D”) activities are expensed as incurred and consist of self-funded R&D costs, the costs associated with work performed under collaborative R&D agreements, regulatory fees, and acquisition and license related milestone payments, if any. As of June 30, 2019, we are developing a number of products, some of which utilize novel drug delivery systems, through a combination of internal and collaborative programs, and we additionally have products in development as part of our life-cycle management strategy for our existing product portfolio. These development projects include but are not limited to the following: Product Therapeutic Area Indication Expected Launch Year Phase Cariprazine Central Nervous System Bipolar Depression 2019 Approved Ubrogepant Central Nervous System Acute Migraine 2020 Review Bimatoprost SR Eye Care Glaucoma 2020 Review Abicipar Eye Care Age Related Macular Degeneration 2020 III Atogepant Central Nervous System Prophylaxis Migraine 2021 III Presbysol Eye Care Presbyopia 2021 III Cenicriviroc Gastrointestinal NASH 2022 III Relamorelin Gastrointestinal Gastroparesis 2023 III Brimonidine DDS Eye Care Geographic Atrophy 2023 II Botox Medical Aesthetics Platysma/Masseter 2025/2024 II Abicipar Eye Care Diabetic Macular Edema 2025 II Brazikumab Gastrointestinal Crohn's Disease 2025 II Brazikumab Gastrointestinal Ulcerative Colitis 2026 II
Recent Accounting Pronouncements	Recent Accounting Pronouncements In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606. The ASU provides more comparability in the presentation of revenue for certain transactions between collaborative arrangement participants and only allows a company to present units of account in collaborative arrangements that are within the scope of the revenue recognition standard together with revenue accounted for under the revenue recognition standard. The parts of the collaborative arrangement that are not in the scope of the revenue recognition standard should be presented separately from revenue accounted for under the revenue recognition standard. The amendments in ASU No. 2018-18 are effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company is evaluating the impact, if any, that this pronouncement will have on our financial position and results of operations. In August 2018, the FASB issued ASU No. 2018-15, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40), relating to a customer's accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement that is hosted by a vendor (i.e., a service contract). Under the new guidance, a customer will apply the same criteria for capitalizing implementation costs as it would for an arrangement that has a software license. The new guidance also prescribes the balance sheet, income statement, and cash flow classification of the capitalized implementation costs and related amortization expense, and requires additional quantitative and qualitative disclosures. The ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early application is permitted. The Company can choose to adopt the new guidance (1) prospectively to eligible costs incurred on or after the date this guidance is first applied or (2) retrospectively. The Company is evaluating the impact, if any, that this pronouncement will have on our financial position and results of operations. In August 2018, the FASB issued ASU No. 2018-14, Compensation - Retirement Benefits - Defined Benefit Plans - General (Subtopic 715-20) – Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans, which amends ASC 715 to add, remove, and clarify disclosure requirements related to defined benefit pension and other postretirement plans. The revisions to the disclosure requirements affect only the year-end financial statements of plan sponsors, as there are no changes related to interim financial statements. The ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early application is permitted. The ASU provisions will be applied on a retrospective basis to all periods presented. This pronouncement only has an impact to disclosure requirements and does not have an impact on our financial position or results of operations. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, which removes, adds and modifies certain disclosure requirements for fair value measurements The Company will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, and the valuation processes of Level 3 fair value measurements. However, the Company will be required to additionally disclose the changes in unrealized gains and losses included in other comprehensive income for recurring Level 3 fair value measurements, and the range and weighted average of assumptions used to develop significant unobservable inputs for Level 3 fair value measurements. permitted to early adopt either the entire ASU or only the provisions that eliminate or modify the requirements.

Reconciliation of Warner Chil_2

Reconciliation of Warner Chilcott Limited Results to Allergan plc Results (Tables)	6 Months Ended
	Jun. 30, 2019
Adjusted Earnings Before Interest Taxes Depreciation And Amortization And Other Non Cash Items [Abstract]
Summary of Financial Position Reconciliation Results of Warner Chilcott Limited to Allergan Plc	As of June 30, 2019 As of December 31, 2018 Allergan plc Warner Chilcott Limited Difference Allergan plc Warner Chilcott Limited Difference Cash and cash equivalents $ 1,651.4 $ 1,650.0 $ 1.4 $ 880.4 $ 878.6 $ 1.8 Prepaid expenses and other current assets 2,508.3 2,505.0 3.3 819.1 818.7 0.4 Accounts payable and accrued liabilities 4,995.3 4,995.2 0.1 4,787.2 4,787.4 (0.2 ) Income taxes payable 91.0 93.6 (2.6 ) 72.4 72.4 - Other taxes payable 1,667.0 1,660.8 6.2 1,615.5 1,615.5 - Deferred tax liabilities 4,968.4 4,968.5 (0.1 ) 5,501.8 5,501.8 - Total equity 59,696.1 57,413.9 2,282.2 65,131.0 62,940.3 2,190.7
Summary of Operations Reconciliation Results of Warner Chilcott Limited to Allergan Plc	Three Months Ended June 30, 2019 Six Months Ended June 30, 2019 Allergan plc Warner Chilcott Limited Difference Allergan plc Warner Chilcott Limited Difference General and administrative expenses $ 324.2 $ 316.4 $ 7.8 $ 632.5 $ 622.5 $ 10.0 Operating (loss) (1,262.9 ) (1,255.1 ) (7.8 ) (3,572.1 ) (3,562.1 ) (10.0 ) (Loss) before income taxes and noncontrolling interest (1,453.3 ) (1,445.5 ) (7.8 ) (3,929.2 ) (3,919.2 ) (10.0 ) Provision for income taxes 301.6 301.6 - 233.0 232.9 0.1 Net (loss) (1,754.9 ) (1,747.1 ) (7.8 ) (4,162.2 ) (4,152.1 ) (10.1 ) Net (loss) attributable to ordinary shareholders/members (1,759.0 ) (1,751.2 ) (7.8 ) (4,167.0 ) (4,156.9 ) (10.1 ) Three Months Ended June 30, 2018 Six Months Ended June 30, 2018 Allergan plc Warner Chilcott Limited Difference Allergan plc Warner Chilcott Limited Difference General and administrative expenses $ 334.1 $ 299.5 $ 34.6 $ 630.0 $ 593.6 $ 36.4 Operating (loss) (467.0 ) (432.4 ) (34.6 ) (1,121.0 ) (1,084.6 ) (36.4 ) Interest income 6.3 71.8 (65.5 ) 23.6 142.1 (118.5 ) (Loss) before income taxes and noncontrolling interest (475.3 ) (375.2 ) (100.1 ) (1,441.4 ) (1,286.5 ) (154.9 ) Net (loss) (470.1 ) (370.0 ) (100.1 ) (754.0 ) (599.1 ) (154.9 ) Dividends on preferred shares - - - 46.4 - 46.4 Net (loss) attributable to ordinary shareholders/members (472.5 ) (372.4 ) (100.1 ) (805.0 ) (603.7 ) (201.3 )

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Schedule of Recognized Lease Liabilities and Corresponding Right of Use Assets	Upon adoption, the Company recognized lease liabilities and corresponding ROU assets as follows ($ in millions): ROU Asset Lease Liability Real estate $ 304.2 $ 370.6 Fleet 100.4 100.4 Other 57.5 77.6 Total operating leases $ 462.1 $ 548.6
Provisions for Sales Returns and Allowances from Continuing Operations Activity	The following table summarizes the activity from operations in the Company’s major categories of SRA ($ in millions): Chargebacks Rebates Returns and Other Allowances Cash Discounts Total Balance at December 31, 2018 $ 61.8 $ 1,908.5 $ 566.6 $ 30.7 $ 2,567.6 Provision related to sales in 2019 553.2 2,876.3 835.8 159.2 4,424.5 Credits and payments (545.1 ) (2,769.3 ) (781.5 ) (156.9 ) (4,252.8 ) Balance at June 30, 2019 $ 69.9 $ 2,015.5 $ 620.9 $ 33.0 $ 2,739.3 Contra accounts receivable at June 30, 2019 $ 69.9 $ 81.1 $ 34.6 $ 33.0 $ 218.6 Accounts payable and accrued expenses at June 30, 2019 $ - $ 1,934.4 $ 586.3 $ - $ 2,520.7
Schedule of Balance Sheet Classification of SRA Reserves	The following table summarizes the balance sheet classification of our SRA reserves ($ in millions): June 30, 2019 December 31, 2018 Contra accounts receivable $ 218.6 $ 207.7 Accounts payable and accrued expenses 2,520.7 2,359.9 Total $ 2,739.3 $ 2,567.6
Summary of Activity in Gross-to-Net Revenue	The SRA provisions recorded to reduce gross product sales to net product sales were as follows ($ in millions): Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Gross product sales $ 6,295.6 $ 6,095.5 $ 11,955.5 $ 11,711.6 Provisions to reduce gross product sales to net product sales (2,284.8 ) (2,087.3 ) (4,424.5 ) (4,122.4 ) Net product sales $ 4,010.8 $ 4,008.2 $ 7,531.0 $ 7,589.2 Percentage of SRA provisions to gross sales 36.3 % 34.2 % 37.0 % 35.2 %
Earnings Per Share	A reconciliation of the numerators and denominators of basic and diluted EPS follows ($ in millions, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Net (loss): Net (loss) attributable to ordinary shareholders $ (1,759.0 ) $ (472.5 ) $ (4,167.0 ) $ (805.0 ) Basic weighted average ordinary shares outstanding 327.8 339.1 329.9 336.9 Basic EPS: Net (loss) per share $ (5.37 ) $ (1.39 ) $ (12.63 ) $ (2.39 ) Dividends per ordinary share $ 0.74 $ 0.72 $ 1.48 $ 1.44 Diluted weighted average ordinary shares outstanding 327.8 339.1 329.9 336.9 Diluted EPS: Net (loss) per share $ (5.37 ) $ (1.39 ) $ (12.63 ) $ (2.39 )
Summary of Products Which Utilize Novel Drug Delivery Systems through Combination of Internal and Collaborative Programs	As of June 30, 2019, we are developing a number of products, some of which utilize novel drug delivery systems, through a combination of internal and collaborative programs, and we additionally have products in development as part of our life-cycle management strategy for our existing product portfolio. These development projects include but are not limited to the following: Product Therapeutic Area Indication Expected Launch Year Phase Cariprazine Central Nervous System Bipolar Depression 2019 Approved Ubrogepant Central Nervous System Acute Migraine 2020 Review Bimatoprost SR Eye Care Glaucoma 2020 Review Abicipar Eye Care Age Related Macular Degeneration 2020 III Atogepant Central Nervous System Prophylaxis Migraine 2021 III Presbysol Eye Care Presbyopia 2021 III Cenicriviroc Gastrointestinal NASH 2022 III Relamorelin Gastrointestinal Gastroparesis 2023 III Brimonidine DDS Eye Care Geographic Atrophy 2023 II Botox Medical Aesthetics Platysma/Masseter 2025/2024 II Abicipar Eye Care Diabetic Macular Edema 2025 II Brazikumab Gastrointestinal Crohn's Disease 2025 II Brazikumab Gastrointestinal Ulcerative Colitis 2026 II

Assets Held for Sale (Tables)

Assets Held for Sale (Tables)	6 Months Ended
	Jun. 30, 2019
Assets Held For Sale Not Part Of Disposal Group [Abstract]
Summary of Products Sale Transaction and Key Financial Results of Business	The following represents the assets held for sale ($ in millions): June 30, December 31, 2019 2018 Assets held for sale: Inventories $ - $ 34.0 Property, plant and equipment, net 32.5 32.8 Product rights and other intangibles - 849.4 Total assets held for sale $ 32.5 $ 916.2

Other (Expense) _ Income (Table

Other (Expense) / Income (Tables)	6 Months Ended
	Jun. 30, 2019
Other Income And Expenses [Abstract]
Components of Other (Expense) / Income, Net	Other (expense) / income, net consisted of the following ($ in millions): Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Teva Share Activity $ - $ 138.6 $ - $ 60.9 Sales of business - 53.0 - 53.0 Debt extinguishment other 0.1 9.1 (0.2 ) 9.1 Other (expense) / income, net (4.8 ) 14.7 9.3 13.6 Other (expense) / income, net $ (4.7 ) $ 215.4 $ 9.1 $ 136.6
Summary of Teva Share Activity	During the three and six months ended June 30, 2018, the Company recorded the following movements in its investment in Teva securities (“Teva Share Activity”) ($ in millions except per share information): Shares Carrying Value per Share Market Price Proceeds Received Value of Marketable Securities Unrealized Gain / (Loss) as a Component of Other Comprehensive Income Gain / (Loss) Recognized in Other Income/ (Expense), Net Derivative Instrument (Liability)/ Asset Retained Earnings Teva securities as of December 31, 2017 95.9 $ 17.60 $ 18.95 n.a. $ 1,817.7 $ 129.3 $ - $ (62.9 ) $ - Impact of ASU No. 2016-01 - - - - - (129.3 ) - - 129.3 Settlement of initial accelerated share repurchase ("ASR"), net (25.0 ) 18.95 16.53 * 413.3 (473.8 ) - 2.5 62.9 - Forward sale entered into during the three months ended March 31, 2018 ** n.a. n.a. 372.3 n.a. - 19.0 (353.3 ) - Open market sales (11.5 ) n.a. 19.95 229.9 (218.5 ) - 11.5 - - Other fair value movements during the three months ended March 31, 2018 - n.a. n.a. n.a. (110.7 ) - (110.7 ) - - Teva securities as of and for the three months ended March 31, 2018 59.4 $ 17.09 $ 17.09 $ 1,015.5 $ 1,014.7 $ - $ (77.7 ) $ (353.3 ) $ 129.3 Settlement of forward sale entered into during the three months ended March 31, 2018, net (25.0 ) 17.09 18.61 *** 93.2 (427.3 ) - 19.2 353.3 - Open market sales (34.4 ) n.a. 20.55 706.8 (587.4 ) - 119.4 - - Teva securities as of and for the six months ended June 30, 2018 - $ - $ - $ 1,815.5 $ - $ - $ 60.9 $ - $ 129.3 * Market price represented average price over the life of the contract. On the January 17, 2018 settlement date, the closing stock price of Teva securities was $21.48. ** On February 13, 2018, the Company entered into a forward sale transaction under which we delivered 25.0 million Teva shares to the transaction counterparty and received proceeds of $372.3 million in exchange for the shares. The forward sale transaction settled during the second quarter of 2018. As a result of the transaction, and in accordance with ASC Topic 860 - Transfers and Servicing, the marketable securities were reported on the Company's balance sheet until the contract settled on May 7, 2018. ***Market price represented average price over the life of the contract. On the May 7, 2018 settlement date, the closing stock price of Teva securities was $18.62.
Summary of Redeemed and Retired Senior Notes	During the three and six months ended June 30, 2019 and 2018, the Company redeemed and retired the following senior notes ($ in millions): Three Months Ended June 30, 2019 Six Months Ended June 30, 2019 Tranche Face Value Retired Cash Paid for Retirement Face Value Retired Cash Paid for Retirement Remaining Value at June 30, 2019 3.000% due 2020 $ 97.8 $ 97.8 $ 180.7 $ 180.7 $ 2,526.0 3.450% due 2022 - - 62.3 62.3 2,878.2 3.800% due 2025 - - 6.8 6.8 3,020.7 Total $ 97.8 $ 97.8 $ 249.8 $ 249.8 $ 8,424.9 Three and Six Months Ended June 30, 2018 Tranche Face Value Retired Cash Paid for Retirement Remaining Value at June 30, 2018 2.450% due 2019 $ 8.8 $ 8.8 $ 491.2 3.000% due 2020 40.7 40.6 3,459.3 3.450% due 2022 59.5 58.6 2,940.5 3.850% due 2024 11.2 10.9 1,188.8 3.800% due 2025 85.0 82.6 3,915.0 4.550% due 2035 115.0 110.1 2,385.0 4.850% due 2044 59.0 57.3 1,441.0 4.750% due 2045 76.7 73.9 1,123.3 Total $ 455.9 $ 442.8 $ 16,944.1

Share-Based Compensation (Table

Share-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Fair Value Assumptions of Options based on Black-Scholes Valuation Model	Using the Black-Scholes valuation model, the fair value of options is based on the following assumptions: 2019 Grants 2018 Grants Dividend yield 1.7 - 1.8% 1.5% Expected volatility 26.4% 27.0% Risk-free interest rate 1.9% 2.2 - 2.9% Expected term (years) 7.0 7.0
Share-Based Compensation Expense Recognized in Company's Results of Operations	Share-based compensation expense recognized in the Company’s results of operations for the three and six months ended June 30, 2019 and 2018 was as follows ($ in millions): Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Equity-based compensation awards $ 59.5 $ 54.9 $ 111.8 $ 127.4 Total share-based compensation expense $ 59.5 $ 54.9 $ 111.8 $ 127.4
Summary of Equity Award Activity for Unvested Restricted Stock and Stock Units	The following is a summary of equity award activity for unvested restricted stock and stock units in the period from December 31, 2018 through June 30, 2019 (in millions, except per share data): Shares Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (Years) Aggregate Grant Date Fair Value Restricted shares / units outstanding at December 31, 2018 2.5 $ 190.27 1.6 $ 472.9 Granted 1.5 139.83 207.8 Vested (0.7 ) 209.91 (138.8 ) Forfeited (0.1 ) 177.79 (19.3 ) Restricted shares / units outstanding at June 30, 2019 3.2 $ 161.46 1.8 $ 522.6
Summary of Equity Award Activity for Non-Qualified Options to Purchase Ordinary Shares	The following is a summary of equity award activity for non-qualified options to purchase ordinary shares in the period from December 31, 2018 through June 30, 2019 (in millions, except per share data): Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding, vested and expected to vest at December 31, 2018 6.3 $ 122.74 4.4 $ 69.0 Granted 0.3 140.29 Exercised (0.3 ) 82.45 Cancelled (0.1 ) 217.07 Outstanding, vested and expected to vest at June 30, 2019 6.2 $ 124.78 4.3 $ 265.2

Reportable Segments (Tables)

Reportable Segments (Tables)	6 Months Ended
	Jun. 30, 2019
Segment Reporting [Abstract]
Schedule of Net Revenues, Operating Expenses Contribution Information by Reportable Segment	Segment net revenues, segment operating expenses and segment contribution information consisted of the following for the three and six months ended June 30, 2019 and 2018 ($ in millions): Three Months Ended June 30, 2019 US Specialized Therapeutics US General Medicine International Total Net revenues $ 1,785.1 $ 1,455.7 $ 847.7 $ 4,088.5 Operating expenses: Cost of sales (1) 151.0 231.3 145.6 527.9 Selling and marketing 368.0 250.1 253.6 871.7 General and administrative 37.6 30.4 28.4 96.4 Segment contribution $ 1,228.5 $ 943.9 $ 420.1 $ 2,592.5 Contribution margin 68.8 % 64.8 % 49.6 % 63.4 % Corporate (2) 352.2 Research and development 450.0 Amortization 1,402.0 Goodwill impairments 1,085.8 In-process research and development impairments 436.0 Asset sales and impairments, net 129.4 Operating (loss) $ (1,262.9 ) Operating margin (30.9 )% (1) (2) Six Months Ended June 30, 2019 US Specialized Therapeutics US General Medicine International Total Net revenues $ 3,328.0 $ 2,705.6 $ 1,649.2 $ 7,682.8 Operating expenses: Cost of sales (1) 271.1 421.8 255.3 948.2 Selling and marketing 724.8 460.6 491.2 1,676.6 General and administrative 92.2 74.2 54.1 220.5 Segment contribution $ 2,239.9 $ 1,749.0 $ 848.6 $ 4,837.5 Contribution margin 67.3 % 64.6 % 51.5 % 63.0 % Corporate (2) 610.2 Research and development 885.0 Amortization 2,801.4 Goodwill impairments 3,552.8 In-process research and development impairments 436.0 Asset sales and impairments, net 124.2 Operating (loss) $ (3,572.1 ) Operating margin (46.5 )% (1) (2) Three Months Ended June 30, 2018 US Specialized Therapeutics US General Medicine International Total Net revenues $ 1,826.7 $ 1,320.0 $ 948.9 $ 4,095.6 Operating expenses: Cost of sales (1) 148.7 201.8 139.4 489.9 Selling and marketing 343.3 254.8 246.2 844.3 General and administrative 48.1 34.7 33.9 116.7 Segment contribution $ 1,286.6 $ 828.7 $ 529.4 $ 2,644.7 Contribution margin 70.4 % 62.8 % 55.8 % 64.6 % Corporate (2) 189.8 Research and development 689.2 Amortization 1,697.1 In-process research and development impairments 276.0 Asset sales and impairments, net 259.6 Operating (loss) $ (467.0 ) Operating margin (11.4 )% (1) (2) Six Months Ended June 30, 2018 US Specialized Therapeutics US General Medicine International Total Net revenues $ 3,405.3 $ 2,543.7 $ 1,812.9 $ 7,761.9 Operating expenses: Cost of sales (1) 282.9 384.4 260.3 927.6 Selling and marketing 656.5 480.3 491.9 1,628.7 General and administrative 98.3 73.6 65.3 237.2 Segment contribution $ 2,367.6 $ 1,605.4 $ 995.4 $ 4,968.4 Contribution margin 69.5 % 63.1 % 54.9 % 64.0 % Corporate (2) 460.1 Research and development 1,163.9 Amortization 3,394.7 In-process research and development impairments 798.0 Asset sales and impairments, net 272.7 Operating (loss) $ (1,121.0 ) Operating margin (14.4 )% (1) (2)
Schedule of Net Revenue Disaggregated by Geography for International Segment	The following table presents our net revenue disaggregated by geography for our international segment for the three and six months ended June 30, 2019 and 2018 ($ in millions): Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Europe $ 386.2 $ 413.3 $ 740.6 $ 811.7 Asia Pacific, Middle East and Africa 261.5 283.6 512.2 524.4 Latin America and Canada 182.1 230.8 360.3 442.9 Other* 17.9 21.2 36.1 33.9 Total International $ 847.7 $ 948.9 $ 1,649.2 $ 1,812.9 *Includes royalty and other revenue
Schedule of Global Net Revenues for Top Products and Reconciliation of Segment Revenues to Total Net Revenues	The following tables present global net revenues for the top products greater than 10% of total revenues of the Company as well as a reconciliation of segment revenues to total net revenues for the three and six months ended June 30, 2019 and 2018 ($ in millions): Three Months Ended June 30, 2019 US Specialized Therapeutics US General Medicine International Total Botox ® $ 699.4 $ - $ 274.6 $ 974.0 Juvederm ® 156.6 - 172.7 329.3 Restasis ® 310.9 - 11.9 322.8 Linzess ® ® - 196.0 4.8 200.8 Vraylar ® - 196.1 - 196.1 Lumigan ® ® 62.1 - 90.4 152.5 Bystolic ® ® - 150.5 0.5 151.0 Lo Loestrin ® - 145.5 - 145.5 Alphagan ® ® 91.6 - 40.9 132.5 Eye Drops 57.8 - 57.3 115.1 Ozurdex ® 29.9 - 81.0 110.9 Viibryd ® ® - 107.8 2.7 110.5 Alloderm ® 101.2 - 2.2 103.4 Coolsculpting ® 60.7 - 20.3 81.0 Zenpep ® - 70.0 - 70.0 Carafate ® ® - 56.2 0.7 56.9 Armour Thyroid - 56.7 - 56.7 Viberzi ® - 50.8 0.3 51.1 Skin Care 42.6 - 3.7 46.3 Asacol ® ® - 31.6 9.7 41.3 Teflaro ® - 37.0 - 37.0 Breast Implants 67.6 - (31.4 ) 36.2 Saphris ® - 32.6 - 32.6 Coolsculpting ® 18.2 - 11.6 29.8 Avycaz ® - 26.7 - 26.7 Namzaric ® - 22.6 - 22.6 Dalvance ® - 20.3 2.2 22.5 Savella ® - 22.3 - 22.3 Liletta ® - 21.9 - 21.9 Canasa ® ® - 8.0 4.1 12.1 Kybella ® ® 8.5 - 0.6 9.1 Namenda ® - 6.1 - 6.1 Rapaflo ® 4.5 - 1.4 5.9 Aczone ® 1.8 - - 1.8 Other 71.7 197.0 85.5 354.2 Total segment revenues $ 1,785.1 $ 1,455.7 $ 847.7 $ 4,088.5 Corporate revenues 1.6 Total net revenues $ 4,090.1 Six Months Ended June 30, 2019 US Specialized Therapeutics US General Medicine International Total Botox ® $ 1,326.5 $ - $ 515.9 $ 1,842.4 Juvederm ® 286.3 - 330.5 616.8 Restasis ® 542.6 - 22.3 564.9 Linzess ® ® - 357.3 10.3 367.6 Vraylar ® - 339.8 - 339.8 Lumigan ® ® 119.8 - 175.5 295.3 Bystolic ® ® - 278.8 0.9 279.7 Lo Loestrin ® - 271.3 - 271.3 Alphagan ® ® 174.6 - 78.5 253.1 Eye Drops 107.2 - 112.7 219.9 Ozurdex ® 60.2 - 144.1 204.3 Alloderm ® 196.2 - 3.8 200.0 Viibryd ® ® - 192.8 4.8 197.6 Coolsculpting ® 108.5 - 38.1 146.6 Zenpep ® - 133.0 - 133.0 Carafate ® ® - 110.5 1.3 111.8 Breast Implants 128.8 - (20.2 ) 108.6 Armour Thyroid - 106.7 - 106.7 Viberzi ® - 88.0 0.6 88.6 Skin Care 77.3 - 6.4 83.7 Asacol ® ® - 56.3 20.0 76.3 Teflaro ® - 70.5 0.2 70.7 Saphris ® - 64.5 - 64.5 Avycaz ® - 56.4 - 56.4 Coolsculpting ® 33.3 - 22.2 55.5 Namzaric ® - 46.0 - 46.0 Savella ® - 43.0 - 43.0 Liletta ® - 36.7 - 36.7 Dalvance ® - 32.3 2.2 34.5 Canasa ® ® - 18.2 7.7 25.9 Rapaflo ® 16.3 - 2.0 18.3 Kybella ® ® 15.8 - 2.2 18.0 Namenda ® - 15.6 - 15.6 Aczone ® 3.4 - - 3.4 Other 131.2 387.9 167.2 686.3 Total segment revenues $ 3,328.0 $ 2,705.6 $ 1,649.2 $ 7,682.8 Corporate revenues 4.4 Total net revenues $ 7,687.2 Three Months Ended June 30, 2018 US Specialized Therapeutics US General Medicine International Total Botox ® $ 658.5 $ - $ 276.0 $ 934.5 Restasis ® 318.2 - 16.0 334.2 Juvederm ® 139.8 - 156.1 295.9 Linzess ® ® - 191.8 6.4 198.2 Lumigan ® ® 73.0 - 100.5 173.5 Bystolic ® ® - 148.1 0.6 148.7 Alphagan ® ® 98.1 - 44.6 142.7 Lo Loestrin ® - 127.8 - 127.8 Eye Drops 53.8 - 72.4 126.2 Breast Implants 75.9 - 39.9 115.8 Vraylar ® - 114.2 - 114.2 Alloderm ® 107.1 - 2.3 109.4 Ozurdex ® 27.6 - 67.9 95.5 Coolsculpting ® 71.9 - 18.5 90.4 Viibryd ® ® - 86.7 1.6 88.3 Zenpep ® - 55.5 - 55.5 Carafate ® ® - 54.3 0.7 55.0 Canasa ® ® - 45.0 4.5 49.5 Armour Thyroid - 49.2 - 49.2 Coolsculpting ® 36.4 - 12.4 48.8 Viberzi ® - 44.9 0.3 45.2 Asacol ® ® - 32.6 12.4 45.0 Skin Care 34.3 - 4.1 38.4 Saphris ® - 33.8 - 33.8 Teflaro ® - 32.4 0.6 33.0 Namzaric ® - 31.8 - 31.8 Avycaz ® - 23.5 - 23.5 Rapaflo ® 19.7 - 1.6 21.3 Aczone ® 21.1 - 0.1 21.2 Savella ® - 19.1 - 19.1 Dalvance ® - 17.7 1.3 19.0 Liletta ® - 15.5 - 15.5 Kybella ® ® 11.2 - 2.3 13.5 Namenda ® - 3.4 - 3.4 Other 80.1 192.7 105.8 378.6 Total segment revenues $ 1,826.7 $ 1,320.0 $ 948.9 $ 4,095.6 Corporate revenues 28.6 Total net revenues $ 4,124.2 Six Months Ended June 30, 2018 US Specialized Therapeutics US General Medicine International Total Botox ® $ 1,231.0 $ - $ 520.8 $ 1,751.8 Restasis ® 574.0 - 34.3 608.3 Juvederm ® 262.6 - 302.2 564.8 Linzess ® ® - 351.1 12.0 363.1 Lumigan ® ® 139.8 - 200.9 340.7 Bystolic ® ® - 280.9 1.1 282.0 Alphagan ® ® 182.3 - 88.8 271.1 Lo Loestrin ® - 242.4 - 242.4 Eye Drops 100.0 - 141.2 241.2 Breast Implants 136.6 - 84.0 220.6 Alloderm ® 206.6 - 4.5 211.1 Vraylar ® - 198.6 - 198.6 Ozurdex ® 53.1 - 132.3 185.4 Viibryd ® ® - 158.4 3.1 161.5 Coolsculpting ® 125.3 - 26.6 151.9 Carafate ® ® - 110.3 1.4 111.7 Zenpep ® - 108.4 - 108.4 Armour Thyroid - 97.4 - 97.4 Asacol ® ® - 70.8 24.1 94.9 Canasa ® ® - 83.6 8.7 92.3 Coolsculpting ® 70.1 - 13.5 83.6 Viberzi ® - 80.8 0.4 81.2 Skin Care 66.2 - 7.9 74.1 Saphris ® - 66.5 - 66.5 Namzaric ® - 65.2 - 65.2 Teflaro ® - 64.6 0.6 65.2 Rapaflo ® 42.5 - 2.8 45.3 Avycaz ® - 45.3 - 45.3 Namenda ® - 44.0 - 44.0 Savella ® - 39.0 - 39.0 Aczone ® 37.1 - 0.2 37.3 Dalvance ® - 29.6 1.3 30.9 Liletta ® - 23.6 - 23.6 Kybella ® ® 19.4 - 3.7 23.1 Other 158.7 383.2 196.5 738.4 Total segment revenues $ 3,405.3 $ 2,543.7 $ 1,812.9 $ 7,761.9 Corporate revenues 34.4 Total net revenues $ 7,796.3

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2019
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consisted of the following ($ in millions): June 30, December 31, 2019 2018 Raw materials $ 335.8 $ 303.2 Work-in-process 145.5 145.7 Finished goods 683.3 520.2 1,164.6 969.1 Less: inventory reserves 160.1 122.2 Total Inventories $ 1,004.5 $ 846.9

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2019
Payables And Accruals [Abstract]
Summary of Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses consisted of the following ($ in millions): June 30, December 31, 2019 2018 Accrued expenses: Accrued third-party rebates $ 1,934.4 $ 1,832.1 Accrued returns and other allowances 586.3 527.8 Accrued payroll and related benefits 484.8 694.3 Accrued R&D expenditures 189.8 215.5 Interest payable 187.5 191.4 Accrued pharmaceutical fees 186.1 145.3 Royalties payable 161.8 155.1 Litigation-related reserves and legal fees 158.0 92.0 Accrued non-provision taxes 67.2 68.5 Accrued selling and marketing expenditures 64.4 61.1 Accrued severance, retention and other shutdown costs 24.6 71.6 Current portion of contingent consideration obligations 10.5 8.3 Dividends payable 1.1 1.4 Other accrued expenses 420.3 373.0 Total accrued expenses $ 4,476.8 $ 4,437.4 Accounts payable 518.5 349.8 Total accounts payable and accrued expenses $ 4,995.3 $ 4,787.2

Goodwill, Product Rights and _2

Goodwill, Product Rights and Other Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2019
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Goodwill Goodwill for the Company’s reporting segments consisted of the following ($ in millions): US Specialized Therapeutics US General Medicine International Total Balance as of December 31, 2018 $ 20,675.6 $ 17,936.6 $ 7,301.1 $ 45,913.3 Acquisitions 34.1 - - 34.1 Impairments - (3,552.8 ) - (3,552.8 ) Re-allocation to current segments (340.0 ) 340.0 - - Foreign exchange and other adjustments - - (53.9 ) (53.9 ) Balance as of June 30, 2019 $ 20,369.7 $ 14,723.8 $ 7,247.2 $ 42,340.7
Schedule of Cost Basis on Product Rights and Other Intangible Assets	Product Rights and Other Intangible Assets Product rights and other intangible assets consisted of the following ($ in millions): Cost Basis Balance as of December 31, 2018 Additions Impairments IPR&D to CMP Transfers Foreign Currency Translation / Other Balance as of June 30, 2019 Intangibles with definite lives: Product rights and other intangibles $ 70,235.1 $ 90.9 $ - $ 75.6 $ 1,809.8 $ 72,211.4 Trade name 690.0 - - - - 690.0 Total definite lived intangible assets $ 70,925.1 $ 90.9 $ - $ 75.6 $ 1,809.8 $ 72,901.4 Intangibles with indefinite lives: IPR&D $ 5,048.1 $ - $ (436.0 ) $ (75.6 ) $ - $ 4,536.5 Total indefinite lived intangible assets $ 5,048.1 $ - $ (436.0 ) $ (75.6 ) $ - $ 4,536.5 Total product rights and other intangibles $ 75,973.2 $ 90.9 $ (436.0 ) $ - $ 1,809.8 $ 77,437.9 Accumulated Amortization Balance as of December 31, 2018 Amortization Impairments IPR&D to CMP Transfers Foreign Currency Translation / Other Balance as of June 30, 2019 Intangibles with definite lives: Product rights and other intangibles $ (31,985.0 ) $ (2,761.4 ) $ (129.6 ) $ - $ (997.6 ) $ (35,873.6 ) Trade name (292.8 ) (40.0 ) - - - (332.8 ) Total definite lived intangible assets $ (32,277.8 ) $ (2,801.4 ) $ (129.6 ) $ - $ (997.6 ) $ (36,206.4 ) Total product rights and other intangibles $ (32,277.8 ) $ (2,801.4 ) $ (129.6 ) $ - $ (997.6 ) $ (36,206.4 ) Net Product Rights and Other Intangibles $ 43,695.4 $ 41,231.5
Schedule of Annual Amortization Expense on Product Rights and Other Related Intangibles	Assuming no additions, disposals or adjustments are made to the carrying values and/or useful lives of the intangible assets, annual amortization expense on product rights and other related intangibles as of June 30, 2019 over the remainder of 2019 and each of the next five years is estimated to be as follows ($ in millions): Amortization Expense 2019 remaining $ 2,884.3 2020 $ 5,485.6 2021 $ 4,560.6 2022 $ 4,211.9 2023 $ 3,787.8 2024 $ 2,955.6

Long-Term Debt (Tables)

Long-Term Debt (Tables)	6 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Schedule of Long-Term Debt	Debt consisted of the following ($ in millions): Balance As of Fair Market Value As of Guarantor Issuance Date / Acquisition Date Interest Payments June 30, 2019 December 31, 2018 June 30, 2019 December 31, 2018 Senior Notes: Floating Rate Notes $500.0 million floating rate notes due March 12, 2020 (1) (4) March 4, 2015 Quarterly 500.0 500.0 503.6 501.9 500.0 500.0 503.6 501.9 Fixed Rate Notes $3,500.0 million 3.000% notes due March 12, 2020 (4) March 4, 2015 Semi-annually 2,526.0 2,706.7 2,533.7 2,694.8 $650.0 million 3.375% notes due September 15, 2020 (5) March 17, 2015 Semi-annually 650.0 650.0 655.6 648.7 $750.0 million 4.875% notes due February 15, 2021 (6) July 1, 2014 Semi-annually 450.0 450.0 463.5 459.4 $1,200.0 million 5.000% notes due December 15, 2021 (6) July 1, 2014 Semi-annually 1,200.0 1,200.0 1,258.5 1,234.8 $3,000.0 million 3.450% notes due March 15, 2022 (4) March 4, 2015 Semi-annually 2,878.2 2,940.5 2,929.9 2,891.0 $1,700.0 million 3.250% notes due October 1, 2022 (5) October 2, 2012 Semi-annually 1,700.0 1,700.0 1,707.6 1,652.2 $350.0 million 2.800% notes due March 15, 2023 (5) March 17, 2015 Semi-annually 350.0 350.0 348.2 332.8 $1,200.0 million 3.850% notes due June 15, 2024 (4) June 10, 2014 Semi-annually 1,036.7 1,036.7 1,073.1 1,021.0 $4,000.0 million 3.800% notes due March 15, 2025 (4) March 4, 2015 Semi-annually 3,020.7 3,027.5 3,119.0 2,956.0 $2,500.0 million 4.550% notes due March 15, 2035 (4) March 4, 2015 Semi-annually 1,789.0 1,789.0 1,818.0 1,690.7 $1,000.0 million 4.625% notes due October 1, 2042 (5) October 2, 2012 Semi-annually 456.7 456.7 447.9 412.4 $1,500.0 million 4.850% notes due June 15, 2044 (4) June 10, 2014 Semi-annually 1,079.4 1,079.4 1,108.8 1,019.1 $2,500.0 million 4.750% notes due March 15, 2045 (4) March 4, 2015 Semi-annually 881.0 881.0 900.2 836.6 18,017.7 18,267.5 18,364.0 17,849.5 Euro Denominated Notes €700.0 million floating rate notes due June 1, 2019 (2) (4) May 26, 2017 Quarterly - 802.7 - 794.9 €700.0 million floating rate notes due November 15, 2020 (3) (4) November 15, 2018 Quarterly 796.1 802.7 795.1 791.3 €750.0 million 0.500% notes due June 1, 2021 (4) May 26, 2017 Annually 853.0 860.0 859.4 849.7 €500.0 million 1.500% notes due November 15, 2023 (4) November 15, 2018 Annually 568.7 573.4 591.7 572.4 €700.0 million 1.250% notes due June 1, 2024 (4) May 26, 2017 Annually 796.1 802.7 815.8 775.5 €500.0 million 2.625% notes due November 15, 2028 (4) November 15, 2018 Annually 568.7 573.4 623.6 573.4 €550.0 million 2.125% notes due June 1, 2029 (4) May 26, 2017 Annually 625.5 630.7 656.3 594.7 4,208.1 5,045.6 4,341.9 4,951.9 Total Senior Notes Gross 22,725.8 23,813.1 23,209.5 23,303.3 Unamortized premium 52.0 64.3 - - Unamortized discount (59.6 ) (64.5 ) - - Total Senior Notes Net $ 22,718.2 $ 23,812.9 $ 23,209.5 $ 23,303.3 Other Indebtedness Debt Issuance Costs (82.4 ) (92.1 ) Other 67.7 69.3 Total Other Borrowings (14.7 ) (22.8 ) Capital Leases (7) n.a. 7.6 Total Indebtedness $ 22,703.5 $ 23,797.7 (1) (2) (3) (4) (5) (6) (7) debt.
Schedule of Annual Debt Maturities	As of June 30, 2019, annual debt maturities of senior notes gross were as follows ($ in millions): Total Payments 2019 remaining $ - 2020 4,472.1 2021 2,503.0 2022 4,578.2 2023 918.7 2024 1,832.8 2025 and after 8,421.0 Total senior notes gross $ 22,725.8

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2019
Leases [Abstract]
Summary of Operating ROU Assets and liabilities	As of June 30, 2019, the Company had the following operating ROU assets and lease liabilities ($ in millions): June 30, 2019 ROU Asset Lease Liability Real estate $ 283.9 $ 350.9 Fleet 117.3 117.3 Other 56.7 69.8 Total operating leases $ 457.9 $ 538.0 June 30, 2019 Current lease liability - operating $ 123.2 Long-term lease liability - operating 414.8 Total lease liability - operating $ 538.0
Schedule of Lease Expense	For the three and six months ended June 30, 2019, the Company noted the following lease expense ($ in millions): Three Months Ended June 30, 2019 Six Months Ended June 30, 2019 Operating lease expense* $ 40.1 $ 72.4 Sublease (income) (3.6 ) (7.0 ) Net operating lease expense $ 36.5 $ 65.4 * Includes short-term and variable lease expenses of $0.7 million and $1.6 million, respectively, for the three and six months ended June 30, 2019.
Schedule of Lease Commitments	As of June 30, 2019, the Company had the following lease commitments ($ in millions): Total Payments 2019 remaining $ 66.8 2020 117.4 2021 103.8 2022 59.6 2023 45.8 2024 39.3 2025 and after 152.3 Total undiscounted cash flows $ 585.0 Future interest (47.0 ) Total lease liability - operating $ 538.0
Schedule of Future Minimum Property Lease Rental Payments under Capital and Operating Leases	As of December 31, 2018, the future anticipated property lease rental payments under both capital and operating leases that had remaining terms in excess of one year were ($ in millions): Total Payments 2019 $ 62.5 2020 52.5 2021 47.9 2022 43.3 2023 39.0 Thereafter 173.8 Total minimum lease payments $ 419.0

Other Long-Term Liabilities (Ta

Other Long-Term Liabilities (Tables)	6 Months Ended
	Jun. 30, 2019
Other Liabilities Disclosure [Abstract]
Summary of Other Long-Term Liabilities	Other long-term liabilities consisted of the following ($ in millions): June 30, December 31, 2019 2018 Acquisition related contingent consideration liabilities $ 376.9 $ 336.3 Long-term pension and post retirement liability 167.8 166.5 Legacy Allergan deferred executive compensation 92.9 90.8 Accrued R&D milestone 75.0 75.0 Deferred revenue 32.8 36.1 Product warranties 28.9 27.9 Long-term severance and restructuring liabilities 11.0 14.2 Long-term contractual obligations - 43.2 Other long-term liabilities 36.1 92.0 Total other long-term liabilities $ 821.4 $ 882.0

Income Taxes (Tables)

Income Taxes (Tables)	6 Months Ended
	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Summary of Acquired U.S. Entities and Taxable Years that are Currently under Audit by IRS	The Company has several concurrent audits open and pending with the IRS as set forth below: IRS Audits Taxable Years Allergan W.C. Holding Inc. f/k/a Actavis W.C. Holding Inc. 2013, 2014, 2015 and 2016 Warner Chilcott Corporation 2010, 2011, 2012 and 2013 Forest Laboratories, Inc. 2010, 2011, 2012, 2013 and 2014 Allergan, Inc. 2009, 2010, 2011, 2012, 2013, 2014 and 3/17/2015

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Schedule of Financial Assets and Liabilities Measured at Fair Value using Fair Value Leveling or Disclosed at Fair Value on Recurring Basis	Assets and liabilities that are measured at fair value using Fair Value Leveling or that are disclosed at fair value on a recurring basis as of June 30, 2019 and December 31, 2018 consisted of the following ($ in millions): Fair Value Measurements as of June 30, 2019 Using: Total Level 1 Level 2 Level 3 Assets: Cash equivalents* $ 1,154.1 $ 1,154.1 $ - $ - Short-term investments 322.3 - 322.3 - Deferred executive compensation investments 92.9 78.0 14.9 - Royalty receivable 50.3 - - 50.3 Investments and other 55.1 39.6 15.5 - Total assets $ 1,674.7 $ 1,271.7 $ 352.7 $ 50.3 Liabilities: Deferred executive compensation liabilities $ 92.9 $ 78.0 $ 14.9 $ - Contingent consideration obligations 387.4 - - 387.4 Total liabilities $ 480.3 $ 78.0 $ 14.9 $ 387.4 * Marketable securities with less than 90 days Fair Value Measurements as of December 31, 2018 Using: Total Level 1 Level 2 Level 3 Assets: Cash equivalents* $ 207.1 $ 207.1 $ - $ - Short-term investments 1,026.9 - 1,026.9 - Deferred executive compensation investments 90.8 73.8 17.0 - Royalty receivable 50.3 - - 50.3 Investments and other 46.0 38.5 7.5 - Total assets $ 1,421.1 $ 319.4 $ 1,051.4 $ 50.3 Liabilities: Deferred executive compensation liabilities $ 90.8 $ 73.8 $ 17.0 $ - Contingent consideration obligations 344.6 - - 344.6 Total liabilities $ 435.4 $ 73.8 $ 17.0 $ 344.6 * Marketable securities with less than 90 days remaining until maturity at the time of acquisition are classified as cash equivalents.
Change in Fair Value of Contingent Consideration Obligations	Changes in the fair value of the contingent consideration obligations, including accretion, are recorded in our consolidated statements of operations as follows ($ in millions): Three Months Ended June 30, Six Months Ended June 30, Expense / (Income) 2019 2018 2019 2018 Cost of sales $ 25.8 $ (128.8 ) $ 42.0 $ (125.4 ) Research and development 2.3 21.7 4.8 23.6 Total $ 28.1 $ (107.1 ) $ 46.8 $ (101.8 )
Summary of Changes in Fair Value of all Financial Assets and Liabilities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs	The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the six months ended June 30, 2019 and 2018 ($ in millions): Balance as of December 31, 2018 Net transfers in to (out of) Level 3 Purchases, settlements, and other net Net accretion and fair value adjustments Balance as of June 30, 2019 Liabilities: Contingent consideration obligations $ 344.6 $ - $ (4.0 ) $ 46.8 $ 387.4 Balance as of December 31, 2017 Net transfers in to (out of) Level 3 Purchases, settlements, and other net Net accretion and fair value adjustments Balance as of June 30, 2018 Liabilities: Contingent consideration obligations $ 476.9 $ - $ (10.7 ) $ (101.8 ) $ 364.4
Schedule of Contingent Consideration Obligations by Acquisitions	During the six months ended June 30, 2019, the activity in contingent consideration obligations by acquisition consisted of the following ($ in millions): Business Acquisition Balance as of December 31, 2018 Fair Value Adjustments and Accretion Payments and Other Balance as of June 30, 2019 Tobira acquisition $ 255.0 $ 4.6 $ - $ 259.6 Medicines 360 acquisition 43.1 42.2 (2.7 ) 82.6 ForSight acquisition 24.1 0.2 0.1 24.4 Forest acquisition 13.6 (0.2 ) (1.2 ) 12.2 AqueSys acquisition 5.4 0.1 - 5.5 Oculeve acquisition 1.7 - - 1.7 Other 1.7 (0.1 ) (0.2 ) 1.4 Total $ 344.6 $ 46.8 $ (4.0 ) $ 387.4

Business Restructuring Charges

Business Restructuring Charges (Tables)	6 Months Ended
	Jun. 30, 2019
Restructuring And Related Activities [Abstract]
Schedule of Activity Related to Business Restructuring and Facility Rationalization Activities	Restructuring activities for the six months ended June 30, 2019 were as follows ($ in millions): Severance and Retention Other Total Reserve balance at December 31, 2018 $ 71.4 $ 14.4 $ 85.8 Charged to expense Cost of sales 1.2 - 1.2 Selling and marketing 0.3 - 0.3 General and administrative 3.7 2.3 6.0 Total expense 5.2 2.3 7.5 Cash payments (54.8 ) (0.8 ) (55.6 ) Non-cash adjustments (2.1 ) - (2.1 ) Reserve balance at June 30, 2019 $ 19.7 $ 15.9 $ 35.6

Warner Chilcott Limited ("WCL_2

Warner Chilcott Limited ("WCL") Guarantor and Non-Guarantor Condensed Consolidating Financial Information (Tables) - Warner Chilcott Acquisition [Member]	6 Months Ended
	Jun. 30, 2019
Consolidating Balance Sheets	Warner Chilcott Limited Consolidating Balance Sheets As of June 30, 2019 (Unaudited; in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited ASSETS Current assets: Cash and cash equivalents $ 0.1 $ 8.1 $ 0.1 $ - $ 1,641.7 $ - $ 1,650.0 Marketable securities - 100.1 - - 222.2 - 322.3 Accounts receivable, net - - - - 3,086.3 - 3,086.3 Receivables from Parents - - - - 210.6 - 210.6 Inventories - - - - 1,004.5 - 1,004.5 Intercompany receivables - 3,298.1 217.2 28.2 27,235.6 (30,779.1 ) - Prepaid expenses and other current assets - - - 33.3 2,471.7 - 2,505.0 Total current assets 0.1 3,406.3 217.3 61.5 35,872.6 (30,779.1 ) 8,778.7 Property, plant and equipment, net - - - - 1,821.0 - 1,821.0 Right of use asset - operating leases - - - - 457.9 - 457.9 Investments and other assets - - - - 335.2 - 335.2 Investment in subsidiaries 57,413.8 65,995.6 25,114.8 95,506.7 - (244,030.9 ) - Non current intercompany receivables - 15,939.7 - - 1,115.4 (17,055.1 ) - Non current assets held for sale - - - - 32.5 - 32.5 Deferred tax assets - 49.6 - - 639.5 - 689.1 Product rights and other intangibles - - - - 41,231.5 - 41,231.5 Goodwill - - - - 42,340.7 - 42,340.7 Total assets $ 57,413.9 $ 85,391.2 $ 25,332.1 $ 95,568.2 $ 123,846.3 $ (291,865.1 ) $ 95,686.6 LIABILITIES AND EQUITY Current liabilities: Accounts payable and accrued expenses - 0.1 154.5 95.6 4,745.0 - 4,995.2 Intercompany payables - 16,431.5 356.5 10,447.6 3,543.5 (30,779.1 ) - Payables to Parents - - - - 2,491.7 - 2,491.7 Income taxes payable - - 2.4 - 91.2 - 93.6 Current portion of long-term debt - - 3,006.4 - 87.8 - 3,094.2 Current portion of lease liability - operating - - - - 123.2 - 123.2 Total current liabilities - 16,431.6 3,519.8 10,543.2 11,082.4 (30,779.1 ) 10,797.9 Long-term debt - - 14,795.2 2,141.0 2,673.1 - 19,609.3 Lease liability - operating - - - - 414.8 - 414.8 Other long-term liabilities - - - - 821.4 - 821.4 Long-term intercompany payables - - - 1,115.4 15,939.7 (17,055.1 ) - Other taxes payable - - - - 1,660.8 - 1,660.8 Deferred tax liabilities - - - - 4,968.5 - 4,968.5 Total liabilities - 16,431.6 18,315.0 13,799.6 37,560.7 (47,834.2 ) 38,272.7 Total equity / (deficit) 57,413.9 68,959.6 7,017.1 81,768.6 86,285.6 (244,030.9 ) 57,413.9 Total liabilities and equity $ 57,413.9 $ 85,391.2 $ 25,332.1 $ 95,568.2 $ 123,846.3 $ (291,865.1 ) $ 95,686.6 Warner Chilcott Limited Consolidating Balance Sheets As of December 31, 2018 (Unaudited; in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited ASSETS Current assets: Cash and cash equivalents $ 0.1 $ 1.8 $ 0.8 $ - $ 875.9 $ - $ 878.6 Marketable securities - 489.9 - - 537.0 - 1,026.9 Accounts receivable, net - - - - 2,868.1 - 2,868.1 Receivables from Parents - - - - 640.9 - 640.9 Inventories - - - - 846.9 - 846.9 Intercompany receivables - 3,534.7 961.0 16.7 24,779.3 (29,291.7 ) - Current assets held for sale - - - - 34.0 - 34.0 Prepaid expenses and other current assets - - - 33.3 785.4 - 818.7 Total current assets 0.1 4,026.4 961.8 50.0 31,367.5 (29,291.7 ) 7,114.1 Property, plant and equipment, net - - - - 1,787.0 - 1,787.0 Investments and other assets - - - - 1,970.6 - 1,970.6 Investment in subsidiaries 62,940.2 73,846.0 26,428.5 99,328.5 - (262,543.2 ) - Non current intercompany receivables - 28,239.4 18,090.2 - 19,674.2 (66,003.8 ) - Non current assets held for sale - - - - 882.2 - 882.2 Deferred tax assets - 43.6 - - 1,020.1 - 1,063.7 Product rights and other intangibles - - - - 43,695.4 - 43,695.4 Goodwill - - - - 45,913.3 - 45,913.3 Total assets $ 62,940.3 $ 106,155.4 $ 45,480.5 $ 99,378.5 $ 146,310.3 $ (357,838.7 ) $ 102,426.3 LIABILITIES AND EQUITY Current liabilities: Accounts payable and accrued expenses - 0.1 156.3 92.9 4,538.1 - 4,787.4 Intercompany payables - 14,315.0 21.7 10,442.6 4,512.4 (29,291.7 ) - Payables to Parents - - - - 2,829.2 - 2,829.2 Income taxes payable - - - - 72.4 - 72.4 Current portion of long-term debt - - 779.6 - 88.7 - 868.3 Total current liabilities - 14,315.1 957.6 10,535.5 12,040.8 (29,291.7 ) 8,557.3 Long-term debt - - 18,090.2 2,135.9 2,703.3 - 22,929.4 Other long-term liabilities - - - - 882.0 - 882.0 Long-term intercompany payables - 18,597.4 - 1,076.8 46,329.6 (66,003.8 ) - Other taxes payable - - - - 1,615.5 - 1,615.5 Deferred tax liabilities - - - - 5,501.8 - 5,501.8 Total liabilities - 32,912.5 19,047.8 13,748.2 69,073.0 (95,295.5 ) 39,486.0 Total equity / (deficit) 62,940.3 73,242.9 26,432.7 85,630.3 77,237.3 (262,543.2 ) 62,940.3 Total liabilities and equity $ 62,940.3 $ 106,155.4 $ 45,480.5 $ 99,378.5 $ 146,310.3 $ (357,838.7 ) $ 102,426.3
Consolidating Statements of Operations	Warner Chilcott Limited Consolidating Statements of Operations For the Three Months Ended June 30, 2019 (Unaudited; in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues $ - $ - $ - $ - $ 4,090.1 $ - $ 4,090.1 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 652.3 - 652.3 Research and development - - - - 450.0 - 450.0 Selling and marketing - - - - 873.3 - 873.3 General and administrative - - - - 316.4 - 316.4 Amortization - - - - 1,402.0 - 1,402.0 Goodwill impairments - - - - 1,085.8 - 1,085.8 In-process research and development impairments - - - - 436.0 - 436.0 Asset sales and impairments, net - - - - 129.4 - 129.4 Total operating expenses - - - - 5,345.2 - 5,345.2 Operating (loss) - - - - (1,255.1 ) - (1,255.1 ) Interest (expense) / income, net - (23.5 ) 48.0 (20.0 ) (190.2 ) - (185.7 ) Other (expense), net - - - - (4.7 ) - (4.7 ) Total other (expense) / income, net - (23.5 ) 48.0 (20.0 ) (194.9 ) - (190.4 ) (Loss) / income before income taxes and noncontrolling interest - (23.5 ) 48.0 (20.0 ) (1,450.0 ) - (1,445.5 ) Provision for income taxes - 1.8 - - 299.8 - 301.6 Losses / (earnings) of equity interest subsidiaries 1,751.2 1,715.8 373.9 1,004.6 - (4,845.5 ) - Net (loss) / income $ (1,751.2 ) $ (1,741.1 ) $ (325.9 ) $ (1,024.6 ) $ (1,749.8 ) $ 4,845.5 $ (1,747.1 ) (Income) attributable to noncontrolling interest - - - - (4.1 ) - (4.1 ) Net (loss) / income attributable to members $ (1,751.2 ) $ (1,741.1 ) $ (325.9 ) $ (1,024.6 ) $ (1,753.9 ) $ 4,845.5 $ (1,751.2 ) Other comprehensive income / (loss), net of tax 65.3 (33.0 ) 42.6 145.9 65.3 (220.8 ) 65.3 Comprehensive (loss) / income attributable to members $ (1,685.9 ) $ (1,774.1 ) $ (283.3 ) $ (878.7 ) $ (1,688.6 ) $ 4,624.7 $ (1,685.9 ) Warner Chilcott Limited Consolidating Statements of Operations For the Six Months Ended June 30, 2019 (Unaudited; in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues $ - $ - $ - $ - $ 7,687.2 $ - $ 7,687.2 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 1,150.1 - 1,150.1 Research and development - - - - 885.0 - 885.0 Selling and marketing - - - - 1,677.3 - 1,677.3 General and administrative - - - - 622.5 - 622.5 Amortization - - - - 2,801.4 - 2,801.4 Goodwill impairments - - - - 3,552.8 - 3,552.8 In-process research and development impairments - - - - 436.0 - 436.0 Asset sales and impairments, net - - - - 124.2 - 124.2 Total operating expenses - - - - 11,249.3 - 11,249.3 Operating (loss) - - - - (3,562.1 ) - (3,562.1 ) Interest (expense), net - (46.9 ) (11.6 ) (39.9 ) (267.8 ) - (366.2 ) Other (expense) / income, net - - (0.1 ) - 9.2 - 9.1 Total other (expense), net - (46.9 ) (11.7 ) (39.9 ) (258.6 ) - (357.1 ) (Loss) before income taxes and noncontrolling interest - (46.9 ) (11.7 ) (39.9 ) (3,820.7 ) - (3,919.2 ) Provision for income taxes - 1.8 - - 231.1 - 232.9 Losses / (earnings) of equity interest subsidiaries 4,156.9 4,060.8 1,183.4 3,382.7 - (12,783.8 ) - Net (loss) / income $ (4,156.9 ) $ (4,109.5 ) $ (1,195.1 ) $ (3,422.6 ) $ (4,051.8 ) $ 12,783.8 $ (4,152.1 ) (Income) attributable to noncontrolling interest - - - - (4.8 ) - (4.8 ) Net (loss) / income attributable to members $ (4,156.9 ) $ (4,109.5 ) $ (1,195.1 ) $ (3,422.6 ) $ (4,056.6 ) $ 12,783.8 $ (4,156.9 ) Other comprehensive (loss) / income, net of tax (63.5 ) (173.8 ) (130.3 ) (439.1 ) (63.5 ) 806.7 (63.5 ) Comprehensive (loss) / income attributable to members $ (4,220.4 ) $ (4,283.3 ) $ (1,325.4 ) $ (3,861.7 ) $ (4,120.1 ) $ 13,590.5 $ (4,220.4 ) Warner Chilcott Limited Consolidating Statements of Operations For the Three Months Ended June 30, 2018 (Unaudited; in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues $ - $ - $ - $ - $ 4,124.2 $ - $ 4,124.2 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 481.8 - 481.8 Research and development - - - - 689.2 - 689.2 Selling and marketing - - - - 853.4 - 853.4 General and administrative - - 1.2 - 298.3 - 299.5 Amortization - - - - 1,697.1 - 1,697.1 In-process research and development impairments - - - - 276.0 - 276.0 Asset sales and impairments, net - - - - 259.6 - 259.6 Total operating expenses - - 1.2 - 4,555.4 - 4,556.6 Operating (loss) - - (1.2 ) - (431.2 ) - (432.4 ) Interest income / (expense), net - 267.4 (5.1 ) (20.7 ) (399.8 ) - (158.2 ) Other (expense) / income, net - - 9.2 - 206.2 - 215.4 Total other income / (expense), net - 267.4 4.1 (20.7 ) (193.6 ) - 57.2 Income / (loss) before income taxes and noncontrolling interest - 267.4 2.9 (20.7 ) (624.8 ) - (375.2 ) (Benefit) / provision for income taxes - - - (4.4 ) (0.8 ) - (5.2 ) Losses / (earnings) of equity interest subsidiaries 372.4 512.4 (118.7 ) (550.8 ) - (215.3 ) - Net (loss) / income $ (372.4 ) $ (245.0 ) $ 121.6 $ 534.5 $ (624.0 ) $ 215.3 $ (370.0 ) (Income) attributable to noncontrolling interest - - - - (2.4 ) - (2.4 ) Net (loss) / income attributable to members $ (372.4 ) $ (245.0 ) $ 121.6 $ 534.5 $ (626.4 ) $ 215.3 $ (372.4 ) Other comprehensive (loss) / income, net of tax (448.6 ) (295.6 ) (59.7 ) (195.6 ) (448.6 ) 999.5 (448.6 ) Comprehensive (loss) / income attributable to members $ (821.0 ) $ (540.6 ) $ 61.9 $ 338.9 $ (1,075.0 ) $ 1,214.8 $ (821.0 ) Warner Chilcott Limited Consolidating Statements of Operations For the Six Months Ended June 30, 2018 (Unaudited; in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Net revenues $ - $ - $ - $ - $ 7,796.3 $ - $ 7,796.3 Operating expenses: Cost of sales (excludes amortization and impairment of acquired intangibles including product rights) - - - - 1,004.6 - 1,004.6 Research and development - - - - 1,163.9 - 1,163.9 Selling and marketing - - - - 1,653.4 - 1,653.4 General and administrative - - 0.5 - 593.1 - 593.6 Amortization - - - - 3,394.7 - 3,394.7 In-process research and development impairments - - - - 798.0 - 798.0 Asset sales and impairments, net - - - - 272.7 - 272.7 Total operating expenses - - 0.5 - 8,880.4 - 8,880.9 Operating (loss) - - (0.5 ) - (1,084.1 ) - (1,084.6 ) Interest income / (expense), net - 526.4 (8.4 ) (41.9 ) (814.6 ) - (338.5 ) Other income, net - - 9.2 - 127.4 - 136.6 Total other income / (expense), net - 526.4 0.8 (41.9 ) (687.2 ) - (201.9 ) Income / (loss) before income taxes and noncontrolling interest - 526.4 0.3 (41.9 ) (1,771.3 ) - (1,286.5 ) Provision / (benefit) for income taxes - - 0.3 (16.6 ) (671.1 ) - (687.4 ) Losses / (earnings) of equity interest subsidiaries 603.7 1,018.4 214.4 99.2 - (1,935.7 ) - Net (loss) / income $ (603.7 ) $ (492.0 ) $ (214.4 ) $ (124.5 ) $ (1,100.2 ) $ 1,935.7 $ (599.1 ) (Income) attributable to noncontrolling interest - - - - (4.6 ) - (4.6 ) Net (loss) / income attributable to members $ (603.7 ) $ (492.0 ) $ (214.4 ) $ (124.5 ) $ (1,104.8 ) $ 1,935.7 $ (603.7 ) Other comprehensive (loss) / income, net of tax (264.8 ) (25.0 ) 59.2 164.4 (264.8 ) 66.2 (264.8 ) Comprehensive (loss) / income attributable to members $ (868.5 ) $ (517.0 ) $ (155.2 ) $ 39.9 $ (1,369.6 ) $ 2,001.9 $ (868.5 )
Consolidating Statement of Cash Flows	Warner Chilcott Limited Consolidating Statements of Cash Flows For the Six Months Ended June 30, 2019 (Unaudited; in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash Flows From Operating Activities: Net (loss) / income $ (4,156.9 ) $ (4,109.5 ) $ (1,195.1 ) $ (3,422.6 ) $ (4,051.8 ) $ 12,783.8 $ (4,152.1 ) Reconciliation to net cash provided by / (used in) operating activities: Losses / (earnings) of equity interest subsidiaries 4,156.9 4,060.8 1,183.4 3,382.7 - (12,783.8 ) - Depreciation - - - - 96.2 - 96.2 Amortization - - - - 2,801.4 - 2,801.4 Provision for inventory reserve - - - - 83.4 - 83.4 Share-based compensation - - - - 111.8 - 111.8 Deferred income tax benefit - - - - (166.4 ) - (166.4 ) Goodwill impairments - - - - 3,552.8 - 3,552.8 In-process research and development impairments - - - - 436.0 - 436.0 Loss on asset sales and impairments, net - - - - 124.2 - 124.2 Non-cash extinguishment of debt - - - - 0.2 - 0.2 Amortization of deferred financing costs - - 8.3 0.8 - - 9.1 Non-cash lease expense - - - - 68.0 - 68.0 Contingent consideration adjustments, including accretion - - - - 46.8 - 46.8 Dividends from subsidiaries 1,288.5 - - - - (1,288.5 ) - Other, net - - (2.5 ) (0.9 ) (15.9 ) - (19.3 ) Changes in assets and liabilities (net of effects of acquisitions) - (134.4 ) 1,036.8 40.0 (1,300.0 ) - (357.6 ) Net cash provided by / (used in) operating activities 1,288.5 (183.1 ) 1,030.9 - 1,786.7 (1,288.5 ) 2,634.5 Cash Flows From Investing Activities: Additions to property, plant and equipment - - - - (152.3 ) - (152.3 ) Additions to product rights and other intangibles - - - - (46.0 ) - (46.0 ) Additions to investments - (100.0 ) - - (638.2 ) - (738.2 ) Proceeds from sale of investments and other assets - 289.4 - - 1,172.6 - 1,462.0 Proceeds from sales of property, plant and equipment - - - - 17.7 - 17.7 Acquisitions of businesses, net of cash acquired - - - - (80.6 ) - (80.6 ) Net cash provided by investing activities - 189.4 - - 273.2 - 462.6 Cash Flows From Financing Activities: Proceeds from borrowings of long-term indebtedness, including credit facility - - - - 3.3 - 3.3 Payments on debt, including finance lease obligations and credit facility - - (1,031.6 ) - (7.5 ) - (1,039.1 ) Payments of contingent consideration and other financing - - - - (4.1 ) - (4.1 ) Dividends to Parents (1,288.5 ) - - - (1,288.5 ) 1,288.5 (1,288.5 ) Net cash (used in) / provided by financing activities (1,288.5 ) - (1,031.6 ) - (1,296.8 ) 1,288.5 (2,328.4 ) Effect of currency exchange rate changes on cash and cash equivalents - - - - 2.7 - 2.7 Net increase / (decrease) in cash and cash equivalents - 6.3 (0.7 ) - 765.8 - 771.4 Cash and cash equivalents at beginning of period 0.1 1.8 0.8 - 875.9 - 878.6 Cash and cash equivalents at end of period $ 0.1 $ 8.1 $ 0.1 $ - $ 1,641.7 $ - $ 1,650.0 Warner Chilcott Limited Consolidating Statements of Cash Flows For the Six Months Ended June 30, 2018 (Unaudited; in millions) Warner Chilcott Limited (Parent Guarantor) Allergan Capital S.a.r.l. (Guarantor) Allergan Funding SCS (Issuer) Allergan Finance, LLC (Issuer and Guarantor) Non- guarantors Eliminations Consolidated Warner Chilcott Limited Cash Flows From Operating Activities: Net (loss) / income $ (603.7 ) $ (492.0 ) $ (214.4 ) $ (124.5 ) $ (1,100.2 ) $ 1,935.7 $ (599.1 ) Reconciliation to net cash provided by / (used in) operating activities: Losses / (earnings) of equity interest subsidiaries 603.7 1,018.4 214.4 99.2 - (1,935.7 ) - Depreciation - - - - 105.2 - 105.2 Amortization - - - - 3,394.7 - 3,394.7 Provision for inventory reserve - - - - 45.4 - 45.4 Share-based compensation - - - - 127.4 - 127.4 Deferred income tax benefit - - - - (1,359.6 ) - (1,359.6 ) In-process research and development impairments - - - - 798.0 - 798.0 Loss on asset sales and impairments, net - - - - 272.7 - 272.7 Gain on sale of Teva securities, net - - - - (60.9 ) - (60.9 ) Gain on sale of business - - - - (53.0 ) - (53.0 ) Non-cash extinguishment of debt - - 4.0 - - - 4.0 Cash charge related to extinguishment of debt - - (13.1 ) - - - (13.1 ) Amortization of deferred financing costs - - 11.1 0.8 - - 11.9 Contingent consideration adjustments, including accretion - - - - (101.8 ) - (101.8 ) Dividends from subsidiaries 2,103.7 - - - - (2,103.7 ) - Other, net - - (1.5 ) (0.4 ) 1.6 - (0.3 ) Changes in assets and liabilities (net of effects of acquisitions) - (1,225.0 ) 3,942.3 24.9 (2,578.4 ) - 163.8 Net cash provided by / (used in) operating activities 2,103.7 (698.6 ) 3,942.8 - (508.9 ) (2,103.7 ) 2,735.3 Cash Flows From Investing Activities: Additions to property, plant and equipment - - - - (106.5 ) - (106.5 ) Additions to investments - (400.0 ) - - (1,055.9 ) - (1,455.9 ) Proceeds from sale of investments and other assets - 800.0 - - 4,851.3 - 5,651.3 Payments to settle Teva related matters - - - - (466.0 ) - (466.0 ) Proceeds from sales of property, plant and equipment - - - - 11.5 - 11.5 Net cash provided by investing activities - 400.0 - - 3,234.4 - 3,634.4 Cash Flows From Financing Activities: Proceeds from borrowings of long-term indebtedness, including credit facility - 700.0 - - 9.0 - 709.0 Payments on debt, including finance lease obligations and credit facility - (700.0 ) (3,956.0 ) - (710.8 ) - (5,366.8 ) Cash charge related to extinguishment of debt - - 13.1 - - - 13.1 Payments of contingent consideration and other financing - - - - (10.6 ) - (10.6 ) Proceeds from forward sale of Teva securities - - - - 465.5 - 465.5 Payments to settle Teva related matters - - - - (234.0 ) - (234.0 ) Dividends to Parents (2,103.7 ) - - - (2,103.7 ) 2,103.7 (2,103.7 ) Net cash (used in) / provided by financing activities (2,103.7 ) - (3,942.9 ) - (2,584.6 ) 2,103.7 (6,527.5 ) Effect of currency exchange rate changes on cash and cash equivalents - - - - 15.0 - 15.0 Net (decrease) / increase in cash and cash equivalents - (298.6 ) (0.1 ) - 155.9 - (142.8 ) Cash and cash equivalents at beginning of period 0.1 593.1 0.1 - 1,223.0 - 1,816.3 Cash and cash equivalents at end of period $ 0.1 $ 294.5 $ - $ - $ 1,378.9 $ - $ 1,673.5

General - Additional Informatio

General - Additional Information (Detail)	Sep. 30, 2018Country
Segment Reporting [Abstract]
Number of operating countries	100

Reconciliation of Warner Chil_3

Reconciliation of Warner Chilcott Limited Results to Allergan Plc Results - Summary of Financial Position Reconciliation Results of Warner Chilcott Limited to Allergan Plc (Detail) - USD ($) $ in Millions	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
Cash and cash equivalents	$ 1,651.4		$ 880.4	$ 1,674.7		$ 1,817.2
Prepaid expenses and other current assets	2,508.3		819.1
Accounts payable and accrued liabilities	4,995.3		4,787.2
Income taxes payable	91		72.4
Other taxes payable	1,667		1,615.5
Deferred tax liabilities	4,968.4		5,501.8
Total equity	59,696.1	$ 61,559.6	65,131	71,264	$ 72,346	73,837.1
Warner Chilcott Limited [Member]
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
Cash and cash equivalents	1,650		878.6	1,673.5		1,816.3
Prepaid expenses and other current assets	2,505		818.7
Accounts payable and accrued liabilities	4,995.2		4,787.4
Income taxes payable	93.6		72.4
Other taxes payable	1,660.8		1,615.5
Deferred tax liabilities	4,968.5		5,501.8
Total equity	57,413.9	$ 59,338.7	62,940.3	$ 78,676.2	$ 79,739	$ 81,282.2
Difference [Member]
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
Cash and cash equivalents	1.4		1.8
Prepaid expenses and other current assets	3.3		0.4
Accounts payable and accrued liabilities	0.1		(0.2)
Income taxes payable	(2.6)
Other taxes payable	6.2
Deferred tax liabilities	(0.1)
Total equity	$ 2,282.2		$ 2,190.7

Reconciliation of Warner Chil_4

Reconciliation of Warner Chilcott Limited Results to Allergan Plc Results - Summary of Operations Reconciliation Results of Warner Chilcott Limited to Allergan Plc (Detail) - USD ($) $ in Millions	3 Months Ended				6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
General and administrative expenses	$ 324.2		$ 334.1		$ 632.5	$ 630
Operating (loss)	(1,262.9)		(467)		(3,572.1)	(1,121)
Interest income	9.7		6.3		31	23.6
(Loss) before income taxes and noncontrolling interest	(1,453.3)		(475.3)		(3,929.2)	(1,441.4)
Provision for income taxes	301.6		(5.2)		233	(687.4)
Net (loss)	(1,754.9)		(470.1)		(4,162.2)	(754)
Dividends on preferred shares						46.4
Net (loss) attributable to ordinary shareholders/members	(1,759)		(472.5)		(4,167)	(805)
Warner Chilcott Limited [Member]
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
General and administrative expenses	316.4		299.5		622.5	593.6
Operating (loss)	(1,255.1)		(432.4)		(3,562.1)	(1,084.6)
Interest income	9.7		71.8		31	142.1
(Loss) before income taxes and noncontrolling interest	(1,445.5)		(375.2)		(3,919.2)	(1,286.5)
Provision for income taxes	301.6		(5.2)		232.9	(687.4)
Net (loss)	(1,747.1)		(370)		(4,152.1)	(599.1)
Net (loss) / income attributable to members	(1,751.2)	$ (2,405.7)	(372.4)	$ (231.3)	(4,156.9)	(603.7)
Difference [Member]
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
General and administrative expenses	7.8		34.6		10	36.4
Operating (loss)	(7.8)		(34.6)		(10)	(36.4)
Interest income			(65.5)			(118.5)
(Loss) before income taxes and noncontrolling interest	(7.8)		(100.1)		(10)	(154.9)
Provision for income taxes					0.1
Net (loss)	(7.8)		(100.1)		(10.1)	(154.9)
Dividends on preferred shares						46.4
Net (loss) attributable to ordinary shareholders/members	$ (7.8)		$ (100.1)		$ (10.1)	$ (201.3)

Reconciliation of Warner Chil_5

Reconciliation of Warner Chilcott Limited Results to Allergan Plc Results - Additional Information (Detail) - Warner Chilcott Limited [Member] - USD ($) $ in Millions	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018
Schedule Of Reconciliation Of Subsidiary Results [Line Items]
Receivable from Parents	$ 210.6	$ 640.9	$ 5,800
Non current receivables from Parents			$ 4,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Schedule of Recognized Lease Liabilities and Corresponding Righ of use Assets (Detail) - USD ($) $ in Millions	Jun. 30, 2019	Jan. 01, 2019
Right of use asset - operating leases	$ 457.9	$ 462.1
Lease Liability	538	548.6
Real Estate [Member]
Right of use asset - operating leases	283.9	304.2
Lease Liability	$ 350.9	370.6
Fleet [Member]
Right of use asset - operating leases		100.4
Lease Liability		100.4
Other [Member]
Right of use asset - operating leases		57.5
Lease Liability		$ 77.6

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Millions	Jan. 01, 2019	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Mar. 01, 2018
Summary Of Significant Accounting Policies [Line Items]
Implementation of new accounting pronouncements					$ 63
Shares repurchased		0				5,300,000
Repurchase of share on EPS basis		3,000,000
Conversion of preferred stock to ordinary shares								3.53
Ordinary Shares [Member]
Summary Of Significant Accounting Policies [Line Items]
Shares not included in the computation of diluted EPS							5,800,000
Shares repurchased			200,000		100,000
Stock Awards [Member]
Summary Of Significant Accounting Policies [Line Items]
Shares not included in the computation of diluted EPS		1,600,000		2,200,000		1,800,000	2,200,000
ASU 2016-02 [Member] | Adjustment [Member]
Summary Of Significant Accounting Policies [Line Items]
Implementation of new accounting pronouncement	$ 22
ASC 606 [Member] | General and Administrative Expense [Member]
Summary Of Significant Accounting Policies [Line Items]
Provision for bad debts		$ 3.9		$ 4		$ 7.3	$ 14.1

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Provisions for Sales Returns and Allowances from Continuing Operations Activity (Detail) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Valuation And Qualifying Accounts Disclosure [Line Items]
Accounts payable and accrued expenses	$ 4,995.3	$ 4,787.2
Chargebacks [Member]
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	61.8
Provision related to sales in 2019	553.2
Credits and payments	(545.1)
Balance at end of period	69.9
Contra accounts receivable at June 30, 2019	69.9
Rebates [Member]
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	1,908.5
Provision related to sales in 2019	2,876.3
Credits and payments	(2,769.3)
Balance at end of period	2,015.5
Contra accounts receivable at June 30, 2019	81.1
Accounts payable and accrued expenses	1,934.4
Returns and Other Allowances [Member]
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	566.6
Provision related to sales in 2019	835.8
Credits and payments	(781.5)
Balance at end of period	620.9
Contra accounts receivable at June 30, 2019	34.6
Accounts payable and accrued expenses	586.3
Cash Discounts [Member]
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	30.7
Provision related to sales in 2019	159.2
Credits and payments	(156.9)
Balance at end of period	33
Contra accounts receivable at June 30, 2019	33
Allowance for Sales Returns [Member]
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	2,567.6
Provision related to sales in 2019	4,424.5
Credits and payments	(4,252.8)
Balance at end of period	2,739.3
Contra accounts receivable at June 30, 2019	218.6	207.7
Accounts payable and accrued expenses	$ 2,520.7	$ 2,359.9

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Summarizes The Balance Sheet Classification of Our SRA Reserves (Details) - USD ($) $ in Millions	Jun. 30, 2019	Dec. 31, 2018
Sales Return Allowance Reserve [Line Items]
Accounts payable and accrued expenses	$ 4,995.3	$ 4,787.2
Allowance for Sales Returns [Member]
Sales Return Allowance Reserve [Line Items]
Contra accounts receivable	218.6	207.7
Accounts payable and accrued expenses	2,520.7	2,359.9
Total	$ 2,739.3	$ 2,567.6

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Summary of Activity in Gross-to-Net Revenue (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Disaggregation Of Revenue [Line Items]
Net product sales	$ 4,090.1	$ 4,124.2	$ 7,687.2	$ 7,796.3
Product [Member]
Disaggregation Of Revenue [Line Items]
Gross product sales	6,295.6	6,095.5	11,955.5	11,711.6
Provisions to reduce gross product sales to net product sales	(2,284.8)	(2,087.3)	(4,424.5)	(4,122.4)
Net product sales	$ 4,010.8	$ 4,008.2	$ 7,531	$ 7,589.2
Percentage of SRA provisions to gross sales	36.30%	34.20%	37.00%	35.20%

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Net (loss):
Net (loss) attributable to ordinary shareholders	$ (1,759)	$ (472.5)	$ (4,167)	$ (805)
Basic weighted average ordinary shares outstanding	327.8	339.1	329.9	336.9
Basic EPS:
(Loss) per share attributable to ordinary shareholders - basic	$ (5.37)	$ (1.39)	$ (12.63)	$ (2.39)
Dividends per ordinary share	$ 0.74	$ 0.72	$ 1.48	$ 1.44
Diluted weighted average ordinary shares outstanding	327.8	339.1	329.9	336.9
Diluted EPS:
(Loss) per share attributable to ordinary shareholders - diluted	$ (5.37)	$ (1.39)	$ (12.63)	$ (2.39)

Business Transactions - Additio

Business Transactions - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	Jun. 25, 2019	Mar. 26, 2019	Jun. 30, 2019	Dec. 31, 2018
Business Acquisition [Line Items]
Product rights and other intangibles			$ 41,231.5	$ 43,695.4
Goodwill			$ 42,340.7	$ 45,913.3
AbbVie, Inc. [Member]
Business Acquisition [Line Items]
Sale of Stock, Price Per Share	$ 188.24
Business Acquisition, consideration to be transferred	$ 63,000
Business acquisition, equity interest issuable, number of shares	0.8660
Business acquisition, share price	$ 120.30
Envy Medical, Inc. [Member]
Business Acquisition [Line Items]
Business acquisition, consideration transferred		$ 81.4
Product rights and other intangibles		67.4
Goodwill		$ 34.1

Assets Held for Sale - Summary

Assets Held for Sale - Summary of Assets Held For Sale (Details) - USD ($) $ in Millions	Jun. 30, 2019	Dec. 31, 2018
Assets held for sale:
Inventories		$ 34
Property, plant and equipment, net	$ 32.5	32.8
Product rights and other intangibles		849.4
Total assets held for sale	$ 32.5	$ 916.2

Assets Held for Sale - Addition

Assets Held for Sale - Additional Information (Detail) $ in Millions	6 Months Ended
	Jun. 30, 2019USD ($)
Assets Held For Sale Not Part Of Disposal Group [Abstract]
Impairment, assets held for sale	$ 129.6

Other Income _ (Expense) - Comp

Other Income / (Expense) - Components of Other (Expense) / Income, Net (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Other Non Operating Income Expense [Line Items]
Sales of business		$ 53		$ 53
Debt extinguishment other	$ 0.1	9.1	$ (0.2)	9.1
Other (expense) / income, net	(4.8)	14.7	9.3	13.6
Other (expense) / income, net	$ (4.7)	215.4	$ 9.1	136.6
Teva [Member]
Other Non Operating Income Expense [Line Items]
Net income impact of other-than-temporary loss on investment		$ 138.6		$ 60.9

Other Income _ (Expense) - Summ

Other Income / (Expense) - Summary of Teva Share Activity (Detail) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	Feb. 13, 2018	Mar. 31, 2018	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2019	Dec. 31, 2018
Other Non Operating Income Expense [Line Items]
Retained earnings					$ 2,581.1	$ 7,258.9
Teva [Member]
Other Non Operating Income Expense [Line Items]
Shares		59.4		95.9
Carrying Value per Share		$ 17.09		$ 17.60
Market Price		$ 17.09		$ 18.95
Proceeds Received	$ 372.3	$ 1,015.5	$ 1,815.5
Value of Marketable ecurities		1,014.7		$ 1,817.7
Unrealized Gain / (Loss) as a Component of Other Comprehensive Income				129.3
Gain / (Loss) Recognized in Other Income/ (Expense), Net		(77.7)	60.9
Derivative Instrument (Liability)/ Asset		(353.3)		$ (62.9)
Retained earnings		129.3	$ 129.3
Teva [Member] | Accounting Standards Update No. 2016-01 [Member]
Other Non Operating Income Expense [Line Items]
Unrealized Gain / (Loss) as a Component of Other Comprehensive Income		(129.3)
Retained earnings		$ 129.3
Teva [Member] | Settlement of Initial Accelerated Share Repurchase ("ASR"), Net [Member]
Other Non Operating Income Expense [Line Items]
Shares		(25)
Carrying Value per Share		$ 18.95
Market Price		$ 16.53
Proceeds Received		$ 413.3
Value of Marketable ecurities		(473.8)
Gain / (Loss) Recognized in Other Income/ (Expense), Net		2.5
Derivative Instrument (Liability)/ Asset		62.9
Teva [Member] | Forward Sale [Member]
Other Non Operating Income Expense [Line Items]
Proceeds Received		372.3
Gain / (Loss) Recognized in Other Income/ (Expense), Net		19
Derivative Instrument (Liability)/ Asset		$ (353.3)
Teva [Member] | Open Market Sales [Member]
Other Non Operating Income Expense [Line Items]
Shares		(11.5)	(34.4)
Market Price		$ 19.95	$ 20.55
Proceeds Received		$ 229.9	$ 706.8
Value of Marketable ecurities		(218.5)	(587.4)
Gain / (Loss) Recognized in Other Income/ (Expense), Net		11.5	$ 119.4
Teva [Member] | Other Fair Value [Member]
Other Non Operating Income Expense [Line Items]
Value of Marketable ecurities		(110.7)
Gain / (Loss) Recognized in Other Income/ (Expense), Net		$ (110.7)
Teva [Member] | Settlement of Forward Sale, Net [Member]
Other Non Operating Income Expense [Line Items]
Shares			(25)
Carrying Value per Share			$ 17.09
Market Price			$ 18.61
Proceeds Received			$ 93.2
Value of Marketable ecurities			(427.3)
Gain / (Loss) Recognized in Other Income/ (Expense), Net			19.2
Derivative Instrument (Liability)/ Asset			$ 353.3

Other Income _ (Expense) - Su_2

Other Income / (Expense) - Summary of Teva Share Activity (Parenthetical) (Detail) - Teva [Member] - USD ($) $ / shares in Units, shares in Millions, $ in Millions	Feb. 13, 2018	Mar. 31, 2018	Jun. 30, 2018	May 07, 2018	Jan. 17, 2018
Other Non Operating Income Expense [Line Items]
Closing stock price of securities				$ 18.62	$ 21.48
Forward sale of investment shares	25
Proceeds from forward sale received	$ 372.3	$ 1,015.5	$ 1,815.5

Other Income _ (Expense) - Addi

Other Income / (Expense) - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Other Non Operating Income Expense [Line Items]
Gain on sale of business			$ 53		$ 53
Senior notes, repurchase amount	$ 97.8		455.9	$ 249.8	455.9
Debt extinguishment other	$ 0.1		9.1	(0.2)	9.1
Other income (expenses) cash discount received					13.1
Redeemable premium interest					4
Mark to market gains (loss) on equity securities		$ 7.2		$ 3.2
Non-Strategic Asset Group [Member]
Other Non Operating Income Expense [Line Items]
Asset held-for-sale in cash			55		55
Asset held-for-sale in deferred consideration			$ 20		20
Gain on sale of business					$ 53

Other Income _ (Expense) - Su_3

Other Income / (Expense) - Summary of Redeemed and Retired Senior Notes (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Other Non Operating Income Expense [Line Items]
Senior notes, repurchase amount	$ 97.8	$ 455.9	$ 249.8	$ 455.9
Cash Paid for Retirement	97.8	442.8	249.8	442.8
Remaining Value at June 30, 2019	8,424.9	16,944.1	8,424.9	16,944.1
3.000% notes due March 12, 2020 [Member]
Other Non Operating Income Expense [Line Items]
Senior notes, repurchase amount	97.8	40.7	180.7	40.7
Cash Paid for Retirement	97.8	40.6	180.7	40.6
Remaining Value at June 30, 2019	2,526	3,459.3	2,526	3,459.3
3.450% notes due March 15, 2022 [Member]
Other Non Operating Income Expense [Line Items]
Senior notes, repurchase amount		59.5	62.3	59.5
Cash Paid for Retirement		58.6	62.3	58.6
Remaining Value at June 30, 2019	2,878.2	2,940.5	2,878.2	2,940.5
3.800% notes due March 15, 2025 [Member]
Other Non Operating Income Expense [Line Items]
Senior notes, repurchase amount		85	6.8	85
Cash Paid for Retirement		82.6	6.8	82.6
Remaining Value at June 30, 2019	$ 3,020.7	3,915	$ 3,020.7	3,915
2.450% Notes Due June 15, 2019 [Member]
Other Non Operating Income Expense [Line Items]
Senior notes, repurchase amount		8.8		8.8
Cash Paid for Retirement		8.8		8.8
Remaining Value at June 30, 2019		491.2		491.2
3.850% Notes Due June 15, 2024 [Member]
Other Non Operating Income Expense [Line Items]
Senior notes, repurchase amount		11.2		11.2
Cash Paid for Retirement		10.9		10.9
Remaining Value at June 30, 2019		1,188.8		1,188.8
4.550% notes due March 15, 2035 [Member]
Other Non Operating Income Expense [Line Items]
Senior notes, repurchase amount		115		115
Cash Paid for Retirement		110.1		110.1
Remaining Value at June 30, 2019		2,385		2,385
4.850% Notes Due June 15, 2044 [Member]
Other Non Operating Income Expense [Line Items]
Senior notes, repurchase amount		59		59
Cash Paid for Retirement		57.3		57.3
Remaining Value at June 30, 2019		1,441		1,441
4.750% notes due March 15, 2045 [Member]
Other Non Operating Income Expense [Line Items]
Senior notes, repurchase amount		76.7		76.7
Cash Paid for Retirement		73.9		73.9
Remaining Value at June 30, 2019		$ 1,123.3		$ 1,123.3

Other Income _ (Expense) - Su_4

Other Income / (Expense) - Summary of Redeemed and Retired Senior Notes (Parenthetical) (Details)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
3.000% notes due March 12, 2020 [Member]
Other Non Operating Income Expense [Line Items]
Senior notes, interest rate	3.00%	3.00%
Senior notes, maturity date	2020	2020
3.450% notes due March 15, 2022 [Member]
Other Non Operating Income Expense [Line Items]
Senior notes, interest rate	3.45%	3.45%
Senior notes, maturity date	2022	2022
3.800% notes due March 15, 2025 [Member]
Other Non Operating Income Expense [Line Items]
Senior notes, interest rate	3.80%	3.80%
Senior notes, maturity date	2025	2025
2.450% Notes Due June 15, 2019 [Member]
Other Non Operating Income Expense [Line Items]
Senior notes, interest rate		2.45%
Senior notes, maturity date		2019
3.850% Notes Due June 15, 2024 [Member]
Other Non Operating Income Expense [Line Items]
Senior notes, interest rate		3.85%
Senior notes, maturity date		2024
4.550% notes due March 15, 2035 [Member]
Other Non Operating Income Expense [Line Items]
Senior notes, interest rate		4.55%
Senior notes, maturity date		2035
4.850% Notes Due June 15, 2044 [Member]
Other Non Operating Income Expense [Line Items]
Senior notes, interest rate		4.85%
Senior notes, maturity date		2044
4.750% notes due March 15, 2045 [Member]
Other Non Operating Income Expense [Line Items]
Senior notes, interest rate		4.75%
Senior notes, maturity date		2045

Share-Based Compensation - Sche

Share-Based Compensation - Schedule of Fair Value Assumptions of Options based on Black-Scholes Valuation Model (Detail)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Two Thousand Nineteen Grants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected volatility	26.40%
Risk-free interest rate	1.90%
Expected term	7 years
Two Thousand Nineteen Grants [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield	1.70%
Two Thousand Nineteen Grants [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield	1.80%
Two Thousand Eighteen Grants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield		1.50%
Expected volatility		27.00%
Risk-free interest rate, Minimum		2.20%
Risk-free interest rate, Maximum		2.90%
Expected term		7 years

Share-Based Compensation - Shar

Share-Based Compensation - Share-Based Compensation Expense Recognized in Company's Results of Operations (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	$ 59.5	$ 54.9	$ 111.8	$ 127.4
Equity Based Compensation Awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	$ 59.5	$ 54.9	$ 111.8	$ 127.4

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Unrecognized future share-based compensation expense	$ 409,100
Remaining weighted average period (years)	1 year 8 months 12 days
Common stock, value	$ 167,430	$ 133,660

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Equity Award Activity for Unvested Restricted Stock and Stock Units (Detail) - Restricted Stock [Member] - USD ($) $ / shares in Units, shares in Millions, $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted shares / units outstanding, beginning balance	2.5
Shares, Granted	1.5
Shares, Vested	(0.7)
Shares, Forfeited	(0.1)
Restricted shares / units outstanding, ending balance	3.2	2.5
Weighted Average Grant Date Fair Value, outstanding, beginning balance	$ 190.27
Weighted Average Grant Date Fair Value, Granted	139.83
Weighted Average Grant Date Fair Value, Vested	209.91
Weighted Average Grant Date Fair Value, Forfeited	177.79
Weighted Average Grant Date Fair Value, outstanding, ending balance	$ 161.46	$ 190.27
Weighted Average Remaining Contractual Term (Years)	1 year 9 months 18 days	1 year 7 months 6 days
Aggregate Grant Date Fair Value, outstanding, beginning balance	$ 472.9
Aggregate Grant Date Fair Value, Granted	207.8
Aggregate Grant Date Fair Value, Vested	(138.8)
Aggregate Grant Date Fair Value, Forfeited	(19.3)
Aggregate Grant Date Fair Value, outstanding, ending balance	$ 522.6	$ 472.9

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of Equity Award Activity for Non-Qualified Options to Purchase Ordinary Shares (Detail) - Non-qualified Options [Member] - USD ($) $ / shares in Units, shares in Millions, $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options, Outstanding, Beginning Balance	6.3
Options, vested and expected to vest, Beginning Balance	6.3
Options, Granted	0.3
Options, Exercised	(0.3)
Options, Cancelled	(0.1)
Options, Outstanding, Ending Balance	6.2	6.3
Options, vested and expected to vest, Ending Balance	6.2	6.3
Weighted Average Exercise Price, Outstanding, Beginning Balance	$ 122.74
Weighted Average Exercise Price, vested and expected to vest, Beginning Balance	122.74
Weighted Average Exercise Price, Granted	140.29
Weighted Average Exercise Price, Exercised	82.45
Weighted Average Exercise Price, Cancelled	217.07
Weighted Average Exercise Price, Outstanding, Ending Balance	124.78	$ 122.74
Weighted Average Exercise Price, vested and expected to vest, Ending Balance	$ 124.78	$ 122.74
Weighted Average Remaining Contractual Term (Years), Outstanding	4 years 3 months 18 days	4 years 4 months 24 days
Weighted Average Remaining Contractual Term (Years), vested and expected to vest	4 years 3 months 18 days	4 years 4 months 24 days
Aggregate Intrinsic Value, Outstanding	$ 265.2	$ 69
Aggregate Intrinsic Value, vested and expected to vest	$ 265.2	$ 69

Reportable Segments - Additiona

Reportable Segments - Additional Information (Detail) $ in Millions	Jul. 24, 2019USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2019USD ($)Segment	Jun. 30, 2018USD ($)
Segment Reporting Information [Line Items]
Number of operating segments | Segment				3
Operating (loss)		$ (1,262.9)	$ (467)	$ (3,572.1)	$ (1,121)
Net revenues		4,090.1	4,124.2	7,687.2	7,796.3
Cost of sales		$ 652.3	$ 481.8	$ 1,150.1	$ 1,004.6
Subsequent Event [Member] | Adjustment [Member]
Segment Reporting Information [Line Items]
Operating (loss)	$ (95.9)
Net revenues	(43.5)
Cost of sales	44.2
Selling, general and administrative expense	$ 8.2

Reportable Segments - Schedule

Reportable Segments - Schedule of Net Revenues, Operating Expenses Contribution Information by Reportable Segment (Detail) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Segment Reporting Information [Line Items]
Net revenues	$ 4,090.1		$ 4,124.2	$ 7,687.2	$ 7,796.3
Operating expenses:
Cost of sales	652.3		481.8	1,150.1	1,004.6
Selling and marketing	873.3		853.4	1,677.3	1,653.4
General and administrative	324.2		334.1	632.5	630
Research and development	450		689.2	885	1,163.9
Amortization	1,402		1,697.1	2,801.4	3,394.7
Goodwill impairments	1,085.8			3,552.8
In-process research and development impairments	436		276	436	798
Asset sales and impairments, net	129.4		259.6	124.2	272.7
Operating (loss)	(1,262.9)		(467)	(3,572.1)	(1,121)
Operating Segments [Member]
Segment Reporting Information [Line Items]
Net revenues	4,088.5		4,095.6	7,682.8	7,761.9
Operating expenses:
Cost of sales	527.9		489.9	948.2	927.6
Selling and marketing	871.7		844.3	1,676.6	1,628.7
General and administrative	96.4		116.7	220.5	237.2
Segment contribution	$ 2,592.5		$ 2,644.7	$ 4,837.5	$ 4,968.4
Contribution margin	63.40%		64.60%	63.00%	64.00%
Research and development	$ 450		$ 689.2	$ 885	$ 1,163.9
Amortization	1,402		1,697.1	2,801.4	3,394.7
Goodwill impairments	1,085.8			3,552.8
In-process research and development impairments	436		276	436	798
Asset sales and impairments, net	129.4		259.6	124.2	272.7
Operating (loss)	$ (1,262.9)		$ (467)	$ (3,572.1)	$ (1,121)
Operating margin	(30.90%)		(11.40%)	(46.50%)	(14.40%)
Corporate Non Segment [Member]
Segment Reporting Information [Line Items]
Net revenues	$ 1.6		$ 28.6	$ 4.4	$ 34.4
Operating expenses:
Corporate	352.2		189.8	610.2	460.1
US Specialized Therapeutics [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Net revenues	1,785.1		1,826.7	3,328	3,405.3
Operating expenses:
Cost of sales	151		148.7	271.1	282.9
Selling and marketing	368		343.3	724.8	656.5
General and administrative	37.6		48.1	92.2	98.3
Segment contribution	$ 1,228.5		$ 1,286.6	$ 2,239.9	$ 2,367.6
Contribution margin	68.80%		70.40%	67.30%	69.50%
International [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Net revenues	$ 847.7		$ 948.9	$ 1,649.2	$ 1,812.9
Operating expenses:
Cost of sales	145.6		139.4	255.3	260.3
Selling and marketing	253.6		246.2	491.2	491.9
General and administrative	28.4		33.9	54.1	65.3
Segment contribution	$ 420.1		$ 529.4	$ 848.6	$ 995.4
Contribution margin	49.60%		55.80%	51.50%	54.90%
US General Medicine [Member]
Operating expenses:
Goodwill impairments	$ 1,085.8	$ 2,467		$ 3,552.8
US General Medicine [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Net revenues	1,455.7		$ 1,320	2,705.6	$ 2,543.7
Operating expenses:
Cost of sales	231.3		201.8	421.8	384.4
Selling and marketing	250.1		254.8	460.6	480.3
General and administrative	30.4		34.7	74.2	73.6
Segment contribution	$ 943.9		$ 828.7	$ 1,749	$ 1,605.4
Contribution margin	64.80%		62.80%	64.60%	63.10%

Reportable Segments - Schedul_2

Reportable Segments - Schedule of Net Revenues, Operating Expenses Contribution Information by Reportable Segment (Parenthetical) (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Segment Reporting Information [Line Items]
Net revenues	$ 4,090.1	$ 4,124.2	$ 7,687.2	$ 7,796.3
Corporate Non Segment [Member]
Segment Reporting Information [Line Items]
Net revenues	$ 1.6	$ 28.6	$ 4.4	$ 34.4

Reportable Segments - Schedul_3

Reportable Segments - Schedule of Net Revenue Disaggregated by Geography for International Segment (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenues From External Customers And Long Lived Assets [Line Items]
Net Revenues	$ 4,090.1	$ 4,124.2	$ 7,687.2	$ 7,796.3
Operating Segments [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net Revenues	4,088.5	4,095.6	7,682.8	7,761.9
Operating Segments [Member] | International [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net Revenues	847.7	948.9	1,649.2	1,812.9
Operating Segments [Member] | International [Member] | Europe [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net Revenues	386.2	413.3	740.6	811.7
Operating Segments [Member] | International [Member] | Asia Pacific, Middle East and Africa [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net Revenues	261.5	283.6	512.2	524.4
Operating Segments [Member] | International [Member] | Latin America and Canada [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net Revenues	182.1	230.8	360.3	442.9
Operating Segments [Member] | International [Member] | Other [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net Revenues	$ 17.9	$ 21.2	$ 36.1	$ 33.9

Reportable Segments - Schedul_4

Reportable Segments - Schedule of Global Net Revenues for Top Products and Reconciliation of Segment Revenues to Total Net Revenues by Segment (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	$ 4,090.1	$ 4,124.2	$ 7,687.2	$ 7,796.3
Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	4,088.5	4,095.6	7,682.8	7,761.9
Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	1,785.1	1,826.7	3,328	3,405.3
Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	1,455.7	1,320	2,705.6	2,543.7
Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	847.7	948.9	1,649.2	1,812.9
Corporate Non Segment [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	1.6	28.6	4.4	34.4
Botox [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	974	934.5	1,842.4	1,751.8
Botox [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	699.4	658.5	1,326.5	1,231
Botox [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	274.6	276	515.9	520.8
Juvederm Collection [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	329.3	295.9	616.8	564.8
Juvederm Collection [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	156.6	139.8	286.3	262.6
Juvederm Collection [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	172.7	156.1	330.5	302.2
Restasis [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	322.8	334.2	564.9	608.3
Restasis [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	310.9	318.2	542.6	574
Restasis [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	11.9	16	22.3	34.3
Lumigan/Ganfort [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	152.5	173.5	295.3	340.7
Lumigan/Ganfort [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	62.1	73	119.8	139.8
Lumigan/Ganfort [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	90.4	100.5	175.5	200.9
Bystolic/Byvalson [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	151	148.7	279.7	282
Bystolic/Byvalson [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	150.5	148.1	278.8	280.9
Bystolic/Byvalson [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	0.5	0.6	0.9	1.1
Linzess/Constella [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	200.8	198.2	367.6	363.1
Linzess/Constella [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	196	191.8	357.3	351.1
Linzess/Constella [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	4.8	6.4	10.3	12
Alphagan/Combigan [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	132.5	142.7	253.1	271.1
Alphagan/Combigan [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	91.6	98.1	174.6	182.3
Alphagan/Combigan [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	40.9	44.6	78.5	88.8
Asacol/Delzicol [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	41.3	45	76.3	94.9
Asacol/Delzicol [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	31.6	32.6	56.3	70.8
Asacol/Delzicol [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	9.7	12.4	20	24.1
Lo Loestrin [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	145.5	127.8	271.3	242.4
Lo Loestrin [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	145.5	127.8	271.3	242.4
Eye Drops [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	115.1	126.2	219.9	241.2
Eye Drops [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	57.8	53.8	107.2	100
Eye Drops [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	57.3	72.4	112.7	141.2
Breast Implants [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	36.2	115.8	108.6	220.6
Breast Implants [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	67.6	75.9	128.8	136.6
Breast Implants [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	(31.4)	39.9	(20.2)	84
Viibryd/Fetzima [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	110.5	88.3	197.6	161.5
Viibryd/Fetzima [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	107.8	86.7	192.8	158.4
Viibryd/Fetzima [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	2.7	1.6	4.8	3.1
Ozurdex [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	110.9	95.5	204.3	185.4
Ozurdex [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	29.9	27.6	60.2	53.1
Ozurdex [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	81	67.9	144.1	132.3
Carafate/Sulcrate [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	56.9	55	111.8	111.7
Carafate/Sulcrate [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	56.2	54.3	110.5	110.3
Carafate/Sulcrate [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	0.7	0.7	1.3	1.4
Coolsculpting Consumables [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	81	90.4	146.6	151.9
Coolsculpting Consumables [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	60.7	71.9	108.5	125.3
Coolsculpting Consumables [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	20.3	18.5	38.1	26.6
Aczone [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	1.8	21.2	3.4	37.3
Aczone [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	1.8	21.1	3.4	37.1
Aczone [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues		0.1		0.2
Zenpep [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	70	55.5	133	108.4
Zenpep [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	70	55.5	133	108.4
Skin Care [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	46.3	38.4	83.7	74.1
Skin Care [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	42.6	34.3	77.3	66.2
Skin Care [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	3.7	4.1	6.4	7.9
Canasa/Salofalk [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	12.1	49.5	25.9	92.3
Canasa/Salofalk [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	8	45	18.2	83.6
Canasa/Salofalk [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	4.1	4.5	7.7	8.7
Vraylar [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	196.1	114.2	339.8	198.6
Vraylar [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	196.1	114.2	339.8	198.6
Saphris [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	32.6	33.8	64.5	66.5
Saphris [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	32.6	33.8	64.5	66.5
Viberzi [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	51.1	45.2	88.6	81.2
Viberzi [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	50.8	44.9	88	80.8
Viberzi [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	0.3	0.3	0.6	0.4
Coolsculpting Systems & Add On Applicators [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	29.8	48.8	55.5	83.6
Coolsculpting Systems & Add On Applicators [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	18.2	36.4	33.3	70.1
Coolsculpting Systems & Add On Applicators [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	11.6	12.4	22.2	13.5
Teflaro [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	37	33	70.7	65.2
Teflaro [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	37	32.4	70.5	64.6
Teflaro [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues		0.6	0.2	0.6
Namzaric [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	22.6	31.8	46	65.2
Namzaric [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	22.6	31.8	46	65.2
Rapaflo [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	5.9	21.3	18.3	45.3
Rapaflo [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	4.5	19.7	16.3	42.5
Rapaflo [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	1.4	1.6	2	2.8
Kybella/Belkyra [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	9.1	13.5	18	23.1
Kybella/Belkyra [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	8.5	11.2	15.8	19.4
Kybella/Belkyra [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	0.6	2.3	2.2	3.7
Alloderm [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	103.4	109.4	200	211.1
Alloderm [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	101.2	107.1	196.2	206.6
Alloderm [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	2.2	2.3	3.8	4.5
Dalvance [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	22.5	19	34.5	30.9
Dalvance [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	20.3	17.7	32.3	29.6
Dalvance [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	2.2	1.3	2.2	1.3
Namenda [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	6.1	3.4	15.6	44
Namenda [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	6.1	3.4	15.6	44
Avycaz [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	26.7	23.5	56.4	45.3
Avycaz [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	26.7	23.5	56.4	45.3
Liletta [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	21.9	15.5	36.7	23.6
Liletta [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	21.9	15.5	36.7	23.6
Armour Thyroid [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	56.7	49.2	106.7	97.4
Armour Thyroid [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	56.7	49.2	106.7	97.4
Savella [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	22.3	19.1	43	39
Savella [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	22.3	19.1	43	39
Other [Member] | Operating Segments [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	354.2	378.6	686.3	738.4
Other [Member] | Operating Segments [Member] | US Specialized Therapeutics [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	71.7	80.1	131.2	158.7
Other [Member] | Operating Segments [Member] | US General Medicine [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	197	192.7	387.9	383.2
Other [Member] | Operating Segments [Member] | International [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Net revenues	$ 85.5	$ 105.8	$ 167.2	$ 196.5

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Millions	Jun. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 335.8	$ 303.2
Work-in-process	145.5	145.7
Finished goods	683.3	520.2
Inventory, Gross	1,164.6	969.1
Less: inventory reserves	160.1	122.2
Total Inventories	$ 1,004.5	$ 846.9

Inventories - Additional Inform

Inventories - Additional Information (Detail) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Inventory [Line Items]
Cost of sales to Inventory Write-down	$ 83.4	$ 45.4
Inventory Reserves [Member]
Inventory [Line Items]
Cost of sales to Inventory Write-down	$ 44.2

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Detail) - USD ($) $ in Millions	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018
Accrued expenses:
Accrued third-party rebates	$ 1,934.4	$ 1,832.1
Accrued returns and other allowances	586.3	527.8
Accrued payroll and related benefits	484.8	694.3
Accrued R&D expenditures	189.8	215.5
Interest payable	187.5	191.4
Accrued pharmaceutical fees	186.1	145.3
Royalties payable	161.8	155.1
Litigation-related reserves and legal fees	158	92
Accrued non-provision taxes	67.2	68.5
Accrued selling and marketing expenditures	64.4	61.1
Accrued severance, retention and other shutdown costs	24.6	71.6
Current portion of contingent consideration obligations	10.5	8.3
Dividends payable	1.1	1.4	$ 1.4
Other accrued expenses	420.3	373
Total accrued expenses	4,476.8	4,437.4
Accounts payable	518.5	349.8
Total accounts payable and accrued expenses	$ 4,995.3	$ 4,787.2

Goodwill, Product Rights and _3

Goodwill, Product Rights and Other Intangible Assets - Schedule of Goodwill (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2019
Goodwill [Line Items]
Balance as of December 31, 2018		$ 45,913.3	$ 45,913.3
Acquisitions			34.1
Impairments	$ (1,085.8)		(3,552.8)
Foreign exchange and other adjustments			(53.9)
Balance as of June 30, 2019	42,340.7		42,340.7
US Specialized Therapeutics [Member]
Goodwill [Line Items]
Balance as of December 31, 2018		20,675.6	20,675.6
Acquisitions			34.1
Re-allocation to current segments			(340)
Balance as of June 30, 2019	20,369.7		20,369.7
US General Medicine [Member]
Goodwill [Line Items]
Balance as of December 31, 2018		17,936.6	17,936.6
Impairments	(1,085.8)	(2,467)	(3,552.8)
Re-allocation to current segments	340		340
Balance as of June 30, 2019	14,723.8		14,723.8
International [Member]
Goodwill [Line Items]
Balance as of December 31, 2018		$ 7,301.1	7,301.1
Foreign exchange and other adjustments			(53.9)
Balance as of June 30, 2019	$ 7,247.2		$ 7,247.2

Goodwill, Product Rights and _4

Goodwill, Product Rights and Other Intangible Assets - Additional Information (Detail) $ in Millions	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2019USD ($)Segment	Mar. 31, 2019USD ($)	Jun. 30, 2018USD ($)	Mar. 31, 2018USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Dec. 31, 2018USD ($)
Goodwill Product Rights And Other Intangible Assets [Line Items]
Number of reporting units | Segment	5
Gross balance of goodwill	$ 48,751.9				$ 48,751.9		$ 48,771.7
Goodwill impairment charge	1,085.8				3,552.8
Goodwill	42,340.7				42,340.7		$ 45,913.3
In-process research and development impairments	436		$ 276		436	$ 798
IPR&D [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments	127
IPR&D [Member] | Allergan, Inc. [Member] | Eye care project [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments			20
IPR&D [Member] | Allergan, Inc. [Member] | Eye care project [Member] | Changes in launch plans [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments			164
IPR&D [Member] | Allergan, Inc. [Member] | Eye care project [Member] | Delay in clinical studies [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments			6
IPR&D [Member] | Allergan, Inc. [Member] | Medical Dermatology Project [Member] | Delay in clinical studies [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments			27
IPR&D [Member] | Allergan, Inc. [Member] | CNS [Member] | Delay in clinical studies [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments			19
IPR&D [Member] | Allergan, Inc. [Member] | Facial Aesthetic Product [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments	133
IPR&D [Member] | Vitae [Member] | Delay in clinical studies [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments			$ 40
IPR&D [Member] | Vitae [Member] | RORyt [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments				$ 522
IPR&D [Member] | Tobira Therapeutics Inc [Member] | GI Project [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
In-process research and development impairments	$ 176
Minimum [Member] | Measurement Input, Discount Rate [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
Rate used for goodwill annual impairment test	9.50%						8.50%
Maximum [Member] | Measurement Input, Discount Rate [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
Rate used for goodwill annual impairment test	11.00%						10.00%
US General Medicine [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
Re-allocation to current segments	$ 340				340
Goodwill impairment charge	1,085.8	$ 2,467			3,552.8
Goodwill	14,723.8				14,723.8		$ 17,936.6
US Specialized Therapeutics [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
Re-allocation to current segments					(340)
Goodwill	20,369.7				20,369.7		$ 20,675.6
US Specialized Therapeutics [Member] | US Eye Care Reporting Unit [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
Goodwill	9,824.8				9,824.8
US Specialized Therapeutics [Member] | US Medical Aesthetics Reporting Unit [Member]
Goodwill Product Rights And Other Intangible Assets [Line Items]
Goodwill	$ 7,698.8				$ 7,698.8

Goodwill, Product Rights and _5

Goodwill, Product Rights and Other Intangible Assets - Schedule of Cost Basis on Product Rights and Other Intangible Assets (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangible assets, gross, Amortization	$ (1,402)	$ (1,697.1)	$ (2,801.4)	$ (3,394.7)
Intangibles with indefinite lives, Impairments	(436)	$ (276)	(436)	$ (798)
Product rights and other intangibles	41,231.5		41,231.5		$ 43,695.4
IPR&D [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangibles with indefinite lives, Impairments	(127)
Cost Basis [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangibles with definite lives, Beginning balance			70,925.1
Intangibles with definite lives, Additions			90.9
Intangibles with definite lives, Impairments			0
Intangibles with definite lives, IPR&D to CMP Transfers			75.6
Intangibles with definite lives, Foreign Currency Translation			1,809.8
Intangibles with definite lives, Ending balance	72,901.4		72,901.4
Intangibles assets, gross, Foreign Currency Translation			1,809.8
Intangibles with indefinite lives, Beginning balance			5,048.1
Intangibles with indefinite lives, Additions			0
Intangibles with indefinite lives, Impairments			(436)
Intangibles with indefinite lives, IPR&D to CMP Transfers			(75.6)
Intangibles with indefinite lives, Foreign Currency Translation			0
Intangibles with indefinite lives, Ending balance	4,536.5		4,536.5
Intangible assets, gross, Beginning balance			75,973.2
Intangible assets, gross, Additions			90.9
Intangible assets, gross, Impairments			(436)
Intangible assets, IPR&D to CMP Transfers			0
Intangible assets, gross, Ending balance	77,437.9		77,437.9
Intangibles with definite lives, Impairments			0
Cost Basis [Member] | Product Rights and Other Intangibles [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangibles with definite lives, Beginning balance			70,235.1
Intangibles with definite lives, Additions			90.9
Intangibles with definite lives, Impairments			0
Intangibles with definite lives, IPR&D to CMP Transfers			75.6
Intangibles with definite lives, Foreign Currency Translation			1,809.8
Intangibles with definite lives, Ending balance	72,211.4		72,211.4
Intangibles with definite lives, Impairments			0
Cost Basis [Member] | Trade Name [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangibles with definite lives, Beginning balance			690
Intangibles with definite lives, Additions			0
Intangibles with definite lives, Impairments			0
Intangibles with definite lives, IPR&D to CMP Transfers			0
Intangibles with definite lives, Foreign Currency Translation			0
Intangibles with definite lives, Ending balance	690		690
Intangibles with definite lives, Impairments			0
Cost Basis [Member] | IPR&D [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangibles with indefinite lives, Beginning balance			5,048.1
Intangibles with indefinite lives, Additions			0
Intangibles with indefinite lives, Impairments			(436)
Intangibles with indefinite lives, IPR&D to CMP Transfers			(75.6)
Intangibles with indefinite lives, Foreign Currency Translation			0
Intangibles with indefinite lives, Ending balance	4,536.5		4,536.5
Accumulated Amortization [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangible assets, Accumulated Amortization, Beginning balance			(32,277.8)
Intangible assets, gross, Amortization			(2,801.4)
Intangibles with definite lives, Impairments			129.6
Intangibles with definite lives, IPR&D to CMP Transfers			0
Intangibles with definite lives, Foreign Currency Translation			(997.6)
Intangibles assets, gross, Foreign Currency Translation			(997.6)
Intangible assets, Accumulated Amortization, Ending balance	(36,206.4)		(36,206.4)
Intangible assets, gross, Impairments			(129.6)
Intangibles with definite lives, Impairments			(129.6)
Accumulated Amortization [Member] | Product Rights and Other Intangibles [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangible assets, Accumulated Amortization, Beginning balance			(31,985)
Intangible assets, gross, Amortization			(2,761.4)
Intangibles with definite lives, Impairments			129.6
Intangibles with definite lives, IPR&D to CMP Transfers			0
Intangibles with definite lives, Foreign Currency Translation			(997.6)
Intangible assets, Accumulated Amortization, Ending balance	(35,873.6)		(35,873.6)
Intangibles with definite lives, Impairments			(129.6)
Accumulated Amortization [Member] | Trade Name [Member]
Finite And Indefinite Lived Intangible Assets By Major Class [Line Items]
Intangible assets, Accumulated Amortization, Beginning balance			(292.8)
Intangible assets, gross, Amortization			(40)
Intangibles with definite lives, Impairments			0
Intangibles with definite lives, IPR&D to CMP Transfers			0
Intangibles with definite lives, Foreign Currency Translation			0
Intangible assets, Accumulated Amortization, Ending balance	$ (332.8)		(332.8)
Intangibles with definite lives, Impairments			$ 0

Goodwill, Product Rights and _6

Goodwill, Product Rights and Other Intangible Assets - Schedule of Annual Amortization Expense on Product Rights and Other Related Intangibles (Detail) - Product Rights and Other Related Intangibles [Member] $ in Millions	Jun. 30, 2019USD ($)
Finite Lived Intangible Assets [Line Items]
2019 remaining	$ 2,884.3
2020	5,485.6
2021	4,560.6
2022	4,211.9
2023	3,787.8
2024	$ 2,955.6

Long-Term Debt and Capital Leas

Long-Term Debt and Capital Leases - Schedule of Long-Term Debt and Capital Leases (Detail) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 22,725.8	$ 23,813.1
Unamortized premium	52	64.3
Unamortized discount	(59.6)	(64.5)
Total Senior Notes Net	22,718.2	23,812.9
Senior Notes, Fair Market Value	23,209.5	23,303.3
Debt Issuance Costs	(82.4)	(92.1)
Total Other Borrowings	(14.7)	(22.8)
Total Indebtedness	22,703.5	23,797.7
Capital Leases [Member]
Debt Instrument [Line Items]
Total Term Loan Indebtedness		7.6
Floating Rate Notes [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	500	500
Senior Notes, Fair Market Value	503.6	501.9
Floating Rate Notes [Member] | Notes Due March 12, 2020 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	500	500
Senior Notes, Fair Market Value	$ 503.6	501.9
Issuance Date	Mar. 4, 2015
Interest Payments	Quarterly
Acquisition Date	Mar. 4, 2015
Euro Denominated Notes [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 4,208.1	5,045.6
Senior Notes, Fair Market Value	$ 4,341.9	4,951.9
Euro Denominated Notes [Member] | Notes Due June 1, 2019 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross		802.7
Senior Notes, Fair Market Value		794.9
Issuance Date	May 26, 2017
Interest Payments	Quarterly
Acquisition Date	May 26, 2017
Euro Denominated Notes [Member] | 0.500% Notes Due June 1, 2021 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 853	860
Senior Notes, Fair Market Value	$ 859.4	849.7
Issuance Date	May 26, 2017
Interest Payments	Annually
Acquisition Date	May 26, 2017
Euro Denominated Notes [Member] | 1.500% Notes Due November 15, 2023 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 568.7	573.4
Senior Notes, Fair Market Value	$ 591.7	572.4
Issuance Date	Nov. 15, 2018
Interest Payments	Annually
Acquisition Date	Nov. 15, 2018
Euro Denominated Notes [Member] | Notes Due November 15, 2020 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 796.1	802.7
Senior Notes, Fair Market Value	$ 795.1	791.3
Issuance Date	Nov. 15, 2018
Interest Payments	Quarterly
Acquisition Date	Nov. 15, 2018
Euro Denominated Notes [Member] | 1.250% Notes Due June 1, 2024 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 796.1	802.7
Senior Notes, Fair Market Value	$ 815.8	775.5
Issuance Date	May 26, 2017
Interest Payments	Annually
Acquisition Date	May 26, 2017
Euro Denominated Notes [Member] | 2.625% Notes Due November 15, 2028 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 568.7	573.4
Senior Notes, Fair Market Value	$ 623.6	573.4
Issuance Date	Nov. 15, 2018
Interest Payments	Annually
Acquisition Date	Nov. 15, 2018
Euro Denominated Notes [Member] | 2.125% Notes Due June 1, 2029 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 625.5	630.7
Senior Notes, Fair Market Value	$ 656.3	594.7
Issuance Date	May 26, 2017
Interest Payments	Annually
Acquisition Date	May 26, 2017
Fixed Rate Notes [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 18,017.7	18,267.5
Senior Notes, Fair Market Value	18,364	17,849.5
Fixed Rate Notes [Member] | 3.000% notes due March 12, 2020 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	2,526	2,706.7
Senior Notes, Fair Market Value	$ 2,533.7	2,694.8
Issuance Date	Mar. 4, 2015
Interest Payments	Semi-annually
Acquisition Date	Mar. 4, 2015
Fixed Rate Notes [Member] | 3.375% Notes Due September 15, 2020 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 650	650
Senior Notes, Fair Market Value	$ 655.6	648.7
Issuance Date	Mar. 17, 2015
Interest Payments	Semi-annually
Acquisition Date	Mar. 17, 2015
Fixed Rate Notes [Member] | 4.875% Notes Due February 15, 2021 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 450	450
Senior Notes, Fair Market Value	$ 463.5	459.4
Issuance Date	Jul. 1, 2014
Interest Payments	Semi-annually
Acquisition Date	Jul. 1, 2014
Fixed Rate Notes [Member] | 5.000% Notes Due December 15, 2021 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 1,200	1,200
Senior Notes, Fair Market Value	$ 1,258.5	1,234.8
Issuance Date	Jul. 1, 2014
Interest Payments	Semi-annually
Acquisition Date	Jul. 1, 2014
Fixed Rate Notes [Member] | 3.450% notes due March 15, 2022 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 2,878.2	2,940.5
Senior Notes, Fair Market Value	$ 2,929.9	2,891
Issuance Date	Mar. 4, 2015
Interest Payments	Semi-annually
Acquisition Date	Mar. 4, 2015
Fixed Rate Notes [Member] | 3.250% Notes Due October 1, 2022 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 1,700	1,700
Senior Notes, Fair Market Value	$ 1,707.6	1,652.2
Issuance Date	Oct. 2, 2012
Interest Payments	Semi-annually
Acquisition Date	Oct. 2, 2012
Fixed Rate Notes [Member] | 2.800% Notes Due March 15, 2023 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 350	350
Senior Notes, Fair Market Value	$ 348.2	332.8
Issuance Date	Mar. 17, 2015
Interest Payments	Semi-annually
Acquisition Date	Mar. 17, 2015
Fixed Rate Notes [Member] | 3.850% Notes Due June 15, 2024 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 1,036.7	1,036.7
Senior Notes, Fair Market Value	$ 1,073.1	1,021
Issuance Date	Jun. 10, 2014
Interest Payments	Semi-annually
Acquisition Date	Jun. 10, 2014
Fixed Rate Notes [Member] | 3.800% notes due March 15, 2025 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 3,020.7	3,027.5
Senior Notes, Fair Market Value	$ 3,119	2,956
Issuance Date	Mar. 4, 2015
Interest Payments	Semi-annually
Acquisition Date	Mar. 4, 2015
Fixed Rate Notes [Member] | 4.550% notes due March 15, 2035 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 1,789	1,789
Senior Notes, Fair Market Value	$ 1,818	1,690.7
Issuance Date	Mar. 4, 2015
Interest Payments	Semi-annually
Acquisition Date	Mar. 4, 2015
Fixed Rate Notes [Member] | 4.625% Notes Due October 1, 2042 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 456.7	456.7
Senior Notes, Fair Market Value	$ 447.9	412.4
Issuance Date	Oct. 2, 2012
Interest Payments	Semi-annually
Acquisition Date	Oct. 2, 2012
Fixed Rate Notes [Member] | 4.850% Notes Due June 15, 2044 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 1,079.4	1,079.4
Senior Notes, Fair Market Value	$ 1,108.8	1,019.1
Issuance Date	Jun. 10, 2014
Interest Payments	Semi-annually
Acquisition Date	Jun. 10, 2014
Fixed Rate Notes [Member] | 4.750% notes due March 15, 2045 [Member]
Debt Instrument [Line Items]
Total Senior Notes Gross	$ 881	881
Senior Notes, Fair Market Value	$ 900.2	836.6
Issuance Date	Mar. 4, 2015
Interest Payments	Semi-annually
Acquisition Date	Mar. 4, 2015
Other [Member]
Debt Instrument [Line Items]
Total Other Borrowings	$ 67.7	$ 69.3

Long-Term Debt and Capital Le_2

Long-Term Debt and Capital Leases - Schedule of Long-Term Debt and Capital Leases (Parenthetical) (Detail)	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018
3.000% notes due March 12, 2020 [Member]
Debt Instrument [Line Items]
Senior notes, interest rate	3.00%		3.00%
3.450% notes due March 15, 2022 [Member]
Debt Instrument [Line Items]
Senior notes, interest rate	3.45%		3.45%
3.850% Notes Due June 15, 2024 [Member]
Debt Instrument [Line Items]
Senior notes, interest rate			3.85%
3.800% notes due March 15, 2025 [Member]
Debt Instrument [Line Items]
Senior notes, interest rate	3.80%		3.80%
4.550% notes due March 15, 2035 [Member]
Debt Instrument [Line Items]
Senior notes, interest rate			4.55%
4.850% Notes Due June 15, 2044 [Member]
Debt Instrument [Line Items]
Senior notes, interest rate			4.85%
4.750% notes due March 15, 2045 [Member]
Debt Instrument [Line Items]
Senior notes, interest rate			4.75%
Floating Rate Notes [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Jun. 1, 2019
Floating Rate Notes [Member] | Notes Due March 12, 2020 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Mar. 12, 2020	Mar. 12, 2020
Percentage of margin	1.255%	1.255%
Debt instrument variable rate basis	three month USD LIBOR	three month USD LIBOR
Interest payment terms	Interest on the 2020 floating rate note is three month USD LIBOR plus 1.255% per annum	Interest on the 2020 floating rate note is three month USD LIBOR plus 1.255% per annum
Fixed Rate Notes [Member] | 3.000% notes due March 12, 2020 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Mar. 12, 2020	Mar. 12, 2020
Senior notes, interest rate	3.00%	3.00%
Fixed Rate Notes [Member] | 3.375% Notes Due September 15, 2020 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Sep. 15, 2020	Sep. 15, 2020
Senior notes, interest rate	3.375%	3.375%
Fixed Rate Notes [Member] | 4.875% Notes Due February 15, 2021 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Feb. 15, 2021	Feb. 15, 2021
Senior notes, interest rate	4.875%	4.875%
Fixed Rate Notes [Member] | 5.000% Notes Due December 15, 2021 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Dec. 15, 2021	Dec. 15, 2021
Senior notes, interest rate	5.00%	5.00%
Fixed Rate Notes [Member] | 3.450% notes due March 15, 2022 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Mar. 15, 2022	Mar. 15, 2022
Senior notes, interest rate	3.45%	3.45%
Fixed Rate Notes [Member] | 3.250% Notes Due October 1, 2022 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Oct. 1, 2022	Oct. 1, 2022
Senior notes, interest rate	3.25%	3.25%
Fixed Rate Notes [Member] | 2.800% Notes Due March 15, 2023 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Mar. 15, 2023	Mar. 15, 2023
Senior notes, interest rate	2.80%	2.80%
Fixed Rate Notes [Member] | 3.850% Notes Due June 15, 2024 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Jun. 15, 2024	Jun. 15, 2024
Senior notes, interest rate	3.85%	3.85%
Fixed Rate Notes [Member] | 3.800% notes due March 15, 2025 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Mar. 15, 2025	Mar. 15, 2025
Senior notes, interest rate	3.80%	3.80%
Fixed Rate Notes [Member] | 4.550% notes due March 15, 2035 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Mar. 15, 2035	Mar. 15, 2035
Senior notes, interest rate	4.55%	4.55%
Fixed Rate Notes [Member] | 4.625% Notes Due October 1, 2042 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Oct. 1, 2042	Oct. 1, 2042
Senior notes, interest rate	4.625%	4.625%
Fixed Rate Notes [Member] | 4.850% Notes Due June 15, 2044 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Jun. 15, 2044	Jun. 15, 2044
Senior notes, interest rate	4.85%	4.85%
Fixed Rate Notes [Member] | 4.750% notes due March 15, 2045 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Mar. 15, 2045	Mar. 15, 2045
Senior notes, interest rate	4.75%	4.75%
Euro Denominated Notes [Member] | 1.500% Notes Due November 15, 2023 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Nov. 15, 2023	Nov. 15, 2023
Senior notes, interest rate	1.50%	1.50%
Euro Denominated Notes [Member] | 1.250% Notes Due June 1, 2024 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Jun. 1, 2024	Jun. 1, 2024
Senior notes, interest rate	1.25%	1.25%
Euro Denominated Notes [Member] | 2.625% Notes Due November 15, 2028 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Nov. 15, 2028	Nov. 15, 2028
Senior notes, interest rate	2.625%	2.625%
Euro Denominated Notes [Member] | 2.125% Notes Due June 1, 2029 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Jun. 1, 2029	Jun. 1, 2029
Senior notes, interest rate	2.125%	2.125%
Euro Denominated Notes [Member] | 0.500% Notes Due June 1, 2021 [Member]
Debt Instrument [Line Items]
Senior notes, maturity date	Jun. 1, 2021	Jun. 1, 2021
Senior notes, interest rate	0.50%	0.50%
Euro Denominated Notes [Member] | Notes Due November 15, 2020 [Member]
Debt Instrument [Line Items]
Percentage of margin	0.35%	0.35%
Debt instrument variable rate basis	three month EURIBOR	three month EURIBOR
Interest payment terms	Interest on the 2020 floating rate notes is the three month EURIBOR plus 0.350% per annum	Interest on the 2020 floating rate notes is the three month EURIBOR plus 0.350% per annum
Euro Denominated Notes [Member] | Notes Due June 1, 2019 [Member]
Debt Instrument [Line Items]
Percentage of margin	0.35%	0.35%
Debt instrument variable rate basis	three month EURIBOR	three month EURIBOR
Interest payment terms	Interest on the 2019 floating rate notes is the three month EURIBOR plus 0.350% per annum	Interest on the 2019 floating rate notes is the three month EURIBOR plus 0.350% per annum

Long-Term Debt and Capital Le_3

Long-Term Debt and Capital Leases - Additional Information (Detail) - 6 months ended Jun. 30, 2019 € in Millions, $ in Millions	EUR (€)	USD ($)
Floating Rate Notes [Member]
Line Of Credit Facility [Line Items]
Repayment Of Debt | €	€ 700
Senior notes, maturity date	Jun. 1, 2019
Senior Notes
Line Of Credit Facility [Line Items]
Senior notes, repurchase amount | $		$ 249.8

Long-Term Debt and Capital Le_4

Long-Term Debt and Capital Leases - Schedule of Annual Debt Maturities (Detail) $ in Millions	Jun. 30, 2019USD ($)
Debt Disclosure [Abstract]
2020	$ 4,472.1
2021	2,503
2022	4,578.2
2023	918.7
2024	1,832.8
2025 and after	8,421
Total senior notes gross	$ 22,725.8

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2019	Dec. 31, 2018
Property Subject To Or Available For Operating Lease [Line Items]
Weighted average remaining lease term for operating leases	7 years	7 years
Weighted average discount rate for operating leases	2.70%	2.70%
Right-of-Use asset obtained in exchange for operating lease liability	$ 40.4	$ 63.8
Cash paid for amounts included in measurement of lease liabilities	$ 33.6	$ 74.4
Property Rental Expense [Member]
Property Subject To Or Available For Operating Lease [Line Items]
Rent expenses for operating leases			$ 63.2
Fleet Rental Expense [Member]
Property Subject To Or Available For Operating Lease [Line Items]
Rent expenses for operating leases			$ 41.1
Minimum [Member]
Property Subject To Or Available For Operating Lease [Line Items]
Remaining lease terms		1 year
Maximum [Member]
Property Subject To Or Available For Operating Lease [Line Items]
Remaining lease terms		9 years
Real Estate [Member] | Minimum [Member]
Property Subject To Or Available For Operating Lease [Line Items]
Remaining lease terms		1 year
Real Estate [Member] | Maximum [Member]
Property Subject To Or Available For Operating Lease [Line Items]
Remaining lease terms		14 years

Leases - Summary of Operating R

Leases - Summary of Operating ROU Assets and liabilities (Detail) - USD ($) $ in Millions	Jun. 30, 2019	Jan. 01, 2019
Property Subject To Or Available For Operating Lease [Line Items]
Right of use asset - operating leases	$ 457.9	$ 462.1
Lease Liability	538	548.6
Current portion of lease liability - operating	123.2
Lease liability - operating	414.8
Real Estate [Member]
Property Subject To Or Available For Operating Lease [Line Items]
Right of use asset - operating leases	283.9	304.2
Lease Liability	350.9	$ 370.6
Fleet Rental Expense [Member]
Property Subject To Or Available For Operating Lease [Line Items]
Right of use asset - operating leases	117.3
Lease Liability	117.3
Other [Member]
Property Subject To Or Available For Operating Lease [Line Items]
Right of use asset - operating leases	56.7
Lease Liability	$ 69.8

Leases - Schedule of Lease Expe

Leases - Schedule of Lease Expense (Detail) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019
Leases [Abstract]
Operating lease expense	$ 40.1	$ 72.4
Sublease (income)	(3.6)	(7)
Net operating lease expense	$ 36.5	$ 65.4

Leases - Schedule of Lease Ex_2

Leases - Schedule of Lease Expense (Detail) (Parenthetical) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019
Leases [Abstract]
Short-term and variable lease expenses	$ 0.7	$ 1.6

Leases - Schedule of Lease Comm

Leases - Schedule of Lease Commitments (Detail) - USD ($) $ in Millions	Jun. 30, 2019	Jan. 01, 2019
Leases [Abstract]
2019 remaining	$ 66.8
2020	117.4
2021	103.8
2022	59.6
2023	45.8
2024	39.3
2025 and after	152.3
Total undiscounted cash flows	585
Future interest	(47)
Lease Liability	$ 538	$ 548.6

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Property Lease Rental Payments under Capital and Operating Leases (Detail) $ in Millions	Dec. 31, 2018USD ($)
Leases [Abstract]
2019	$ 62.5
2020	52.5
2021	47.9
2022	43.3
2023	39
Thereafter	173.8
Total minimum lease payments	$ 419

Other Long-Term Liabilities - S

Other Long-Term Liabilities - Summary of Other Long-Term Liabilities (Detail) - USD ($) $ in Millions	Jun. 30, 2019	Dec. 31, 2018
Other Liabilities Disclosure [Abstract]
Acquisition related contingent consideration liabilities	$ 376.9	$ 336.3
Long-term pension and post retirement liability	167.8	166.5
Legacy Allergan deferred executive compensation	92.9	90.8
Accrued R&D milestone	75	75
Deferred revenue	32.8	36.1
Product warranties	28.9	27.9
Long-term severance and restructuring liabilities	11	14.2
Long-term contractual obligations		43.2
Other long-term liabilities	36.1	92
Total other long-term liabilities	$ 821.4	$ 882

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2018
Income Tax [Line Items]
Company's effective tax rate		5.90%	(47.70%)
Tax benefit for impairment		$ 107.3	$ 231
Tax charge to establish valuation allowance on non- US deferred tax assets		375
Uncertain tax position		49
Goodwill impairments	$ 1,085.8	3,552.8
Tax benefit for impairment		0
Income tax benefit related to restructuring of acquired business			421.9
Tax detriments for gain on sale of investments			21.2
Change in applicable tax rate on certain temporary differences			25.9
U.S. Subsidiaries [Member]
Income Tax [Line Items]
Income tax benefit for investment		118	$ 79.8
Income tax benefit for capital loss		$ 50.8

Income Taxes - Summary of Acqui

Income Taxes - Summary of Acquired U.S. Entities and Taxable Years that are Currently under Audit by IRS (Detail) - U.S. Federal Income Tax Authority [Member]	6 Months Ended
	Jun. 30, 2019
Allergan W C Holding Inc. [Member]
Income Tax Examination [Line Items]
Tax Years	2013 2014 2015 2016
Warner Chilcott Corporation [Member]
Income Tax Examination [Line Items]
Tax Years	2010 2011 2012 2013
Forest Laboratories, Inc. [Member]
Income Tax Examination [Line Items]
Tax Years	2010 2011 2012 2013 2014
Allergan, Inc. [Member]
Income Tax Examination [Line Items]
Tax Years	2009 2010 2011 2012 2013 2014
Taxable Years, date	Mar. 17, 2015

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Detail) - USD ($)	Mar. 01, 2018	Jun. 30, 2019
Shareholders Equity [Line Items]
Share repurchase program, Approved amount		$ 2,000,000,000
Number of shares repurchased under program		12,500,000
Shares repurchased amount under program		$ 2,000,000,000
Dividends on preferred shares		$ 69,600,000
Convertible Preferred Share, conversion date		Mar. 1, 2018
Convertible Preferred Stock, shares issued upon each share conversion	3.53
Ordinary Shares [Member]
Shareholders Equity [Line Items]
Convertible Preferred Stock, shares issued upon conversion	17,876,930
July 26, 2018 Share Repurchase Program [Member]
Shareholders Equity [Line Items]
Number of shares repurchased under program		5,300,000
Shares repurchased amount under program		$ 800,000,000

Derivative Instruments and He_2

Derivative Instruments and Hedging Activities - Additional Information (Detail) € in Millions, $ in Millions	1 Months Ended		3 Months Ended		6 Months Ended
	Jan. 31, 2019USD ($)	Nov. 30, 2018EUR (€)	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Dec. 31, 2018USD ($)
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Derivative, Maturity Date		May 31, 2019
Derivative instrument offsetting revaluation impact on variable interest debt | €		€ 700
Fair value of forward contract							$ 5.9
Outstanding third-party foreign currency instruments			$ 21.7		$ 21.7		42.1
Designated as Hedging Instrument [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Derivative notional amount			5,100		5,100		$ 5,100
Gain (Loss) on Derivative Used in Net Investment Hedge, Net of Tax			(69)	$ 197.1	41.8	$ 102
Designated as Hedging Instrument [Member] | Cash Flow Hedge [Member] | Interest Rate Swap [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Derivative notional amount	$ 500
Debt instrument, maturity date	Mar. 12, 2020
Derivative, average interest rate	3.98%
Interest rate swaps fair value			2.2		2.2
Unrealized loss on interest rate swaps			1.2		2.2
Foreign Currency Gain [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Loss on derivatives			$ (7.3)		$ (29.8)
Forward Contract [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Forward contract to buy Euros | €		€ 700

Fair Value Measurement - Schedu

Fair Value Measurement - Schedule of Financial Assets and Liabilities Measured at Fair Value using Fair Value Leveling or Disclosed at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Millions	Jun. 30, 2019	Dec. 31, 2018
ASSETS
Short-term investments	$ 322.3	$ 1,026.9
Deferred executive compensation investments	92.9	90.8
Royalty receivable	50.3	50.3
Investments and other	55.1	46
Total assets	1,674.7	1,421.1
Liabilities:
Deferred executive compensation liabilities	92.9	90.8
Contingent consideration obligations	387.4	344.6
Total liabilities	480.3	435.4
Cash Equivalents [Member]
ASSETS
Cash equivalents	1,154.1	207.1
Quoted Prices In Active Markets for Identical Assets (Level 1) [Member]
ASSETS
Deferred executive compensation investments	78	73.8
Investments and other	39.6	38.5
Total assets	1,271.7	319.4
Liabilities:
Deferred executive compensation liabilities	78	73.8
Total liabilities	78	73.8
Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Cash Equivalents [Member]
ASSETS
Cash equivalents	1,154.1	207.1
Significant Other Observable Inputs (Level 2) [Member]
ASSETS
Short-term investments	322.3	1,026.9
Deferred executive compensation investments	14.9	17
Investments and other	15.5	7.5
Total assets	352.7	1,051.4
Liabilities:
Deferred executive compensation liabilities	14.9	17
Total liabilities	14.9	17
Significant Unobservable Inputs (Level 3) [Member]
ASSETS
Royalty receivable	50.3	50.3
Total assets	50.3	50.3
Liabilities:
Contingent consideration obligations	387.4	344.6
Total liabilities	$ 387.4	$ 344.6

Fair Value Measurement - Sche_2

Fair Value Measurement - Schedule of Financial Assets and Liabilities Measured at Fair Value using Fair Value Leveling or Disclosed at Fair Value on Recurring Basis (Parenthetical) (Detail)	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Maximum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities remaining maturity period at the time of acquisition	90 days	90 days

Fair Value Measurement - Change

Fair Value Measurement - Change in Fair Value of Contingent Consideration Obligations (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Change in fair value of contingent consideration obligation	$ 28.1	$ (107.1)	$ 46.8	$ (101.8)
Cost of Sales [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Change in fair value of contingent consideration obligation	25.8	(128.8)	42	(125.4)
R&D Expense [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Change in fair value of contingent consideration obligation	$ 2.3	$ 21.7	$ 4.8	$ 23.6

Fair Value Measurement - Summar

Fair Value Measurement - Summary of Changes in Fair Value of all Financial Assets and Liabilities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Detail) - Contingent Consideration Obligations [Member] - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 344.6	$ 476.9
Purchases, settlements, and other net	(4)	(10.7)
Net accretion and fair value adjustments	46.8	(101.8)
Ending balance	$ 387.4	$ 364.4

Fair Value Measurement - Sche_3

Fair Value Measurement - Schedule of Contingent Consideration Obligations by Acquisitions (Detail) - Contingent Consideration Obligations [Member] - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Business Acquisition [Line Items]
Beginning balance	$ 344.6	$ 476.9
Fair Value Adjustments and Accretion	46.8	(101.8)
Payments and Other	(4)
Ending balance	387.4	$ 364.4
Tobira [Member]
Business Acquisition [Line Items]
Beginning balance	255
Fair Value Adjustments and Accretion	4.6
Ending balance	259.6
Medicines 360 Acquisition [Member]
Business Acquisition [Line Items]
Beginning balance	43.1
Fair Value Adjustments and Accretion	42.2
Payments and Other	(2.7)
Ending balance	82.6
AqueSys Acquisition [Member]
Business Acquisition [Line Items]
Beginning balance	5.4
Fair Value Adjustments and Accretion	0.1
Ending balance	5.5
ForSight [Member]
Business Acquisition [Line Items]
Beginning balance	24.1
Fair Value Adjustments and Accretion	0.2
Payments and Other	0.1
Ending balance	24.4
Oculeve Acquisition [Member]
Business Acquisition [Line Items]
Beginning balance	1.7
Ending balance	1.7
Forest Laboratories, Inc. [Member]
Business Acquisition [Line Items]
Beginning balance	13.6
Fair Value Adjustments and Accretion	(0.2)
Payments and Other	(1.2)
Ending balance	12.2
Other Acquisition [Member]
Business Acquisition [Line Items]
Beginning balance	1.7
Fair Value Adjustments and Accretion	(0.1)
Payments and Other	(0.2)
Ending balance	$ 1.4

Business Restructuring Charge_2

Business Restructuring Charges - Schedule of Activity Related to Business Restructuring and Facility Rationalization Activities (Detail) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Restructuring Cost And Reserve [Line Items]
Reserve beginning balance		$ 85.8
Charged to expense	$ 6.4	7.5	$ 24.3
Cash payments		(55.6)
Non-cash adjustments		(2.1)
Reserve ending balance		35.6
Cost of Sales [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense		1.2
Selling and Marketing Expense [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense		0.3
General and Administrative Expense [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense		6
Severance and Retention [Member]
Restructuring Cost And Reserve [Line Items]
Reserve beginning balance		71.4
Charged to expense		5.2
Cash payments		(54.8)
Non-cash adjustments		(2.1)
Reserve ending balance		19.7
Severance and Retention [Member] | Cost of Sales [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense		1.2
Severance and Retention [Member] | Selling and Marketing Expense [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense		0.3
Severance and Retention [Member] | General and Administrative Expense [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense		3.7
Other [Member]
Restructuring Cost And Reserve [Line Items]
Reserve beginning balance		14.4
Charged to expense		2.3
Cash payments		(0.8)
Non-cash adjustments		0
Reserve ending balance		15.9
Other [Member] | Cost of Sales [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense		0
Other [Member] | Selling and Marketing Expense [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense		0
Other [Member] | General and Administrative Expense [Member]
Restructuring Cost And Reserve [Line Items]
Charged to expense		$ 2.3

Business Restructuring Charge_3

Business Restructuring Charges - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Restructuring And Related Activities [Abstract]
Restructuring charges recognized	$ 6.4	$ 7.5	$ 24.3
Severance and other employee related charges	$ 6.4		$ 21.6

Commitments & Contingencies - A

Commitments & Contingencies - Additional Information (Detail) - USD ($)	Aug. 01, 2018	Jun. 30, 2019	Dec. 31, 2018
Loss Contingencies [Line Items]
Accrued loss contingencies		$ 80,000,000	$ 65,000,000
Sandoz [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Litigation plaintiff preliminary injunction bond amount	$ 157,300,000
Prinston [Member]
Loss Contingencies [Line Items]
Settlement agreement date		June 6, 2019
Slayback [Member]
Loss Contingencies [Line Items]
Settlement agreement date		June 12, 2019
Sun And Sun Certain Affiliates
Loss Contingencies [Line Items]
Dismissal date		Jan. 18, 2018
Aurobindo
Loss Contingencies [Line Items]
Dismissal date		May 7, 2018
Mylan [Member]
Loss Contingencies [Line Items]
Dismissal date		Dec. 27, 2018
Deva [Member]
Loss Contingencies [Line Items]
Dismissal date		Apr. 30, 2019
Argentum [Member] | Restasis [Member]
Loss Contingencies [Line Items]
Settlement agreement date		December 7, 2016

Commitments & Contingencies -_2

Commitments & Contingencies - Additional Information 1 (Detail)	Dec. 28, 2015ProductPatent	Jun. 30, 2019EUR (€)TrademarkCasesDefendant
Botox [Member]
Loss Contingencies [Line Items]
Number of putative class actions filed | Product	2
Saint Regis Mohawk Tribe [Member] | Restasis [Member]
Loss Contingencies [Line Items]
Number of patents acquired | Patent	6
Dermavita Limited Partnership [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Liquidated damages for violation of preliminary injunction | €		€ 75,000
Number of trademark opposition and cancellation pending | Trademark		150
Product Liability Litigation [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of plaintiffs		2
Product Liability Litigation [Member] | Pending Litigation [Member] | Canada [Member]
Loss Contingencies [Line Items]
Number of cases pending		3
Product Liability Litigation [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Number of defendant cases		500
Juvederm [Member] | KBC [Member]
Loss Contingencies [Line Items]
Settlement agreement date		June 2017
Breast Implant Litigation [Member] | Product Liability Litigation [Member] | Canada [Member]
Loss Contingencies [Line Items]
Number of putative class actions filed		5
Celexa/Lexapro Litigation [Member] | Product Liability Litigation [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Number of defendant cases | Defendant		150
RepliForm Litigation [Member] | Product Liability Litigation [Member]
Loss Contingencies [Line Items]
Cases settled or dismissed		200
RepliForm Litigation [Member] | Product Liability Litigation [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Number of defendant cases		300

Warner Chilcott Limited ("WCL_3

Warner Chilcott Limited ("WCL") Guarantor and Non-Guarantor Condensed Consolidating Financial Information - Consolidating Balance Sheets (Detail) - USD ($) $ in Millions	Jun. 30, 2019	Mar. 31, 2019	Jan. 01, 2019	Dec. 31, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 1,651.4			$ 880.4	$ 1,674.7		$ 1,817.2
Marketable securities	322.3			1,026.9
Accounts receivable, net	3,086.3			2,868.1
Inventories	1,004.5			846.9
Current assets held for sale				34
Prepaid expenses and other current assets	2,508.3			819.1
Total current assets	8,572.8			6,475.4
Property, plant and equipment, net	1,821			1,787
Right of use asset - operating leases	457.9		$ 462.1
Investments and other assets	335.2			1,970.6
Non current assets held for sale	32.5			882.2
Deferred tax assets	689.1			1,063.7
Product rights and other intangibles	41,231.5			43,695.4
Goodwill	42,340.7			45,913.3
Total assets	95,480.7			101,787.6
Current liabilities:
Accounts payable and accrued expenses	4,995.3			4,787.2
Income taxes payable	91			72.4
Current portion of long-term debt	3,094.2			868.3
Current portion of lease liability - operating	123.2
Total current liabilities	8,303.7			5,727.9
Long-term debt	19,609.3			22,929.4
Lease liability - operating	414.8
Other long-term liabilities	821.4			882
Other taxes payable	1,667			1,615.5
Deferred tax liabilities	4,968.4			5,501.8
Total liabilities	35,784.6			36,656.6
Total equity / (deficit)	59,696.1	$ 61,559.6		65,131	71,264	$ 72,346	73,837.1
Total liabilities and equity	95,480.7			101,787.6
Warner Chilcott Limited Parent Guarantor [Member]
Current assets:
Cash and cash equivalents	0.1			0.1	0.1		0.1
Total current assets	0.1			0.1
Investment in subsidiaries	57,413.8			62,940.2
Total assets	57,413.9			62,940.3
Current liabilities:
Total equity / (deficit)	57,413.9			62,940.3
Total liabilities and equity	57,413.9			62,940.3
Allergan Capital S.a.r.l. (Guarantor) [Member]
Current assets:
Cash and cash equivalents	8.1			1.8	294.5		593.1
Marketable securities	100.1			489.9
Intercompany receivables	3,298.1			3,534.7
Total current assets	3,406.3			4,026.4
Investment in subsidiaries	65,995.6			73,846
Non current intercompany receivables	15,939.7			28,239.4
Deferred tax assets	49.6			43.6
Total assets	85,391.2			106,155.4
Current liabilities:
Accounts payable and accrued expenses	0.1			0.1
Intercompany payables	16,431.5			14,315
Total current liabilities	16,431.6			14,315.1
Long-term intercompany payables				18,597.4
Total liabilities	16,431.6			32,912.5
Total equity / (deficit)	68,959.6			73,242.9
Total liabilities and equity	85,391.2			106,155.4
Allergan Funding SCS (Issuer) [Member]
Current assets:
Cash and cash equivalents	0.1			0.8			0.1
Intercompany receivables	217.2			961
Total current assets	217.3			961.8
Investment in subsidiaries	25,114.8			26,428.5
Non current intercompany receivables				18,090.2
Total assets	25,332.1			45,480.5
Current liabilities:
Accounts payable and accrued expenses	154.5			156.3
Intercompany payables	356.5			21.7
Income taxes payable	2.4
Current portion of long-term debt	3,006.4			779.6
Total current liabilities	3,519.8			957.6
Long-term debt	14,795.2			18,090.2
Total liabilities	18,315			19,047.8
Total equity / (deficit)	7,017.1			26,432.7
Total liabilities and equity	25,332.1			45,480.5
Allergan Finance LLC (Issuer and Guarantor) [Member]
Current assets:
Intercompany receivables	28.2			16.7
Prepaid expenses and other current assets	33.3			33.3
Total current assets	61.5			50
Investment in subsidiaries	95,506.7			99,328.5
Total assets	95,568.2			99,378.5
Current liabilities:
Accounts payable and accrued expenses	95.6			92.9
Intercompany payables	10,447.6			10,442.6
Total current liabilities	10,543.2			10,535.5
Long-term debt	2,141			2,135.9
Long-term intercompany payables	1,115.4			1,076.8
Total liabilities	13,799.6			13,748.2
Total equity / (deficit)	81,768.6			85,630.3
Total liabilities and equity	95,568.2			99,378.5
Non-Guarantors [Member]
Current assets:
Cash and cash equivalents	1,641.7			875.9	1,378.9		1,223
Marketable securities	222.2			537
Accounts receivable, net	3,086.3			2,868.1
Receivables from Parents	210.6			640.9
Inventories	1,004.5			846.9
Intercompany receivables	27,235.6			24,779.3
Current assets held for sale				34
Prepaid expenses and other current assets	2,471.7			785.4
Total current assets	35,872.6			31,367.5
Property, plant and equipment, net	1,821			1,787
Right of use asset - operating leases	457.9
Investments and other assets	335.2			1,970.6
Non current intercompany receivables	1,115.4			19,674.2
Non current assets held for sale	32.5			882.2
Deferred tax assets	639.5			1,020.1
Product rights and other intangibles	41,231.5			43,695.4
Goodwill	42,340.7			45,913.3
Total assets	123,846.3			146,310.3
Current liabilities:
Accounts payable and accrued expenses	4,745			4,538.1
Intercompany payables	3,543.5			4,512.4
Payables to Parents	2,491.7			2,829.2
Income taxes payable	91.2			72.4
Current portion of long-term debt	87.8			88.7
Current portion of lease liability - operating	123.2
Total current liabilities	11,082.4			12,040.8
Long-term debt	2,673.1			2,703.3
Lease liability - operating	414.8
Other long-term liabilities	821.4			882
Long-term intercompany payables	15,939.7			46,329.6
Other taxes payable	1,660.8			1,615.5
Deferred tax liabilities	4,968.5			5,501.8
Total liabilities	37,560.7			69,073
Total equity / (deficit)	86,285.6			77,237.3
Total liabilities and equity	123,846.3			146,310.3
Warner Chilcott Limited [Member]
Current assets:
Cash and cash equivalents	1,650			878.6	1,673.5		1,816.3
Marketable securities	322.3			1,026.9
Accounts receivable, net	3,086.3			2,868.1
Receivables from Parents	210.6			640.9
Inventories	1,004.5			846.9
Current assets held for sale				34
Prepaid expenses and other current assets	2,505			818.7
Total current assets	8,778.7			7,114.1
Property, plant and equipment, net	1,821			1,787
Right of use asset - operating leases	457.9
Investments and other assets	335.2			1,970.6
Non current assets held for sale	32.5			882.2
Deferred tax assets	689.1			1,063.7
Product rights and other intangibles	41,231.5			43,695.4
Goodwill	42,340.7			45,913.3
Total assets	95,686.6			102,426.3
Current liabilities:
Accounts payable and accrued expenses	4,995.2			4,787.4
Payables to Parents	2,491.7			2,829.2
Income taxes payable	93.6			72.4
Current portion of long-term debt	3,094.2			868.3
Current portion of lease liability - operating	123.2
Total current liabilities	10,797.9			8,557.3
Long-term debt	19,609.3			22,929.4
Lease liability - operating	414.8
Other long-term liabilities	821.4			882
Other taxes payable	1,660.8			1,615.5
Deferred tax liabilities	4,968.5			5,501.8
Total liabilities	38,272.7			39,486
Total equity / (deficit)	57,413.9	$ 59,338.7		62,940.3	$ 78,676.2	$ 79,739	$ 81,282.2
Total liabilities and equity	95,686.6			102,426.3
Eliminations [Member]
Current assets:
Intercompany receivables	(30,779.1)			(29,291.7)
Total current assets	(30,779.1)			(29,291.7)
Investment in subsidiaries	(244,030.9)			(262,543.2)
Non current intercompany receivables	(17,055.1)			(66,003.8)
Total assets	(291,865.1)			(357,838.7)
Current liabilities:
Intercompany payables	(30,779.1)			(29,291.7)
Total current liabilities	(30,779.1)			(29,291.7)
Long-term intercompany payables	(17,055.1)			(66,003.8)
Total liabilities	(47,834.2)			(95,295.5)
Total equity / (deficit)	(244,030.9)			(262,543.2)
Total liabilities and equity	$ (291,865.1)			$ (357,838.7)

Warner Chilcott Limited ("WCL_4

Warner Chilcott Limited ("WCL") Guarantor and Non-Guarantor Condensed Consolidating Financial Information - Consolidating Statements of Operations (Detail) - USD ($) $ in Millions	3 Months Ended				6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Condensed Income Statements Captions [Line Items]
Net revenues	$ 4,090.1		$ 4,124.2		$ 7,687.2	$ 7,796.3
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)	652.3		481.8		1,150.1	1,004.6
Research and development	450		689.2		885	1,163.9
Selling and marketing	873.3		853.4		1,677.3	1,653.4
General and administrative	324.2		334.1		632.5	630
Amortization	1,402		1,697.1		2,801.4	3,394.7
Goodwill impairments	1,085.8				3,552.8
Asset sales and impairments, net	129.4		259.6		124.2	272.7
Total operating expenses	5,353		4,591.2		11,259.3	8,917.3
Operating (loss)	(1,262.9)		(467)		(3,572.1)	(1,121)
Other (expense) / income, net	(4.7)		215.4		9.1	136.6
Total other income (expense), net	(190.4)		(8.3)		(357.1)	(320.4)
Income / (loss) before income taxes and noncontrolling interest	(1,453.3)		(475.3)		(3,929.2)	(1,441.4)
Provision (benefit) for income taxes	301.6		(5.2)		233	(687.4)
Net (loss) / income	(1,754.9)		(470.1)		(4,162.2)	(754)
(Income) attributable to noncontrolling interest	(4.1)		(2.4)		(4.8)	(4.6)
Other comprehensive income / (loss), net of tax	65.3		(448.6)		(63.5)	(264.8)
Warner Chilcott Limited Parent Guarantor [Member]
Operating expenses:
Losses / (earnings) of equity interest subsidiaries	1,751.2		372.4		4,156.9	603.7
Net (loss) / income	(1,751.2)		(372.4)		(4,156.9)	(603.7)
Net (loss) / income attributable to members	(1,751.2)		(372.4)		(4,156.9)	(603.7)
Other comprehensive income / (loss), net of tax	65.3		(448.6)		(63.5)	(264.8)
Comprehensive (loss) attributable to members	(1,685.9)		(821)		(4,220.4)	(868.5)
Allergan Capital S.a.r.l. (Guarantor) [Member]
Operating expenses:
Interest (expense) / income, net	(23.5)		267.4		(46.9)	526.4
Total other income (expense), net	(23.5)		267.4		(46.9)	526.4
Income / (loss) before income taxes and noncontrolling interest	(23.5)		267.4		(46.9)	526.4
Provision (benefit) for income taxes	1.8				1.8
Losses / (earnings) of equity interest subsidiaries	1,715.8		512.4		4,060.8	1,018.4
Net (loss) / income	(1,741.1)		(245)		(4,109.5)	(492)
Net (loss) / income attributable to members	(1,741.1)		(245)		(4,109.5)	(492)
Other comprehensive income / (loss), net of tax	(33)		(295.6)		(173.8)	(25)
Comprehensive (loss) attributable to members	(1,774.1)		(540.6)		(4,283.3)	(517)
Allergan Funding SCS (Issuer) [Member]
Operating expenses:
General and administrative			1.2			0.5
Total operating expenses			1.2			0.5
Operating (loss)			(1.2)			(0.5)
Interest (expense) / income, net	48		(5.1)		(11.6)	(8.4)
Other (expense) / income, net			9.2		(0.1)	9.2
Total other income (expense), net	48		4.1		(11.7)	0.8
Income / (loss) before income taxes and noncontrolling interest	48		2.9		(11.7)	0.3
Provision (benefit) for income taxes						0.3
Losses / (earnings) of equity interest subsidiaries	373.9		(118.7)		1,183.4	214.4
Net (loss) / income	(325.9)		121.6		(1,195.1)	(214.4)
Net (loss) / income attributable to members	(325.9)		121.6		(1,195.1)	(214.4)
Other comprehensive income / (loss), net of tax	42.6		(59.7)		(130.3)	59.2
Comprehensive (loss) attributable to members	(283.3)		61.9		(1,325.4)	(155.2)
Allergan Finance LLC (Issuer and Guarantor) [Member]
Operating expenses:
Interest (expense) / income, net	(20)		(20.7)		(39.9)	(41.9)
Total other income (expense), net	(20)		(20.7)		(39.9)	(41.9)
Income / (loss) before income taxes and noncontrolling interest	(20)		(20.7)		(39.9)	(41.9)
Provision (benefit) for income taxes			(4.4)			(16.6)
Losses / (earnings) of equity interest subsidiaries	1,004.6		(550.8)		3,382.7	99.2
Net (loss) / income	(1,024.6)		534.5		(3,422.6)	(124.5)
Net (loss) / income attributable to members	(1,024.6)		534.5		(3,422.6)	(124.5)
Other comprehensive income / (loss), net of tax	145.9		(195.6)		(439.1)	164.4
Comprehensive (loss) attributable to members	(878.7)		338.9		(3,861.7)	39.9
Non-Guarantors [Member]
Condensed Income Statements Captions [Line Items]
Net revenues	4,090.1		4,124.2		7,687.2	7,796.3
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)	652.3		481.8		1,150.1	1,004.6
Research and development	450		689.2		885	1,163.9
Selling and marketing	873.3		853.4		1,677.3	1,653.4
General and administrative	316.4		298.3		622.5	593.1
Amortization	1,402		1,697.1		2,801.4	3,394.7
Goodwill impairments	1,085.8				3,552.8
In-process research and development impairments	436		276		436	798
Asset sales and impairments, net	129.4		259.6		124.2	272.7
Total operating expenses	5,345.2		4,555.4		11,249.3	8,880.4
Operating (loss)	(1,255.1)		(431.2)		(3,562.1)	(1,084.1)
Interest (expense) / income, net	(190.2)		(399.8)		(267.8)	(814.6)
Other (expense) / income, net	(4.7)		206.2		9.2	127.4
Total other income (expense), net	(194.9)		(193.6)		(258.6)	(687.2)
Income / (loss) before income taxes and noncontrolling interest	(1,450)		(624.8)		(3,820.7)	(1,771.3)
Provision (benefit) for income taxes	299.8		(0.8)		231.1	(671.1)
Net (loss) / income	(1,749.8)		(624)		(4,051.8)	(1,100.2)
(Income) attributable to noncontrolling interest	(4.1)		(2.4)		(4.8)	(4.6)
Net (loss) / income attributable to members	(1,753.9)		(626.4)		(4,056.6)	(1,104.8)
Other comprehensive income / (loss), net of tax	65.3		(448.6)		(63.5)	(264.8)
Comprehensive (loss) attributable to members	(1,688.6)		(1,075)		(4,120.1)	(1,369.6)
Warner Chilcott Limited [Member]
Condensed Income Statements Captions [Line Items]
Net revenues	4,090.1		4,124.2		7,687.2	7,796.3
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)	652.3		481.8		1,150.1	1,004.6
Research and development	450		689.2		885	1,163.9
Selling and marketing	873.3		853.4		1,677.3	1,653.4
General and administrative	316.4		299.5		622.5	593.6
Amortization	1,402		1,697.1		2,801.4	3,394.7
Goodwill impairments	1,085.8				3,552.8
In-process research and development impairments	436		276		436	798
Asset sales and impairments, net	129.4		259.6		124.2	272.7
Total operating expenses	5,345.2		4,556.6		11,249.3	8,880.9
Operating (loss)	(1,255.1)		(432.4)		(3,562.1)	(1,084.6)
Interest (expense) / income, net	(185.7)		(158.2)		(366.2)	(338.5)
Other (expense) / income, net	(4.7)		215.4		9.1	136.6
Total other income (expense), net	(190.4)		57.2		(357.1)	(201.9)
Income / (loss) before income taxes and noncontrolling interest	(1,445.5)		(375.2)		(3,919.2)	(1,286.5)
Provision (benefit) for income taxes	301.6		(5.2)		232.9	(687.4)
Net (loss) / income	(1,747.1)		(370)		(4,152.1)	(599.1)
(Income) attributable to noncontrolling interest	(4.1)		(2.4)		(4.8)	(4.6)
Net (loss) / income attributable to members	(1,751.2)	$ (2,405.7)	(372.4)	$ (231.3)	(4,156.9)	(603.7)
Other comprehensive income / (loss), net of tax	65.3		(448.6)		(63.5)	(264.8)
Comprehensive (loss) attributable to members	(1,685.9)		(821)		(4,220.4)	(868.5)
Eliminations [Member]
Operating expenses:
Losses / (earnings) of equity interest subsidiaries	(4,845.5)		(215.3)		(12,783.8)	(1,935.7)
Net (loss) / income	4,845.5		215.3		12,783.8	1,935.7
Net (loss) / income attributable to members	4,845.5		215.3		12,783.8	1,935.7
Other comprehensive income / (loss), net of tax	(220.8)		999.5		806.7	66.2
Comprehensive (loss) attributable to members	$ 4,624.7		$ 1,214.8		$ 13,590.5	$ 2,001.9

Warner Chilcott Limited ("WCL_5

Warner Chilcott Limited ("WCL") Guarantor and Non-Guarantor Condensed Consolidating Financial Information - Consolidating Statement of Cash Flows (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Cash Flows From Operating Activities:
Net (loss) / income	$ (1,754.9)	$ (470.1)	$ (4,162.2)	$ (754)
Reconciliation to net cash provided by operating activities:
Depreciation			96.2	105.2
Amortization			2,801.4	3,394.7
Provision for inventory reserve			83.4	45.4
Share-based compensation			111.8	127.4
Deferred income tax benefit			(166.4)	(1,359.6)
Goodwill impairments	1,085.8		3,552.8
In-process research and development impairments	436	276	436	798
Loss on asset sales and impairments, net			124.2	272.7
Non-cash extinguishment of debt			0.2	4
Amortization of deferred financing costs			9.1	11.9
Non-cash lease expense			68
Contingent consideration adjustments, including accretion			46.8	(101.8)
Other, net			(19.3)	(0.3)
Sales of business		53		53
Cash charge related to extinguishment of debt				13.1
Net cash provided by operating activities			2,644.3	2,698.5
Cash Flows From Investing Activities:
Additions to property, plant and equipment			(152.3)	(106.5)
Additions to product rights and other intangibles			(46)
Additions to investments			(738.2)	(1,455.9)
Proceeds from sale of investments and other assets			1,462	5,651.3
Proceeds from sales of property, plant and equipment			17.7	11.5
Acquisitions of businesses, net of cash acquired			(80.6)
Net cash provided by investing activities			462.6	3,634.4
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness, including credit facility			3.3	709
Payments on debt, including finance lease obligations and credit facility			(1,039.1)	(5,366.8)
Payments of contingent consideration and other financing			(4.1)	(10.6)
Net cash (used in) financing activities			(2,338.6)	(6,490.4)
Cash charge related to extinguishment of debt				(13.1)
Effect of currency exchange rate changes on cash and cash equivalents			2.7	15
Net increase / (decrease) in cash and cash equivalents			771	(142.5)
Cash and cash equivalents at beginning of period			880.4	1,817.2
Cash and cash equivalents at end of period	1,651.4	1,674.7	1,651.4	1,674.7
Warner Chilcott Limited Parent Guarantor [Member]
Cash Flows From Operating Activities:
Net (loss) / income	(1,751.2)	(372.4)	(4,156.9)	(603.7)
Reconciliation to net cash provided by operating activities:
Losses / (earnings) of equity interest subsidiaries	1,751.2	372.4	4,156.9	603.7
Dividends from subsidiaries			1,288.5	2,103.7
Net cash provided by operating activities			1,288.5	2,103.7
Cash Flows From Financing Activities:
Dividends to Parent			(1,288.5)	(2,103.7)
Net cash (used in) financing activities			(1,288.5)	(2,103.7)
Cash and cash equivalents at beginning of period			0.1	0.1
Cash and cash equivalents at end of period	0.1	0.1	0.1	0.1
Allergan Capital S.a.r.l. (Guarantor) [Member]
Cash Flows From Operating Activities:
Net (loss) / income	(1,741.1)	(245)	(4,109.5)	(492)
Reconciliation to net cash provided by operating activities:
Losses / (earnings) of equity interest subsidiaries	1,715.8	512.4	4,060.8	1,018.4
Changes in assets and liabilities (net of effects of acquisitions)			(134.4)	(1,225)
Net cash provided by operating activities			(183.1)	(698.6)
Cash Flows From Investing Activities:
Additions to investments			(100)	(400)
Proceeds from sale of investments and other assets			289.4	800
Net cash provided by investing activities			189.4	400
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness, including credit facility				700
Payments on debt, including finance lease obligations and credit facility				(700)
Net increase / (decrease) in cash and cash equivalents			6.3	(298.6)
Cash and cash equivalents at beginning of period			1.8	593.1
Cash and cash equivalents at end of period	8.1	294.5	8.1	294.5
Allergan Funding SCS (Issuer) [Member]
Cash Flows From Operating Activities:
Net (loss) / income	(325.9)	121.6	(1,195.1)	(214.4)
Reconciliation to net cash provided by operating activities:
Losses / (earnings) of equity interest subsidiaries	373.9	(118.7)	1,183.4	214.4
Non-cash extinguishment of debt				4
Amortization of deferred financing costs			8.3	11.1
Other, net			(2.5)	(1.5)
Changes in assets and liabilities (net of effects of acquisitions)			1,036.8	3,942.3
Cash charge related to extinguishment of debt				13.1
Net cash provided by operating activities			1,030.9	3,942.8
Cash Flows From Financing Activities:
Payments on debt, including finance lease obligations and credit facility			(1,031.6)	(3,956)
Net cash (used in) financing activities			(1,031.6)	(3,942.9)
Cash charge related to extinguishment of debt				(13.1)
Net increase / (decrease) in cash and cash equivalents			(0.7)	(0.1)
Cash and cash equivalents at beginning of period			0.8	0.1
Cash and cash equivalents at end of period	0.1		0.1
Allergan Finance LLC (Issuer and Guarantor) [Member]
Cash Flows From Operating Activities:
Net (loss) / income	(1,024.6)	534.5	(3,422.6)	(124.5)
Reconciliation to net cash provided by operating activities:
Losses / (earnings) of equity interest subsidiaries	1,004.6	(550.8)	3,382.7	99.2
Amortization of deferred financing costs			0.8	0.8
Other, net			(0.9)	(0.4)
Changes in assets and liabilities (net of effects of acquisitions)			40	24.9
Non-Guarantors [Member]
Cash Flows From Operating Activities:
Net (loss) / income	(1,749.8)	(624)	(4,051.8)	(1,100.2)
Reconciliation to net cash provided by operating activities:
Depreciation			96.2	105.2
Amortization			2,801.4	3,394.7
Provision for inventory reserve			83.4	45.4
Share-based compensation			111.8	127.4
Deferred income tax benefit			(166.4)	(1,359.6)
Goodwill impairments	1,085.8		3,552.8
In-process research and development impairments			436	798
Loss on asset sales and impairments, net			124.2	272.7
Gain on sale of Teva securities, net				(60.9)
Non-cash extinguishment of debt			0.2
Non-cash lease expense			68
Contingent consideration adjustments, including accretion			46.8	(101.8)
Other, net			(15.9)	1.6
Changes in assets and liabilities (net of effects of acquisitions)			(1,300)	(2,578.4)
Gain on sale of Teva securities, net				60.9
Sales of business				53
Net cash provided by operating activities			1,786.7	(508.9)
Cash Flows From Investing Activities:
Additions to property, plant and equipment			(152.3)	(106.5)
Additions to product rights and other intangibles			(46)
Additions to investments			(638.2)	(1,055.9)
Proceeds from sale of investments and other assets			1,172.6	4,851.3
Payments to settle Teva related matters				(466)
Proceeds from sales of property, plant and equipment			17.7	11.5
Acquisitions of businesses, net of cash acquired			(80.6)
Net cash provided by investing activities			273.2	3,234.4
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness, including credit facility			3.3	9
Payments on debt, including finance lease obligations and credit facility			(7.5)	(710.8)
Payments of contingent consideration and other financing			(4.1)	(10.6)
Proceeds from forward sale of Teva securities				465.5
Payments to settle Teva related matters				(234)
Dividends to Parent			(1,288.5)	(2,103.7)
Net cash (used in) financing activities			(1,296.8)	(2,584.6)
Effect of currency exchange rate changes on cash and cash equivalents			2.7	15
Net increase / (decrease) in cash and cash equivalents			765.8	155.9
Cash and cash equivalents at beginning of period			875.9	1,223
Cash and cash equivalents at end of period	1,641.7	1,378.9	1,641.7	1,378.9
Warner Chilcott Limited [Member]
Cash Flows From Operating Activities:
Net (loss) / income	(1,747.1)	(370)	(4,152.1)	(599.1)
Reconciliation to net cash provided by operating activities:
Depreciation			96.2	105.2
Amortization			2,801.4	3,394.7
Provision for inventory reserve			83.4	45.4
Share-based compensation			111.8	127.4
Deferred income tax benefit			(166.4)	(1,359.6)
Goodwill impairments	1,085.8		3,552.8
In-process research and development impairments	436	276	436	798
Loss on asset sales and impairments, net			124.2	272.7
Gain on sale of Teva securities, net				(60.9)
Non-cash extinguishment of debt			0.2	4
Amortization of deferred financing costs			9.1	11.9
Non-cash lease expense			68
Contingent consideration adjustments, including accretion			46.8	(101.8)
Other, net			(19.3)	(0.3)
Changes in assets and liabilities (net of effects of acquisitions)			(357.6)	163.8
Gain on sale of Teva securities, net				60.9
Sales of business				53
Cash charge related to extinguishment of debt				13.1
Net cash provided by operating activities			2,634.5	2,735.3
Cash Flows From Investing Activities:
Additions to property, plant and equipment			(152.3)	(106.5)
Additions to product rights and other intangibles			(46)
Additions to investments			(738.2)	(1,455.9)
Proceeds from sale of investments and other assets			1,462	5,651.3
Payments to settle Teva related matters				(466)
Proceeds from sales of property, plant and equipment			17.7	11.5
Acquisitions of businesses, net of cash acquired			(80.6)
Net cash provided by investing activities			462.6	3,634.4
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness, including credit facility			3.3	709
Payments on debt, including finance lease obligations and credit facility			(1,039.1)	(5,366.8)
Payments of contingent consideration and other financing			(4.1)	(10.6)
Proceeds from forward sale of Teva securities				465.5
Payments to settle Teva related matters				(234)
Dividends to Parent			(1,288.5)	(2,103.7)
Net cash (used in) financing activities			(2,328.4)	(6,527.5)
Cash charge related to extinguishment of debt				(13.1)
Effect of currency exchange rate changes on cash and cash equivalents			2.7	15
Net increase / (decrease) in cash and cash equivalents			771.4	(142.8)
Cash and cash equivalents at beginning of period			878.6	1,816.3
Cash and cash equivalents at end of period	1,650	1,673.5	1,650	1,673.5
Eliminations [Member]
Cash Flows From Operating Activities:
Net (loss) / income	4,845.5	215.3	12,783.8	1,935.7
Reconciliation to net cash provided by operating activities:
Losses / (earnings) of equity interest subsidiaries	$ (4,845.5)	$ (215.3)	(12,783.8)	(1,935.7)
Dividends from subsidiaries			(1,288.5)	(2,103.7)
Net cash provided by operating activities			(1,288.5)	(2,103.7)
Cash Flows From Financing Activities:
Dividends to Parent			1,288.5	2,103.7
Net cash (used in) financing activities			$ 1,288.5	$ 2,103.7